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Abstract 
Duchenne muscular dystrophy (DMD) is a hereditary, X-linked, muscle wasting disease with 
no known cure. It is caused by altered mechanical stability of muscle cell membranes 
combined with altered cell signalling and inflammatory infiltrations due the absence of the 
cytoskeletal protein dystrophin, the product of the DMD gene. Progressive muscle fibre 
degeneration combined with chronic inflammation leads to a severe functional impairment, 
progressive disability, and ultimately to premature death. DMD presents predominantly in 
skeletal muscles but brain and bone are also affected. 
Analyses in the mdx mouse, the most commonly used model of DMD, has led to the 
identification of an increased expression and function of the P2X7 purinoceptor in dystrophic 
muscle cells and muscles in situ. This ATP-gated receptor has been implicated in a number of 
human diseases that, combined with its well-known role in inflammatory cells, suggested that 
P2X7 upregulation might also be important for the pathogenesis of DMD. 
 To test the role of the P2X7 purinoceptor in DMD pathogenesis and its potential as a 
target for treatment, two mdx/P2X7-/- double mutant mouse strains were generated and 
compared to the mdx mouse with respect to several critical disease parameters during an 
acute degenerative stage of disease. Histological, molecular, biochemical, and functional 
analyses revealed reductions in both muscle and non-muscle pathology in mdx/P2X7-/- mice, 
with significant improvements in key molecular and structural parameters. These included 
lower serum creatine kinase levels and decreased sarcolemma permeability to blood-born 
molecules, indicative of less sarcolemma damage. P2X7 ablation also resulted in increased 
minimum Feret’s diameter, a morphological indicator of muscle regeneration. While the 
fraction of muscle fibres with centralised nuclei was not significantly different, levels of 
myogenin, a protein indicator of muscle differentiation, were also higher in mdx/P2X7-/- 
mice. These changes were concomitant with an overall decreased inflammatory signature in 
mdx/P2X7-/- mice compared to mdx and an increase in muscle strength, in vitro. Examination 
of diaphragms (undergoing continuous degeneration/regeneration in the mdx mouse) from 20 
month old mice also showed the increase in minimum Feret’s diameter and continued 
reduced inflammation in the mdx/P2X7-/- group. Aged heart tissue from these mdx/P2X7-/- 
also presented less inflammatory infiltrate and reduced fibrosis compared to mdx. Moreover, 
micro-CT analyses showed greatly reduced osteopenia in mdx/P2X7-/- bones when compared 
to 6 month mdx mice. Amelioration of all symptoms was proportional to the extent of 
I 
receptor depletion, where single P2X7 isoform loss was less effective than the complete 
knockout. 
 These observations support involvement of the P2X7 purinoceptor in the dystrophic 
pathology in this model of DMD and are consistent with the well-known role of this receptor 
in other disorders. P2X7 purinoceptors are likely to act via several different molecular 
pathways, for example increased Ca2+ influx that affects dystrophic cells directly as well as 
through reduced inflammation. Indeed, this study represents the first known analysis of an 
effect of P2X7 ablation on a chronic inflammatory phenotype localised to skeletal muscle.  
These data from the most widely used model of DMD suggest that the P2X7 receptor 
can be also involved in human pathology and specific receptor antagonists could be 
considered for targeted pharmacological intervention to delay progression of this lethal 
disease.
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1 
General Introduction 
 
1.1 Duchenne muscular dystrophy: A multicomponent disorder 
 
Duchenne muscular dystrophy (DMD) is the most common and one of the most 
severe of the muscular dystrophies (Emery, 2001; Kaplan, 2011). DMD was first 
described by Edward Meryon and Guillaume Benjamin Amand Duchenne in the 1850 
and 60s (Meryon, 1852; Duchenne, 1867). They defined a degenerative 
neuromuscular disorder that was hereditary. It is now established that DMD is an X-
linked congenital muscle wasting disease affecting approximately 1 in 3500 of all 
male births (Emery, 1991). Symptoms include progressive skeletal muscle 
degeneration leading to generalised muscle wasting and loss of function, particularly 
of the proximal muscle groups: First affected by wasting are legs and pelvis muscles 
followed by shoulder, neck and arm, and eventually respiratory muscles. The lost 
muscle is replaced by connective tissue and accompanying fibrosis hampers muscle 
regeneration further still. Cardiomyopathy is present but heart failure is not the 
leading cause of death (Mosqueira et al., 2013). DMD patients show the first 
symptoms in early childhood, typically lose ambulation by adolescence and the 
natural progression of this disease often leads to death in the second decade of life 
(Eagle et al., 2002). Death is most often caused by respiratory failure directly 
attributed to the progressive weakening of breathing muscle activity (Mosqueira et al., 
2013). With improved treatment and care strategies patients can live even into their 
40s and, subsequently, death by heart failure is becoming more common (Hermans et 
al., 2010). 
In addition to lethal muscle symptoms, DMD is also associated with less pronounced 
and often less known brain and bone phenotypes. Specifically, reduced cognitive 
ability is observed in many DMD patients (Rapaport et al., 1991; Anderson et al, 
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2002; Taylor et al., 2010). For instance, in one of the largest single centre studies, 
Taylor et al. (2010) reported that reduced full-scale intelligence quotients positively 
correlated with DMD gene mutations resulting in the loss of CNS dystrophin isoforms 
(see next chapters) that are expressed in specific brain regions as well as muscle 
(Lidov et al., 1990; 1993; 1995; Man et al., 1991; Gorecki et al., 1992; Lidov, 1996; 
Austin et al., 2000; Aleman et al., 2001). It is now recognised that the cognitive 
impairment is a pleiotropic effect of the mutant DMD gene in non-muscle tissues with 
other molecular factors contributing to the widespread phenotype. 
A second non-muscle abnormality associated with the DMD pathology is a reduced 
bone mineral density (BMD), evident even in childhood. Initially considered to be 
related to the known role of locomotion-induced mechanical stress contributing to 
normal bone development, low BMD is now considered another effect of the mutant 
DMD gene and not a result of reduced muscle loading alone (Hsu, 1982; Larson & 
Henderson, 2000).  
 
Molecular mechanisms of DMD 
The primary dysfunction in DMD is the loss of the cytoskeletal protein dystrophin 
(Hoffman et al., 1987a). Full length dystrophin is a large (427kDa) structural protein 
that couples the intracellular actin cytoskeleton of the muscle-fibre to extracellular 
matrix proteins. There are several isoforms of dystrophin, each derived from 
alternative transcription from one of at least seven promoters, many of which are 
tissue specific (for review see Blake et al., 2002). Further complexity arises due to 
alternative splicing of the primary transcripts, resulting in a plethora of structurally 
diverse dystrophin isoforms, which are expressed in a tissue-specific and 
developmentally regulated manner (Sironi et al., 2002). Full length dystrophin is 
comprised of four major domains, of which the N-terminus allows binding to actin via 
three main sites (Way et al., 1992; Norwood et al., 2000), and the cysteine rich C-
terminus allows sarcolemmal localisation and stabilisation via binding a unique set of  
dystrophin-associated proteins (see below) (Arahata et al., 1991; Sweeney & Barton, 
2000). The other two include central rod and cysteine-rich domains (Figures 1.1). 
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Although encoded for by the largest currently identified gene (~2.5 Mb) and 
encompassing over 14 kb, full-length dystrophin mRNA represents only around 0.01 
to 0.001 percent of total muscle transcripts (Hoffman et al., 1987a; 1987b). Protein 
expression, despite its functional importance, is similarly sparse (Hoffman et al., 
1987a). The subcellular location of dystrophin, rather than its load, is important for its 
function. Dystrophin helps to protect muscle from contraction-induced injury and is 
also important as an intracellular scaffold and binding partner, helping to regulate cell 
signalling via its interaction with a sarcolemmal protein complex termed the 
dystrophin-associated protein complex (DAPC; also referred to as the dystroglycan 
complex [DGC]) (Rando, 2001; 2002) (Figure 1.2). The core DAPC of skeletal 
muscle consists of  and -dystroglycans,  sarcoglycans and the sarcospan 
situated in and on the sarcolemma and of the intracellular -dystrobrevin and 
syntrophins. Dystroglycans form a receptor for extracellular matrix proteins such as 
laminin, agrin, and perlecan, while syntrophin and dystrobrevin have additional 
downstream interacting partners (see below). 
Muscle dystrophin interacts with the actin cytoskeleton via a binding site in the 30 
kDa N-terminal domain (Way et al., 1992; Norwood et al., 2000), while the C-
 
Figure 1.1. Schematic representations of the dystrophin gene and subsequent protein 
isoforms. The tissues in which isoforms are expressed and animal variants lacking 
particular isoforms are shown (from Willmann et al., 2009). 
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terminal domain interacts with DAPC members, thus linking the sub-sarcolemmal 
cytoskeleton to the cell membrane and further to the extracellular matrix (Figure 1.2) 
(Campbell & Kahl, 1989; Ervasti et al., 1990; Ervasti & Campbell, 1991; Ibraghimov-
Beskrovnaya et al., 1992). This link between the cytoskeleton, cell membrane, and 
extracellular matrix provides structural stability to the sarcolemma during 
physiological muscle contraction and stretch. The loss of mechanical stability of 
sarcolemma in the absence of dystrophin has been considered the key mechanism of 
DMD pathology and explains the elevated serum creatine kinase (CK) levels. 
 
 
 
Figure 1.2. Schematic representation of the dystrophin associated protein complex 
(DAPC) (from Rando, 2001). Grb2: growth factor receptor-bound protein 2. 
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The DAPC is also found in the central and peripheral nervous systems, in secretory 
tissues such as the pituitary gland (Pocsai et al., 2010), and at restricted access 
boundaries like the blood-brain and blood-testis barrier (Vajda et al., 2002; Nico et 
al., 2005; Lien et al., 2007; 2012), the choroid plexus (Haenggi et al., 2004), and in 
kidneys (Loh et al., 2001). Its composition in different tissues may vary from the 
skeletal muscle complex and it is anchored there by specific dystrophin isoforms.  
Therefore, loss of dystrophin leads to the destabilisation of the DAPC, which may 
directly contribute to muscle as well as non-muscle symptoms including the cognitive 
deficits observed in at least a subset of DMD patients (Taylor et al., 2010; Nardes et 
al., 2012). At the molecular level, the heterogeneous penetration of cognitive 
dysfunctions might be due to various mutations causing the loss of specific dystrophin 
isoforms whilst sparing other variants. The severity of mental retardation has been 
correlated with the loss or modification of C-terminal dystrophin regions, indicating 
the importance of distally located DAPC binding domains for the function of brain 
dystrophins (Moizard et al., 1998; Taylor et al., 2010).  
The loss or alteration of many of the proteins that make up the DAPC due to 
mutations of their encoding genes also result in a variety of specific muscle disorders 
of diverse severity. For instance, several of the limb girdle muscular dystrophies are 
caused by mutations in the genes for sarcoglycan and dystroglycan (Kaplan, 2011). 
This points to the importance of the complex. However, while the impaired 
sarcolemmal integrity and homeostatic function are recognised consequences of the 
loss of dystrophin and the DAPC, the downstream cellular and molecular events 
leading to specific DMD abnormalities are still not understood fully and some are 
subject of a long-lasting debate (Carpenter & Karpati, 1979; Fong et al., 1990; Turner 
et al., 1991; Yoshida et al., 1997). 
The lack of dystrophin reducing membrane resistance to mechanical stress can explain 
some but not all abnormalities in skeletal muscles and offers no explanation for 
altered cell signalling or pathology occurring in non-contractile tissues, for example 
the cognitive deficit associated with loss of specific dystrophin isoforms in the brain.  
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1.2 The mdx mouse as an animal model of DMD  
The use of animal models in the study of human diseases relies on the conservation of 
biology between related species. 
Several models of DMD are non-mammalian, such as zebrafish (Chambers et al., 
2001; Rubinstein, 2003) and C. elegans (Baumeister & Ge, 2002). Mammalian 
models include dystrophic dog (Cooper et al., 1988; Sharp et al., 1992), cat (Winand 
et al., 1994) and, the recently developed, pig (Klymiuk et al., 2013). The most widely 
used model for pre-clinical studies of DMD (http://treat-
nmd.eu/research/preclinical/dmd-sops/) is the mdx dystrophic mouse (Bulfield et al., 
1984). 
The mdx mouse was discovered as a spontaneous dystrophin mutant in 
C57BL/10ScSn line. It lacks full length dystrophin as a result of a cytosine to thymine 
missense mutation in exon 23 (Sicinski et al., 1989). The mRNA transcript with a 
premature stop codon is unstable, which results in its degradation and no protein 
translation. Therefore, both DMD patients and the mdx mouse share a common 
aetiology, which is the lack of a functional dystrophin protein. 
Despite a shared causal mechanism, the mdx mouse is not an exact model for human 
DMD. Progression of muscle degeneration follows a different time course in mdx 
mice to that seen in humans. The main difference is that mdx mice present a sudden 
onset of skeletal muscle necrosis, which peaks at 28 days and decreases to low-level 
degeneration-regeneration until the cumulative effects become more apparent again at 
later ages. The exception is mdx diaphragm, which shows progressive damage 
throughout life yet does not lead to significantly premature death. Several 
explanations have been offered for the overall less severe presentation of the disease 
in mdx mice. From a biophysical perspective, it has been noted that body-size 
dependent properties such as muscle force generation, tendon mass, and biomolecule 
diffusion do not scale linearly, relative to total mass, between mice and humans 
(Partridge, 2013). Also, the pattern of growth differs between humans and mice, 
where mice gradually and uniformly accrue weight over their juvenile-to-adolescent-
to-adult development, whilst humans undergo saltatory bouts of growth during early 
juvenile development and again during adolescence. Beyond these factors, there are 
species-specific features of a cellular and molecular nature. For instance, one of the 
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molecular differences used to explain, albeit partially, differences between the mdx 
mouse and human DMD patients is the compensatory expression of the dystrophin 
analogue, utrophin. This protein is found in adult mdx and DMD patients but 
considered to provide more protection in mice (Kleopa et al., 2006) where 
mdx/utrophin double mutants present with more severe phenotype (Grady et al., 
1997). Another example is a greater regenerative potential of satellite cells in mice 
relative to humans, which might depend on longer telomeres found in mice (Sacco et 
al., 2010) and, in general, DMD patients express fewer regeneration-associated genes 
than mdx mice (Turk et al. 2005).  
Nevertheless, the acute phase of dystrophic pathology provides an appropriate model 
for testing the pathological mechanisms as well as therapeutic approaches for DMD 
(Shelton & Engvall, 2005). Any delay in the onset of damage or improvement in 
disease parameters indicating alleviation of the disease progression in this acute phase 
can be easily detected. The mouse model of DMD is therefore accepted as the most 
suitable and affordable for pre-clinical studies of disease biology and the testing of 
new treatment modalities. The other mammalian models of DMD such as dog and pig 
are used for therapeutic studies in the more advanced stages as it is thought treatment 
strategies proven in these large animal models may be more applicable to humans 
(Partridge, 2013). Work with these larger mammals is considerably more expensive 
and it is less acceptable to perform terminal or invasive procedures for early-stage 
hypothesis testing in these more sentient species.  
In short, analyses and comparisons of pathological features and dystrophic processes 
in DMD patients and in animal models led to a much better understanding of disease 
mechanisms than would be afforded by studies using clinical material only.  
 
1.3 Downstream effects of the absence of dystrophin  
Major secondary systemic and cellular level abnormalities that are faithfully 
replicated in animal models of this disease include: 
 Chronic inflammation of dystrophic muscles. 
 Chronically elevated intracellular Ca2+ levels in skeletal muscle fibres. 
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 A regeneration defect, such that damaged muscle is increasingly less able to be 
repaired over time. 
 Cell signalling dysregulation. 
 A metabolic crisis, such that muscle becomes less efficient at utilising and 
managing nutrients. 
 Elevated levels of oxidative stress mediators. 
Many of these features of DMD are directly associated with the biology of the main 
affected tissue, namely skeletal muscles. In vertebrates, skeletal muscle accounts for 
up to half of the total body mass and thus represents the single largest organ. The 
primary function of skeletal muscle is voluntary force production, allowing body 
movement and stabilizing body position. To fulfil its role, skeletal muscle has a 
unique combination of properties including excitability, conductivity, contractility, 
extensibility, and elasticity, which allow the tissue to respond to and propagate 
signals, shorten when generating force and then return to its original shape.  
The main muscle cell, the myofibre, is a multi-nucleated and post-mitotic highly 
specialised and metabolically active cell containing finely tuned assemblies of 
contractile force-generating proteins. Its growth and repair are maintained by a 
resident stem cell population termed satellite cells giving rise to myoblasts, which can 
fuse with existing fibres or with each other to form new myofibres, thus re-enacting 
early muscle development. However, developmental pathways within individual 
muscles are different with significant changes in gene expression between head and 
trunk and between slow and fast myofibres (Mok & Sweetman, 2011; Porter et al., 
2001), with further complexity imposed by genetic modifiers active in specific muscle 
groups (Swaggart et al., 2011). This diversity, albeit not fully understood, appears 
responsible for specific muscle diseases affecting specific muscle groups or distinct 
muscle fibres only.  
Moreover, skeletal muscle is one of the major sites of glucose (Benito, 2011) and fatty 
acid (Phillips et al., 1996; Pan et al., 1997; Furler et al., 2001) homeostasis and also 
helps to control total body pH (Robergs et al., 2004; Kemp, 2005). These functions 
highlight the metabolic influence skeletal muscle imposes on the organism and can 
explain the widespread impact of muscle wasting.  
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Furthermore, in response to acute damage or in pathological states, muscle contains 
various infiltrating cells releasing molecules, which significantly influence the local 
microenvironment and contribute to its growth and repair but may also, when released 
into the bloodstream, affect distant organs (Pedersen & Febbraio, 2012). 
Muscle loading is a key catalyst for osteogenesis and increased bone mineral density, 
especially during adolescence (Slemenda et al., 1994; Wang et al., 2007). Reduced 
muscle loading contributes to the lower bone mineral densities of DMD patients 
(Bianchi et al., 2003; Soderpalm et al., 2007; Rufo et al., 2011; Mayo et al., 2012). 
The multicomponent nature of the DMD phenotype has been uncovered using global 
expression profiling strategies like microarray analysis. Chen et al. (2000) found 
multiple cellular pathways to be systematically altered in human DMD patients 
compared to healthy individuals. These included the overexpression of genes 
encoding for embryonic myosin heavy chain, inflammatory mediators, as well as 
those indicative of a general metabolic breakdown. All of these disease pathways have 
been later confirmed as differentially activated between dystrophic and non-
dystrophic muscles in both humans and mdx mice (Haslett & Kunkel, 2002; Haslett et 
al., 2002; Porter et al., 2002). Generally, it was found that more genes are upregulated 
than downregulated in dystrophic compared to healthy muscle, consistent with the 
degeneration-regeneration profile of a tissue containing increased numbers of 
activated endogenous and infiltrating cell types (Porter et al., 2002). Some disease-
related genes have been found expressed with a pathological weighting in DMD 
patients even at pre-symptomatic ages (Pescatori et al., 2007).  
 
Inflammation 
As many as 30% of all genes that are differentially expressed in DMD muscle are 
related to inflammation (Porter et al., 2002). Even before acute periods of 
degeneration, mdx mouse muscle is infiltrated by a variety of leukocytes 
predominately comprised of neutrophils, macrophages, and activated T-cells (Spencer 
et al., 2001; Wehling et al., 2001; Wehling-Henricks et al., 2008).  
Both the innate and the adaptive system responses are important in DMD. The form of 
inflammation present in dystrophic muscle is termed ‘sterile' as no pathogens are 
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involved and it may also be found in chronic inflammatory conditions including 
arthritis and atherosclerosis. The role of immunity in the pathology of DMD is 
consistent with the prevailing view that the immune system responds not only to ‘non-
self’, but also to autologous ‘danger’ signals (danger-associated molecular patterns; 
DAMPs). DAMPs can contain molecular patterns shared by microorganisms and 
cytoplasmic components but can also be self-molecules, such as adenosine 
triphosphate (ATP), heat shock proteins, reactive oxygen species (ROS), uric acid or 
high-mobility group box 1 (HMGB1), that are usually shielded from the immune 
system, or normally expressed at only marginal levels. Recognition of DAMPS is 
therefore believed to act as an alert to non-physiologic, necrotic cell death (Rock et al., 
2010; Lukens et al., 2012). 
Components of the innate immune system are recruited in response to DAMPS. 
Therefore, macrophages make up the bulk of inflammatory cells in DMD muscles 
(Spencer et al., 2001; Wehling et al., 2001; Evans et al., 2009). Along with 
neutrophils, this cell type is responsible for cytolysis, which may further exacerbate 
the inflammatory condition. However, macrophages infiltrating muscles are 
heterogeneous and the phenotype of these infiltrating macrophages changes upon 
acute muscle injury and over the course of disease progression. As found in the mdx 
mouse, at an acute degenerative period around 4 weeks of age, muscle is mainly 
infiltrated by type M1 macrophages (Villalta et al., 2009). This cell-type is largely 
responsible for the cytolysis of muscle fibres and is linked with the Th1 T-cell 
activation profile. Later in time, M2a and M2c macrophages increase in number 
(Tidball & Villalta, 2010). These macrophages have been found to reduce 
inflammation (Gordon, 2003; Martinez et al., 2008; Villalta et al., 2009) and promote 
regeneration of injured muscle, although they may also promote the extracellular 
matrix (ECM) build-up that is a well-known disease feature of dystrophic muscle 
(Vidal et al., 2008).  
The inflammatory response to muscle injury is different in DMD compared to that 
found in acute muscle injury, as the pro-inflammatory component dominates over the 
pro-regenerative one. The reason for this might be that DMD inflammation may also 
be coupled to a breakdown in peripheral tolerance to self-molecules (Tidball & 
Villalta, 2010), which appears to occur in chronic myopathic conditions. Dystrophin is 
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also immunogenic under certain circumstances. Moreover, other proteins that are 
normally excluded from muscle are found in the dystrophic tissue. For instance, the 
fibrin matrix precursor, fibrinogen, is found in human and mouse dystrophic muscle 
whereas it is restricted inside blood vessels in healthy subjects (Vidal et al., 2008; 
2012). Fibrinogen induces the classical inflammatory cascade, resulting in IL-1β, 
TNFα, and IL-6 release and thus exacerbates the problem.  
Therefore, therapies reducing inflammation have the potential to reduce DMD 
damage, providing that they would not result in reduced muscle regeneration. 
 
Altered muscle regeneration 
Protecting and enhancing dystrophic muscle regeneration is particularly important as 
dystrophic muscle precursor (satellite) cells develop a reduced potential for muscle re-
growth caused by a process of replicative senescence (Sacco et al., 2010). Satellite 
cells are able to respond to acute muscle injury but in the chronic disease state they 
become exhausted.  Muscle tissue in DMD patients, and to a lesser extent the mdx 
mouse (see above), progressively lose ability to regenerate properly. Myoblasts 
derived from patients with DMD have been shown to have a reduced differentiation 
potential in vitro (Melone et al., 1999). In this sense, muscular dystrophy mimics 
many other muscle wasting conditions such as cancer cachexia, diabetes, renal failure, 
heart failure, and age-related sarcopenia. 
 
Elevated intracellular Ca2+ and DMD 
Abnormal ion homeostasis is yet another secondary feature of DMD pathology. This 
includes an increase in intracellular Ca2+ (Bodensteiner & Engel, 1978; Bertorini et 
al., 1982; Dunn & Radda, 1991) and Na+ (Dunn & Radda, 1991; Dunn et al., 1993), 
although the rise in Ca2+ is considered more important for disease pathogenesis or 
progression and it is indeed one of cellular hallmarks of DMD. 
Experimentally introduced intracellular Ca2+ is sufficient to cause a dystrophic 
phenotype in mice, independent of sarcolemmal membrane fragility (Millay et al., 
2009) while drugs that reduce intracellular Ca2+ levels significantly reduced muscle 
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degeneration in mdx mice in vivo (Iwata et al., 2005). Furthermore, the majority of 
proteolytic activity in damaged muscle is considered the result of an increased level of 
cytosolic Ca2+, subsequent calpain activation (Spencer et al., 1995; Spencer & 
Mellgren, 2002), and thiol protease activity also independent of lysosomal 
degradation pathways (Zeman et al., 1985; Furuno & Goldberg, 1986; Goldberg et al., 
1986). Additionally, a chronic increase in intracellular Ca2+ has been implicated in 
altered developmental program in adult myofibres associated with aforementioned 
reduced differentiation potential (Chen et al., 2000). 
Despite endogenous differences in the basal levels of cytosolic Ca2+ between mice 
(~82nM) and humans (~55nM), the loss of the full-length dystrophin was shown to 
result in an attenuated Ca2+ regulation in single fibre in vitro assays in both models 
(Fong et al., 1990). This reduction in Ca2+ regulation was deemed more pronounced 
when there was a higher extracellular Ca2+ level, indicating the involvement of a 
calcium leak channel (Turner et al. 1991; for review see Whitehead et al., 2006). Ca2+ 
sequestration impairment in dystrophic muscles also has the potential to contribute to 
this ionergic disease pathway (Culligan et al., 2002; Goonasekera et al., 2011).  
 
Cell signalling abnormalities resulting from the absence of dystrophin 
Lack of dystrophin leads to disruption of the DAPC and the aforementioned decrease 
in sarcolemmal stability. In addition to these structural abnormalities, lack of 
dystrophin also results in the loss of anchoring for cell signalling molecules. The best 
known example is the neuronal nitric oxide (NO) synthase (nNOS). nNOS is a 
constitutive protein present within muscle cells and is localised to the intracellular 
side of cell membrane via an attachment to syntrophins within the DAPC (Miyagoe-
Suzuki & Takeda, 2001) (Figure 1.2). Metabolic instability and muscle sarcolemma 
breakdown has been partly ascribed to the delocalisation of nNOS in the absence of 
dystrophin in DMD (Li et al., 2011b). At the cell membrane, NO donated by nNOS is 
thought essential for promoting satellite cell activation and fusion but when 
delocalised it may contribute to overall nitrosative stress leading to nitrosylative 
protein modifications and the loss of muscle force (Eu et al., 2003; Bellinger et al., 
2008a; 2008b; 2009). 
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A less understood abnormality resulting from the absence of dystrophin involves 
extracellular ATP (ATPe) breakdown. Signalling by ATPe (see below) is regulated by 
specific mechanisms such as direct receptor desensitization and degradation of ATP 
by ecto-ATPases present in the extracellular space (Robson et al., 2006). The latter 
both eliminates the ATP and generates new signalling molecules (ADP, adenosine) 
with actions often opposing those of ATP. In addition to nucleoside triphosphate 
diphosphohydrolases (NTPDases) and ectonucleotide pyrophosphatase/ 
phosphodiesterases found expressed in muscles (Yegutkin, 2008), the -sarcoglycan 
of the DAPC (Figure 1.2) has been found to be an atypical ATP-hydrolase activated 
by very high ATP concentrations (Betto et al., 1999; Sandona et al., 2004). In 
myotubes in vitro, about 25% of the overall ATP-hydrolyzing activity has been 
ascribed to -sarcoglycan. In dystrophic muscles, sarcoglycan is depleted or missing, 
which affects the ectoATPase-mediated regulatory circuit and tips the balance towards 
ATP release over degradation. Moreover, mutations in the sarcoglycan gene result in 
limb-girdle muscular dystrophy despite the presence of dystrophin and generally 
intact links between intracellular cytoskeleton, the cell membrane, and extracellular 
matrix proteins (Lim & Campbell, 1998). This points to the importance of this DAPC 
member in the dystrophic pathology.  
 
1.4 ATP signalling and the dystrophic pathology  
Several of the secondary abnormalities in dystrophin-deficient muscles, such as 
decreased ATPe degradation due to loss of ectonucleotidase activity of -sarcoglycan, 
the chronic inflammation, and increased intracellular Ca2+ levels in dystrophic fibres, 
may suggest ATP signalling alterations in dystrophic tissues. ATP is a nucleotide best 
known for its role in cellular metabolic processes, providing the final hydrolysable 
energy source for numerous ATPase controlled mechanisms. In skeletal muscle, ATP 
is normally present in cell cytoplasm at levels reaching ~5-9mM (Hochachka & 
Matheson, 1992; Kushmerick et al., 1992; Hetherington et al., 2001), where it is 
regularly hydrolysed to drive the actin-myosin cross-bridge cycle, leading to muscle 
contraction (Drury & Szent-Gyorgyi, 1929; Lymn & Taylor, 1971; Ma & Taylor, 
1994; Gordon et al., 2000; Barclay, 2003). Since the pioneering work of Burnstock in 
the 1970s (Burnstock, 1971; 1972), it has been confirmed that under physiological 
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conditions small quantities of ATP are released and this ATPe acts as autocrine and 
paracrine signalling molecule (Burnstock, 2006). For example, at the neuromuscular 
junction ATP is released with acetylcholine (ACh) to potentiate skeletal muscle fibre 
contraction (Buchthal & Folkow, 1948).  
While small amounts are released under physiological conditions, very high levels of 
ATPe are released from injured muscles and, acting as a DAMP, can promote 
inflammatory cell infiltrations (see below).  Therefore, ATPe in skeletal muscle can 
be involved in a range of processes, from physiologically beneficial to pathologically 
catastrophic.  ATP exerts these actions via activation of specific purinoceptors.  
 
P2 receptors 
The physiological and pathological actions of ATP are mediated by specific 
transmembrane receptors (Burnstock & Kennedy, 1985). These purinergic receptors 
consist of two families of nucleotide gated transmembrane proteins. One set, the 
metabotropic P2Y, are G-protein coupled receptors (GPCRs) linked to a variety of 
intracellular signalling cascades that are driven by primary effector proteins including 
phospholipase C, adenylate cyclase, and the small soluble GTPase RhoA. Eight P2Y 
(1, 2, 4, 6, 11, 12, 13, and 14) receptor subtypes responding to purines have been 
identified so far in man (for review see Erb et al., 2006). Although several P2Y 
receptors have been identified in skeletal muscles they are not the subject of this work 
and therefore will not be discussed further. 
The other family is ionotropic P2X receptors, ATP gated ion channels with seven 
identified subtypes (P2X1-7) having various affinities for ATPe. The P2X receptors 
are transmembrane proteins between 379 (P2X6) and 595 (P2X7) amino acids in 
length that display 40-50% protein sequence homology. Each P2X receptor consists 
of two transmembrane domains separating a large extracellular loop from cytoplasmic 
C- and N-termini (North, 2002; Kawate et al., 2009) (Figure 1.3).  
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Figure 1.3. Schematic representation of a P2X receptor. This receptor has a single ~280aa 
extracellular-loop and two trans-membrane domains (M1 and M2) separating intracellular N- 
and C-termini. The extracellular loop is shown with 10 conserved cysteine residues that may 
allow disulphide bridge formation. (adopted from Dunn et al., 2001). The ATP binding site is 
located within the extracellular loop of the protein. The most up-to-date models for the 
receptor class are derived from zebrafish P2X4 crystallography study (Kawate et al., 2009; 
Hattori & Gouaux, 2012). 
P2X receptor subunits co-assemble into homo- or hetero-trimers to form a functional 
receptor channel (Nicke et al., 1998; Barrera et al., 2005; Gonzales et al., 2009; 
Kawate et al., 2009; Li et al., 2010b).  
These receptors, when activated, form a non-selective pore permeable to small 
cations, including Ca2+. When the channel is in its open state, cations are allowed to 
travel along an electrochemical gradient. P2X2, 2/3, 2/5, 4, and 7 receptors can also 
exhibit multiple open states in response to ATP, characterized by a still ill-understood 
permeability to larger (molecular weights of several hundred Da) molecules such as 
N-methyl-D-glucamine (NMDG) or ethidium bromide (Khakh et al., 1999; Virginio 
et al., 1999; Compan et al., 2012; Browne et al., 2013). The P2X receptors are 
variously sensitive to their primary ligand ATP, with P2X7 displaying the lowest 
sensitivity to ATP coupled with a slow desensitisation (Gever et al., 2006). The P2X7 
receptor is structurally notable amongst the P2X receptors for possessing a long C-
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terminal tail, accounting for the majority of the increased amino acids in the 
polypeptide sequence (Figure 1.4). 
During development and regeneration in adults, muscle fibres in species ranging from 
chick to rodents to humans have been shown to express P2Y1 and 2 (Tung et al., 
2004), and P2X1, 2, 4, 5, 6, and 7 receptors (Ryten et al., 2001; 2004; Jiang et al., 
2005; Yeung et al., 2006). Our understanding of the specific physiological roles of 
these receptors is, however, still incomplete. They have been implicated in numerous 
cellular processes, including, but probably not restricted to, the proliferation of 
myoblasts (Martinello et al., 2011), the differentiation of myotubes (Ryten et al., 
2002), vasoconstriction, ion homeostasis, and apoptosis. 
For example, secondary myotube generation and ACh expression was related to 
P2X2, P2X5, and P2X6, expression in developing rat skeletal muscles (Ryten et al., 
2001; 2002). It was also shown that P2X7 receptors may have a role in proliferation 
and differentiation in C2C12 mouse skeletal muscle cells (Araya et al., 2004; 
Martinello et al., 2011).  
P2X1 receptors have been found to mediate vasoconstriction and blood flow is 
integral to maintaining the metabolic integrity of skeletal muscle (Buckwalter et al., 
2003; 2004; Kluess et al., 2005a; 2005b). However, this effect has been linked with 
P2X1 receptor expression in smooth muscles (Ralevic & Burnstock, 1996; Lewis & 
Evans, 2000a; 2000b; Jiang et al., 2005). 
In addition, several P2X receptors have been implicated in paracrine/autocrine 
signalling especially related to inflammation. It is in this second role, signalling in 
pathological conditions, where specific P2X receptors have been found of particular 
importance for the pathogenesis of DMD.  
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Figure 1.4. P2X7 receptor amino acid sequence comparison across species. Amino acid 
sequences corresponding to both transmembrane domains (TM1 and TM2) are highlighted. 
Noticeable is the conserved length across mammalian P2X7 receptors of different species 
despite the pronounced polymorphisms (blue colour indicates less conserved residues and red 
indicates highly conserved ones). Query submitted to NCBI: BLAST. 
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Purinergic receptor involvement in skeletal muscle pathology 
It has been predicted that that at ATPe concentrations in excess of 100μM, 
ectoATPases cannot cope with ATPe overload (Bodin & Burnstock, 1996). Taking 
into account that skeletal muscle has the largest ATP reserves of all tissues, it seems 
unlikely that ecto-ATPases would abate the effects of cellular ATP released from 
damaged cells. When combined with decreased ectoATPase activity in the absence of 
sarcoglycan, ATPe levels would become high, forming an environment that would 
clearly favour over-activation of P2 purinoceptors. This led our laboratory to 
hypothesise that the dystrophic phenotype may involve abnormalities in purinergic 
signalling. DNA microarray analysis of dystrophic muscle from mdx mice revealed 
upregulated expression of P2X4 purinoceptor transcripts (Porter et al., 2002) that may 
be caused by infiltrating macrophages. This finding is consistent with a very strong 
inflammatory component associated with the DMD pathology (Ichim et al., 2010). It 
is also the case that tissue macrophages express P2X4 in addition to the P2X7 
purinoceptor (Yeung et al., 2004).  
Intriguingly, further studies showed that mdx myoblasts expressed significantly higher 
levels of P2X7 purinoceptor proteins than wild type controls (Young et al., 2012). 
This up-regulated P2X7 purinoceptor expression has been shown to be retained 
following the differentiation of dystrophic mouse myoblasts to myotubes. Moreover, 
elevated expression and function of P2X7 purinoceptor in dystrophic skeletal muscle 
groups have been demonstrated in situ (Yeung et al., 2004; 2006; Young et al., 2012). 
These observations correlated with an earlier discovery of an altered P2X7 
purinoceptor function in DMD patient lymphoblasts (Ferrari et al., 1994). 
 
1.5 P2X7 and DMD 
Among the P2X receptors, P2X7 has many properties that make it well suited to 
potentiate DMD disease characteristics. P2X7 purinoceptors are activated by a much 
higher [ATPe] concentration than other P2X purinoceptors. Thus, P2X7 has been 
dubbed a “danger receptor” responding to excessive, non-physiologic ATPe levels 
(“danger signal”) released in cases of necrotic cell death. The P2X7 receptor is also 
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known as the canonical death receptor, due to an association with both apoptotic and 
necrotic pathways in numerous cell types (Schulze-Lohoff et al., 1998; Wang et al., 
2004; Kong et al., 2005; Sugiyama et al., 2005; 2010; Haanes et al., 2012).  
The up-regulated expression and function of P2X7 purinoceptors in dystrophic cells 
suggests that it may there play roles that were recognized in several other disorders.  
The well-documented involvement of P2X7 purinoceptors in ATP-induced cell death 
and in release of immune/inflammatory modulators (see below) is of particular 
relevance in dystrophic muscles, where degenerating fibres provide potential sources 
of ATPe at concentrations exceeding those that could be reached anywhere else in the 
body. Death of myofibres would exacerbate the disease while death of myoblasts 
would further prevent their regeneration. 
In humans, P2X7 cDNA has been detected under physiological conditions in a variety 
of tissue types, including glia (Pannicke et al., 2000; Wang et al., 2002; Chen et al., 
2008; Murphy et al., 2012), airway epithelia (Groschel-Stewart et al., 1999), salivary 
glands (Soltoff et al., 1990; Nakamoto et al., 2009), pancreas (McMillian et al., 1993; 
Christoffersen et al., 1998; Novak et al., 2010), pituitary gland (Kimm-Brinson et al., 
2001), kidney (Rassendren et al., 1997; Harada et al., 2000; Hillman et al., 2002), 
skin fibroblasts (Solini et al., 1999), smooth muscle (Cario-Toumaniantz et al., 1998), 
cells of haematopoietic origin including osteoblasts, osteoclasts and most innate and 
adaptive immune cells (Collo et al., 1997), as well as in skeletal muscle (Rassendren 
et al., 1997). 
It is now recognised that, in certain cellular contexts, basal activation of P2X7 may be 
pro-survival and growth promoting (Adinolfi et al., 2005a; 2005b; Di Virgilio et al., 
2009). The relative significance of either cell death or growth-promoting effects 
depend on the expressing cell type but data from our laboratory suggests that in 
myoblasts P2X7 stimulation is able to switch between tonically beneficial (e.g. 
growth), and excitotoxically catastrophic effects depending on the receptor expression 
and ATPe levels.  Enhanced P2X7 receptor activation in dystrophic muscle cells leads 
to a whole range of effects including increased intracellular Ca2+ levels, extracellular-
signal-regulated kinase (ERK) phosphorylation, altered muscle regeneration potential 
(Yeung et al., 2006; Young et al., 2012) and autophagic cell death (Young et al., 
2015). 
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Based on pharmacological experiments, Ca2+ imaging studies, and protein expression 
comparisons, it is reasonable to suppose that P2X7 receptors could contribute to the 
significant increase in intracellular Ca2+ in dystrophic muscle (Ryten et al., 2004; 
Yeung et al., 2006; Young et al., 2012). The myofibre damage in DMD has been 
shown to result from increased cytosolic Ca2+ levels that is not attributable to 
sarcolemmal damage alone (Millay et al., 2009). While abnormal increases in Ca2+ 
influx via L-type, transient-receptor-potential, and stretch-activated channels into mdx 
myotubes have been documented (Vandebrouck et al., 2002; Millay et al., 2009; 
Kumar et al., 2004; Friedrich et al., 2004; 2008) further increases could be caused by 
the elevated expression and activity of P2X7 ion channels. 
Additionally, upon prolonged activation, the P2X7 receptor has the capacity to form 
or to promote formation of a transmembrane pore capable of passing large molecules 
into the cell (Ferrari et al., 1996; Browne et al., 2013). This pore formation allows 
massive influx of ions and release of the intracellular content (DAMPs), therefore 
facilitating a sterile inflammatory response that can ultimately lead to cell death. 
Therefore, P2X7 stimulation has the potential to mediate muscle cell lysis also via the 
activation or modification of a sterile inflammatory response. In this regard, P2X7 
receptor overexpression has been linked to numerous chronic inflammatory conditions 
including rheumatoid arthritis (Baroja-Mazo & Pelegrin, 2012), atherosclerosis 
(Solini et al., 1999), glomerulonephritis (Turner et al., 2007), and Crohn’s disease 
(Kurashima et al., 2012). Again related to the relative expression of P2X7 receptors, it 
has been shown that 1) the receptor responds to ATP as an autocrine/paracrine danger 
sensor and 2) the receptor may be modulating the immune cell phenotype to promote 
prolonged pro-inflammatory infiltrations. In one recent example, P2X7 receptors were 
implicated in the deterioration of immune self-tolerance known to perpetuate chronic 
inflammatory psoriasis (Mathers et al., 2012). In another example study, 
pharmacological inhibition of P2X7 receptors was used to improve post cardiac 
transplant survival rates in a mouse model (Vergani et al., 2013).  
Considering that inflammation is a hallmark of DMD, the abnormal function of P2X7 
purinoceptors appears to close the loop whereby damaged dystrophic muscle would 
release large quantities of ATP but also other autologous DAMPs, which initiate and 
perpetuate immunity in response to tissue damage. Infiltrating macrophages, as 
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described earlier, have been shown to contribute to both skeletal muscle degeneration 
and regeneration. This intricacy of crosstalk between myoblasts, macrophages, 
and probably other cell types in dystrophic muscles, as well as the balance 
between tonically beneficial (e.g. growth) and toxic, catastrophic, effects of P2X7 
purinoceptor activation on myoblasts and muscle fibres, requires elucidation. 
This signalling network has a potential fundamental influence over disease 
progression and thus presents a good candidate target for pharmacological 
interventions, providing that P2X7 blockade could alleviate muscle damage without 
down-regulation of potentially beneficial regenerative processes.    
One of the fundamental strategies used in functional investigations of P2X7 receptors 
has been the generation and analyses of mice in which the P2X7 gene has been 
disrupted.   
 
1.6 P2X7 knock-out mice and their relevance to this study 
There are currently two P2X7 KO mice available for use. These were created by 
researchers working for Glaxo Smith Kline (Chessell et al., 2005) and Pfizer (Solle et 
al., 2001). The Glaxo P2X7r KO mouse contains a lacZ insertion in exon 1 (of 13) of 
the P2X7 gene, whilst the Pfizer KO mouse has a neomycin cassette replacing a 
region of exon 13 (also see Methods 2.1 and Results 3.3.1). Both mice are viable and 
superficially indistinguishable from wild-type controls. Analyses of P2X7 KO mice, 
from either Glaxo or Pfizer, have supported hypotheses indicating the involvement of 
the purinergic receptor in numerous biological pathways. For instance, the P2X7 
receptor has been linked with IL-1β maturation and release from macrophages (Solle 
et al., 2001) and adjuvant-induced inflammation and neuropathic pain (Chessell et al., 
2005). These observations reflect the aforementioned associations between P2X7 and 
chronic inflammatory conditions. In other studies the P2X7 KO mice were used to test 
associations between the receptor and diseases. In one example, the Glaxo P2X7 KO 
mouse showed significant renoprotection in an established model of 
glomerulonephritis (Taylor et al., 2009b) and P2X7 KO reduced collagen deposition 
and TGFβ levels (Goncalves et al., 2006). In another study, Pfizer P2X7 KO mice 
were protected from experimentally induced carotid artery thrombosis (Furlan-
Freguia et al., 2011). The P2X7 KO mice have, therefore, an established role in 
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testing the involvement of this receptor in disease and there are clear similarities in 
pathobiology between several of the abovementioned disorders and DMD, for 
instance associated with immune and inflammatory responses.  
The two P2X7 receptor KO animals differ in important ways, precluding their use as 
interchangeable KO models. Indeed, our laboratory has been involved in 
identification of the molecular differences in both available P2X7 KO mouse strains 
(Nicke et al., 2009; Masin et al., 2012). The Glaxo P2X7 KO mouse is a hypomorph 
where one of the receptor isoforms, the P2X7 ‘K’ variant, resulting from the use of an 
alternative promoter, escapes inactivation (Nicke et al., 2009). Although expressed at 
very low levels, P2X7 ‘K’ is highly active when compared to the predominant full-
length ‘A’ variant and can explain the residual responses observed in some tissues 
from this KO. The biological significance of this P2X7 variant is unclear as it is not 
found in man but, in terms of this study, the Glaxo P2X7 KO mouse has been 
considered against the full-functional Pfizer P2X7 KO for effects of dose-
dependency, to compare cellular and biochemical features of mdx dystrophinopathy 
between the two models. To establish the impact of the P2X7 receptor on the 
dystrophic pathology and to assess its suitability as a specific therapeutic target, we 
have used selective breeding to develop two lines of mdx mice with the P2X7 gene 
disrupted (see 1.8 Aims and hypothesis for a more detailed breakdown of 
subsequent work-flow).  
 
1.7 Summary: a recapitulation 
DMD is a complex disease involving cell-structural and metabolic abnormalities, for 
which there are currently palliative therapies only. Skeletal muscle is an important 
organ, ordinarily helping to regulate total body metabolism, blood pH, and 
osteogenesis, in addition to being the primary effector unit of voluntary force 
production. Downstream of dystrophin absence, secondary pathological features of 
DMD include the loss of the DAPC and the accompanying mechanical tether between 
the intracellular actin cytoskeleton and extracellular matrix proteins; an increase in 
muscle intracellular Ca2+; a reduction in muscle regeneration potential over increasing 
cycles of degeneration and regeneration; chronic inflammation; delocalised cellular 
nNOS leading to increased protein nitrosylation and reduced potential for muscle 
force generation; a neurological deficit; and an osteopenic phenotype with increased 
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risk of bone fracture. Although it is likely that DMD pathology includes many other 
salient cellular and molecular features, all of the above mentioned pathways are 
shared, to a greater or lesser extent, between mice and humans. 
The P2X7 receptor shows increased expression in dystrophic mouse muscle cells 
compared to healthy controls, in vitro, and at both acute degenerative and regenerative 
phases of disease progression in vivo. Furthermore, dystrophic muscle cells are more 
sensitive to ATP induced permeablisation and calcium build-up, as well as phospho-
ERK1/2 activation. 
Given the known role of the receptor in cell death and growth processes, and related 
to the potential of the receptor to mediate chronic inflammatory conditions, it was 
decided to further explore the role of P2X7 in the pathogenesis of DMD, using a well-
established model of this disease, the mdx mouse. By comparing the mdx mouse to 
two dystrophic P2X7 KO (dKO) mice according to several key cellular and molecular 
disease parameters, it was hoped to derive particular biological functions of the P2X7 
receptor in DMD disease progression. It was expected that, by removing P2X7 
function, it would be possible to alleviate mdx disease pathology, also providing data 
relevant for the evaluation of the potential for P2X7 pharmacological interventions 
with recourse for clinical therapeutic purpose in human DMD patients (Figure 1.5). 
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Figure 1.5. Schematic depiction of hypothetical involvements of the P2X7 receptor in mdx 
and DMD pathogenesis. a) Loss of dystrophin leads to multiple secondary molecular, 
cellular, and system level disease features. Each of these may be exacerbated by P2X7 hyper-
activation. b) The P2X7R is depicted as mainly coinciding and slightly preceding 
pathological progression over non-linear time. Pathology is here defined as the sum of the 
compounding and interacting disease features depicted in ‘a’. In mdx hindlimb skeletal 
muscle, the phase of acute degeneration begins after ~3 weeks and is waning from ~6 weeks 
(top panel). Natural progression of the disease also results in late-term atrophy and disease 
pathology, including exaggerated fibrosis, that we have provisionally ascribed to one 
published time-point, at 62 weeks (Pastoret & Sebille, 1995). Our hypothesis is that P2X7R 
ablation may be capable of reducing or delaying pathology over disease development (Purple 
trajectory). Onset and disease severity may also be modified in an activity dependent manner, 
such that exercised mdx mice would present increased pathology, but this has not been 
purposefully integrated into this model. In mdx diaphragm, disease progression is considered 
progressive, similar in principle to human DMD, in general (lower panel).   
Chapter 1: General introduction 
Page 45 
1.8 Hypothesis, aims, and objectives  
The main aim of this study is to evaluate the effects of P2X7 receptor knock-out on 
histological, biochemical, molecular, and functional parameters of mdx pathology. 
Given the known roles of P2X7 in cell death, chronic inflammatory diseases, and its 
functional upregulation in dystrophic mouse muscle, this receptor has the potential to 
exacerbate multiple aspects of mdx disease progression through triggering muscle cell 
death, abnormal regeneration and Ca2+ homeostasis, as well as maintaining chronic 
inflammation. It is hypothesised that inactivation of the P2X7 receptor will 
ameliorate disease in the mdx mouse model of muscular dystrophy.  
Specific objectives are as follows: 
 To characterise mdx/P2X7-/- double mutant mice generated by crossing mdx with 
two different strains of P2X7 KO mouse and to compare morphological and 
molecular parameters at the acute phase of muscle disease progression in 4 week 
old mice. 
 To profile P2X7 receptor expression and co-localisation with immune cell sub-
populations in mdx skeletal muscle and to compare infiltrating cells between 4 
week old mdx and mdx/P2X7-/- muscles 
 To measure and compare functional aspects of disease such as sarcolemmal 
breakdown and muscle force generation ex vivo and in vivo. 
 To test the influence of P2X7 depletion on secondary features of dystrophic 
pathology by comparing bone mineral density and in behavioural tests in vivo in 
mdx and mdx/P2X7-/- mice. 
 To perform preliminary pharmacological experiments in vivo on the effects of 
administration of P2X7 antagonist, CBB, on serum CK levels at the acute phase 
of muscle disease progression in 4 week old mice. 
 Histologically assess aged diaphragm and heart tissue, to see if mdx disease 
pathology continues to be alleviated or is worsened over a longer-term by P2X7 
ablation. 
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2 
Materials and methods 
 
2.1 Animals 
Mice were bred and maintained in a controlled environment (12 hour light/dark cycle, 
19-23ºC ambient temperature, 45-65% humidity). They were fed a standard pellet diet 
(Economy rodent breeder diet, Special Diet Services, Witham, UK) and allowed tap 
water ad libitum. 
To limit heterogeneity in outcome measures, only male mice were used for 
experimentation. 
Mice were killed by CO2 asphyxiation followed by cervical dislocation. 
Wild-type control 
The C57BL/10ScSnJ wild-type (WT) mouse strain was used as a healthy control 
(Jackson laboratory s/n: 000476; from here abbreviated to C57 BL/10). This mouse 
was derived from the C57BL/10J sub-strain. 
DMD mouse model 
The dystrophic mouse used in this study was the C57BL/10ScSn-Dmdmdx/J (Jackson 
lab. s/n: 001801; abbreviated to mdx). This mouse was discovered in 1976 as a 
spontaneous mutant in C57BL/10ScSn mice at the Agricultural Research Centre, U.K 
(http://jaxmice.jax.org/strain/001801.html). 
P2X7 knock-out mice 
Two P2X7 receptor KO mice were used in this project. 
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One P2X7-/- KO mouse (Jackson lab s/n: 005576) was created in the C57BL/6 strain 
by introduction of a neomycin resistance cassette into exon 13 of the P2X7 gene. This 
mouse was created by Christopher A. Gabel of Pfizer Pharmaceuticals (Solle et al., 
2001). In this study we refer to this animal as Pfizer P2X7-/- KO. 
The other P2X7-/- KO mouse was also created in the C57BL/6 mouse, this time by 
insertion of a LacZ gene into exon1 of the mouse P2X7 gene. This mouse was created 
by researchers working for Glaxo Smith Kline (Chessell et al., 2005). In this study we 
refer to this animal as Glaxo P2X7-/- KO. 
mdx/P2X7 double-KO mice 
Two mdx/P2X7-/- dKO mice were generated by selective breeding of mdx with either a 
Pfizer or Glaxo dKO (Figure 2.1). A female mdx mouse was crossed with a male 
homozygous KO mouse from one of two P2X7 KO mouse strains, developed by 
Pfizer and Glaxo. From the subsequent litter, all male F1 mice were dystrophic and 
P2X7+/- heterozygous. Back-crossing these males with parental P2X7+/+ mdx females 
led to a heterogeneous litter composed of 100% dystrophic males, of which 50% were 
P2X7+/+ and 50% were P2X7+/-. Genotyping was used to select P2X7+/- heterozygous 
males and females. These P2X7+/- mdx males and females were crossed. Mating 
individuals from this litter together resulted in a litter of 100% dystrophic animals of 
which 25% were also P2X7-/-. Double mutant individuals from this cross were 
identified via genotyping to establish the mdx/P2X7-/- colony. The characterisation of 
the resultant litters are defined in Chapter 3. 
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2.2 Ethical considerations 
The major ethical consideration in this study related to the use of an experimental 
mouse model for biomedical research. University local ethical approval and Home 
Office licenses have been granted for the use of animals in this research. All mice 
were processed in accordance with recommended UK Home Office animal welfare 
guidelines governing the treatment of experimental animals  
(https://www.gov.uk/research-and-testing-using-animals). 
 
 Mouse husbandry, including day-to-day cleaning and monitoring of animal living 
conditions, was performed by specialist senior animal technicians under the 
Fig 2.1. Diagram of the breeding scheme implemented to generate the mdx/P2X7-/- mouse 
line. Semi-colons indicate chromosome separation. Small black arrows indicate 
movement of a genotype for reuse in another breeding. Large arrows indicate the result of 
a breeding: Brown arrows depict useful genotypes, white showing other genotypes. Also 
note, the F2 litter is 50% P2X7+/- and 100% dystrophic independent of sex, hence dmd 
alleles are not shown.
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supervision of a veterinary surgeon. This team have been trained and have experience 
to identify symptoms of disease and stress in the mice, and can react appropriately to 
minimise suffering or to aid recovery. This can also include removing specific 
animals from certain test regimes if conditions change or humanely killing animals 
whose health deteriorates without signs of improvement. 
  
 Various levels of animal discomfort are to be expected in many experimental 
procedures involving animals. All procedures used in this study, including breeding of 
harmful mutants (knockout mice), general handling, occasional collecting of ear 
punches for genotyping, and the use of intraperitoneal injections for drug delivery, are 
classified as “Mild” or below (unclassified) according to the Home Office directives. 
Mdx or P2X7 receptor knockouts are known to be mild conditions not associated with 
pain or decreased viability. Adopting the 3R principles, every attempt was made to 
minimise any discomfort associated with experimental procedures. All the 
preliminary testing of the effects of P2X7 receptor inhibition that could be performed 
in vitro has been completed for previous published studies (Jiang et al., 2005; Yeung 
et al., 2004; 2006; Young et al., 2012; Masin et al., 2012). There is no reasonable 
non-animal alternative to test the effects of receptor ablation on this complex disease 
involving interplay between muscle degeneration and regeneration, inflammation, as 
well as bone and CNS abnormalities. 
 The numbers of animals used in each experiment were based on statistical power 
calculations (e.g. appendix 9.10) and previous experience with specific methods. To 
minimise the numbers of animals euthanised, as many individual tissues were 
collected from each animal as was possible. Samples not immediately used were 
stored. 
 
2.3 List of reagents 
Product Manufacturer Associated assay(s)* 
2-Methylbutane Sigma Aldrich Cryosectioning 
Acetic acid, glacial Sigma Aldrich Masson’s Trichrome 
Acrylamide/bis (30%) Bio-Rad Laboratories Western blotting 
Agarose Life Technologies Nucleotide electrophoresis 
Agarose gel loading buffer Life Technologies Nucleotide electrophoresis 
Ammonium chloride Sigma Aldrich Immunolocalisation 
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Ammonium persulphate [APS] Sigma Aldrich Western blotting 
Aniline blue diammonium salt Sigma Aldrich Masson’s Trichrome 
β-mecaptoethanol Sigma Aldrich Western blotting 
Bicinchoninic acid [BCA] Sigma Aldrich Protein quantification 
Bovine serum albumin [BSA] 
(1mg/mL) 
Sigma Aldrich Protein quantification 
Calcium chloride Sigma Aldrich Tissue bath 
Chemiluminescent substrate, 
Luminata Crescendo 
Merk Millipore Western blotting 
Chemiluminescent substrate, 
Luminata Forte 
Merk Millipore Western blotting 
Chloroform Sigma Aldrich RNA extraction 
Complete Lysis-M protein 
extraction reagent 
Roche Applied Science Protein extraction 
Complete Mini Protease Inhibitor 
Cocktail Tablets 
Roche Applied Science Protein extraction 
Coomassie Brilliant Blue G [CBB] Sigma Aldrich P2X7 inhibitor study 
Copper (II) sulphate (4% w/v) Sigma Aldrich Protein quantification 
DDH2O, RNase free Thermo Scientific Many 
DNA ladder, 100 bp Life Technologies Nucleotide electrophoresis 
DNA ladder, 1 kb Life Technologies Nucleotide electrophoresis 
DNA polymerase, Taq Life Technologies PCR 
DNA polymerase buffer (x5) Life Technologies PCR 
DNeasy™ blood and tissue DNA 
extraction kit 
Qiagen DNA extraction 
dNTPs Life Technologies PCR 
Dibutyl Polystyrene Xylenes 
synthetic mounting media [DPX] 
Thermo Scientific Histology 
ethylenediaminetetraacetic acid 
[EDTA] 
Sigma Aldrich Buffer constituent 
Eosin Y solution, alcoholic Vector Labs Histology 
Ethanol Thermo Scientific Many 
Fluor Save™ fluorescence 
mounting media 
Merk Millipore Immunolocalisation 
Glacial acetic acid Sigma Aldrich Buffer constituent 
Glucose Sigma Aldrich Tissue bath 
Glycerol Sigma Aldrich Nucleotide electrophoresis 
Glycine Sigma Aldrich Western blotting 
GoTaq® 2xGreen Master Mix Promega PCR 
Haematoxylin QS nuclear 
counterstain 
Vector Labs Histology 
Hoechst 33342 fluorescent nuclear 
counterstain 
Life Technologies Immunolocalisation 
Hydrochloric acid Thermo Scientific pH acid 
Hydrogen peroxide (30% solution) Sigma Aldrich IHC, western blotting 
ImmPACT NovaRed Vector Labs IHC 
ImmPRESS polymerised reporter Vector Labs IHC 
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enzyme staining system 
Isopropanol Sigma Aldrich RNA extraction 
Laemmli sample buffer Bio-Rad Western blotting 
Magnesium chloride (25mM 
solution) 
Life Technologies PCR 
Magnesium sulphate Sigma Aldrich Tissue bath 
Methanol Thermo Scientific Western blotting 
Milk, dried skimmed TESCO or Sainsbury’s Western blotting 
N, N, N’, N’-
Tetramethylethylenediamine 
[TEMED] 
Sigma Aldrich Western blotting 
OCT cryo-resin LAMB, Thermo 
Scientific 
Cryosectioning 
Paraformaldehyde Sigma Aldrich Immunolocalisation 
Phosphomolybdic acid Sigma Aldrich Masson’s Trichrome 
Phosphotungstic acid Sigma Aldrich Masson’s Trichrome 
PhosSTOP Phosphatase Inhibitor 
Cocktail Tablets 
Roche Applied Science Protein extraction 
Picric acid Sigma Aldrich Masson’s Trichrome 
Poly-L-lysine Sigma Aldrich Histology 
Potassium chloride Sigma Aldrich Tissue bath 
Potassium phosphate monobasic 
[KH2PO4] 
Sigma Aldrich Tissue bath 
PROTEAN® TGX™ pre-cast 
polyacrylamide gel 
Bio-Rad Western blotting 
Polyvinylidene fluoride (PVDF) 
membrane 
GE Healthcare Western blotting 
Protein Ladder, PageRuler™ Plus Thermo Scientific Western blotting 
Proteinase K Qiagen DNA extraction 
Sodium bicarbonate Sigma Aldrich Tissue bath 
Sodium dodecyl sulphate [SDS] Sigma Aldrich Western blotting 
Sodium borohydride Sigma Aldrich Immunolocalisation 
Sodium chloride Sigma Aldrich Buffer constituent 
Sodium hydroxide Sigma Aldrich pH alkali 
Tris base Sigma Aldrich Buffer constituent 
Tris HCl Sigma Aldrich Buffer constituent 
TRIzol® Life Technologies RNA extraction 
Tween® 20 Sigma Aldrich Buffer constituent 
Web green DNA stain Web Scientific PCR 
Xylene Sigma Aldrich Histology 
Table 2.1. List of reagents. *main assays associated with products in the current study; not 
exhaustive. 
 
2.4 Buffers and solutions 
Buffer or solution Composition 
TAE buffer (x1) Tris (40mM), Glacial acetic acid (19mM), EDTA (0.5mM), in 
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DDH2O, ~pH8 
Poly-L-lysine (x50) Poly-L-lysine (5mg/mL), in molecular grade DDH2O 
4% PFA Paraformaldehyde (2-4% w/v), in TBSt 
TBS(t) Tris HCl (15.2mM), Tris base (4.62mM), NaCl (150.7mM), in 
DDH2O, pH7.6 (+ 0.05% Tween® 20) 
Autofluorescence 
quenching solution 
Sodium borohydride (100mM), Ammonium chloride (50mM), in 
TBSt 
BCA reagent Copper (II) sulphate (2% v/v) in Bicinchoninic acid 
Tris-HCl (stacking) Tris HCl (0.5M), DDH2O, pH 6.8 
Tris-HCl (resolving) Tris HCl (1.5M), DDH2O, pH 8.8 
Western blot running 
buffer 
Tris Base (27.2mM), Glycine (0.192M), SDS (3.468mM), 
DDH2O 
Western blot transfer 
buffer 
Tris Base (27.2mM), Glycine (0.192M), Methanol (20% v/v), 
DDH2O 
Western blot stripping 
buffer 
SDS (2% w/v), β-mecaptoethanol (2mM), Tris-HCl (50mM; pH 
6.7), DDH2O 
Krebs Ringer solution NaCl (118mM), KCl (4.7mM), NaHCO3 (24.88mM), KH2PO4 
(1.18mM), Glucose (11.1mM), MgSO4 (0.82mM), CaCl2 
(2.52mM) 
Bouin’s fixative 71.43% Picric acid (saturated), 23.81% PFA (4% w/v, in PBS), 
4.76% Glacial acetic acid 
Phosphotungstic/ 
Phosphomolybdic acid 
solution 
Phosphotungstic acid (69.44mM, w/v), Phosphomolybdic acid 
(109.58mM, w/v), DDH2O 
Aniline Blue solution Aniline blue diammonium salt (31.77mM, w/v), Glacial acetic acid 
(2% v/v), DDH2O 
Table 2.2. List of buffers and solutions. 
 
2.5 List of antibodies 
Protein Manufacturer Host Antigen 
Spec. 
Size on 
WB 
Rec. 
Dilution 
Actin Sigma Rabbit Many 42 kDa 1/1000 
β-tubulin Imgenex Rabbit Many ~40-55 
kDa 
1/2000 WB 
CD11b BD Biosciences Rat M ~170 
kDa 
1/500 WB 
1/300 IF 
CD163 Santa Cruz Rabbit M 130 kDa 1/500 WB 
1/500 IF 
CD4 eBiosciences Rat M 55 kDa 1/250 WB 
1/200 IHC 
CD68 AbD Serotec Rat M 87-115 
kDa 
1/750 WB 
1/500 IF 
CD8 eBiosciences Rat M 32-34 
kDa 
1/250 WB 
1/200 IHC 
Collagen-Ia Abcam Rabbit H, M, Rat, 
B, G 
Not 
tested 
1/500 IF 
Collagen-IV Chemicon 
(Millipore) 
Goat M Not 
tested 
1/500 IF 
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Dystrophin Gift from Derek 
Blake 
DSHB 
Rabbit 
 
Mouse 
M 
 
M 
427 kDa 
Full 
length 
427 kDa 
1/500 WB 
1/200 IF 
1/200 WB 
EyMHC Santa Cruz, 
DSHB 
Mouse  
M 
200+ 
kDa 
 
1/200 WB 
F4/80 Abcam Rabbit M 130 kDa 1/500 WB 
1/250 IF 
Foxp3 eBioscience Rat M 49-55 
kDa 
1/200 WB 
1/100 IHC 
GAPDH Sigma Rabbit Many 37 kDa <1/2000 
WB 
IL-6 R&D systems Goat M ~22-28 
kDa 
1/200 WB 
Ly6G 
(Gr-1) 
eBioscience Rat M 21-25 
kDa 
1/200 WB 
1/100 IF 
Myogenin Santa Cruz Mouse M ~34 kDa 1/200 WB 
Osteopontin R&D systems, 
 
DSHB 
Goat 
 
Mouse 
M 
 
Rat 
H, Rb, M 
 
 
Main 
band 
~66 kDa 
1/2000 WB 
1/20 IHC 
1/100 WB 
P2X4 Alomone Rabbit M ~60-70 
kDa 
1/500 WB 
P2X7 Synaptic Systems Rabbit M, Rat 75 kDa 1/1000 WB 
1/800 IF 
Pax7 Abcam, 
DSHB 
Rabbit 
Mouse 
M 
C, 
(+many) 
57+ kDa 
 
1/100 IF 
1/500 WB 
TGF-β Abcam Rabbit H, M, Rat 13 kDa 1/500 WB 
Utrophin (MANCHO 
8A4) 
DSHB Mouse H 
M 
400 kDa 1/200 WB 
Table 2.3. Primary antibodies used for Western blotting and immunolocalisation analysis. M 
= mouse, H = human, C = chicken, Rb = rabbit, B=bovine. 
 
Manufacturer Host Antigen Spec. Conjugate Rec. Dilution 
Sigma Goat Rabbit HRP <1/5000 WB 
Sigma Goat Mouse HRP <1/5000 WB 
Life Technologies Rabbit Goat HRP <1/5000 WB 
Life Technologies Goat Rat HRP <1/5000 WB 
Life Technologies Goat Rabbit Alexa Fluor 488 1/1000 IF 
Life Technologies Chicken Rat Alexa Fluor 647 1/1000 IF 
Life Technologies Chicken Rabbit Alexa Fluor 488 1/1000 IF 
Life Technologies Chicken Mouse Alexa Fluor 488 1/1000 IF 
Life Technologies Chicken Goat Alexa Fluor 594 1/1000 IF 
Life Technologies Donkey Rabbit Alexa Fluor 555 1/1000 IF 
Life Technologies Donkey Rabbit Alexa Fluor 594 1/1000 IF 
Jackson labs Donkey Mouse Cy3 1/1000 IF 
Life Technologies Donkey Rat Alexa Fluor 594 1/1000 IF 
Life Technologies Donkey Goat Alexa Fluor 546 1/1000 IF 
Table 2.4. Secondary antibodies used for Western blotting and immunolocalisation analyses. 
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2.6 Nucleic acid analyses 
2.6.1 Genomic DNA extraction 
Mouse tail clip samples were removed from recently killed mice and ear punches 
were collected from living animals. Samples were incubated in proteinase K 
(40mAU/mg of tissue) for 6-8 hours or overnight in a shaking incubator at 55°C, to 
hydrolyse proteins and to inactive RNases and DNases. Next, a commercial DNA 
extraction spin kit (Qiagen DNeasy™ blood and tissue DNA extraction kit) was used 
to trap, purify, and then elute total genomic DNA, as follows: Digested sample 
containing intact DNA was mixed with a binding solution and centrifuged at 6,000 x 
gav for 1 minute. DNA, trapped in the silica column, was then washed by centrifuging 
two volumes of ethanol solution through the column at 6,000 and then 20,000 x gav for 
1 minute and 3 minutes, respectively. Finally, DNA was eluted in a Tris EDTA buffer 
(10mM Tris.Cl, 0.5mM EDTA, pH 9.0) ready for immediate use or long term storage 
at -80°C. 
 
2.6.2 RNA extraction 
RNA was extracted from tissue that had been crushed under liquid nitrogen using a 
pestle and mortar. Half of the tissue powder was set aside and used for protein 
extraction (see below). 1mL of TRIzol reagent was added per 100mg of muscle tissue. 
Following homogenisation by lavage through a 23 gauge needle and syringe, the 
sample-TRIzol solution was centrifuged at 12,000 x gav for 10 minutes at 4°C. A fatty 
layer was then removed. Supernatant was incubated at RT for 5 minutes. 0.2mL of 
chloroform was then added per 1mL of TRIzol used for homogenisation. Following a 
short vigorous mixing for 15 seconds and 2-3 minutes of incubation at RT, samples 
were centrifuged at 12,000 x gav for 15 minutes at 4°C. The aqueous phase was 
removed and 0.5mL of 100% isopropanol was added to this aqueous phase per 1mL 
of TRIzol used for initial homogenisation. Samples were incubated for 10 minutes and 
then centrifuged at 12,000 x gav for 10 minutes at 4°C to form an RNA pellet. The 
supernatant was discarded and the pellet was washed with 75% v/v RNase-free 
ethanol. Following a final centrifugation at 7,500 x gav for 5 minutes at 4°C, the pellet 
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was resuspended in RNase free water for storage at -80°C or immediate downstream 
applications. 
 
2.6.3 Nucleic acid quantification by spectrophotometry 
2μl of neat nucleic-acid solution was placed on the measuring pedestal of a 
NanoDrop™ 1000 (Thermo Fisher Scientific) spectrophotometer, after zero 
calibration with Tris EDTA buffer. Nucleotide concentration was determined by 
measuring the peak absorbance of the solution at the optical wavelength of 260nm and 
protein contamination was quantified by calculating the ratio of the absorbance at 280 
compared to 260nm. DNA and RNA have a known peak absorbance of light with a 
wavelength of 260nm, where an undiluted sample of DNA with an optical density of 1 
will contain 50μg/mL of DNA and 40μg/mL for RNA. Samples with a 260/280 
absorbance ratio equal to or greater than 1.8 were considered free from protein 
contamination and suitable to be used for PCR. 
 
2.6.4 Polymerase Chain Reaction (PCR) 
PCR was used to genotype experimental animals. 1-2μl of template DNA (<250ng) 
was added to a reaction tube containing 0.125μl of Taq DNA polymerase (NEB, 0.625 
units/25µl reaction), 5μl DNA polymerase buffer (x5 stock), 1.5μl MgCl2 (25mM), 
0.5μl dNTPs (10mM), 0.5μl forward primers (20pmol/μl), 0.5μl reverse primers 
(20pmol/μl), made up to 25μl with double distilled H2O. For convenience, a pre-
prepared commercial master-mix (Promega™ GoTaq® 2xGreen Master Mix) was 
also sometimes used, to which forward primers, reverse primers, and DNA template 
were added. The following PCR amplification cycle profile was then applied using a 
thermal cycler (Primus 96 Plus®, Peqlab Biotechnologie GmbH, Erlangen, Germany): 
Denaturing at 94°C for 3 minutes, followed by 35-40 cycles of 94°C for 30-40 
seconds, 50-62°C annealing for 30-40 seconds, and elongation at 72°C for 1 min per 
kb of expected PCR product length. This was followed by a final 10 minute 
elongation step at 72°C.  
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Specific primer pairs were used to discriminate between the WT, mdx, and P2X7-/- 
KO alleles. See Table 2.5 
PCR product were stored at 4°C overnight or <-20°C indefinitely. 
 
 Primer pair sequences Product 
size 
Annealing 
temp. 
Dystrophin 
WT 
Fv = p9427 (5’-AACTCATCAAATATGCGTGT) 
Rv = p260E (5’-
GTCACTCAGATAGTTGAAGCCATTTAG) 
105 bp 55-56°C 
Dystrophin 
mdx 
Fv = p9427 (5’-AACTCATCAAATATGCGTGT) 
Rv = p259E (5’-
GTCACTCAGATAGTTGAAGCCATTTAA) 
105 bp 55-56°C 
P2X7 WT 
(Pfizer) 
Fv = (5’-TGGACTTCTCCGACCTGTCT) 
Rv = (5’-TGGCATAGCACCTGTAAGCA) 
363 bp 59°C 
Pfizer KO 
(neomycin) 
Fv = (5’-CTTGGGTGGAGAGGCTATTC) 
Rv = (5’-AGGTGAGATGACAGGAGATC) 
280 bp 59°C 
P2X7 WT 
(Glaxo) 
Fv = ‘A’ (5’-TGCCCATCTTCTGAACAC) 
Rv = ‘C’ (5’-CTTCCTCTTACTGTTTCCTCCC) 
565 bp 59°C 
Glaxo KO 
(lacZ) 
Fv = ‘A’ (5’- TGCCCATCTTCTGAACAC) 
Rv = ‘E’ (5’-GCAAGGCGATTAAGTTGGG) 
393 bp 59°C 
Table 2.5. Sequences of PCR primers used for genotyping. 
 
2.6.5 Agarose gel electrophoresis of PCR products 
PCR product was mixed 4:1 with a loading buffer (10% v/v glycerol, 0.05% v/v 
bromophenol blue), prior to loading onto a 2% w/v agarose gel, unless the Promega™ 
GoTag® 2xGreen Master Mix was used, in which case the PCR product could be 
loaded immediately following PCR. Agarose gels were prepared by mixing 2g of 
electrophoresis grade agarose per 100ml TAE buffer. The TAE buffer-agarose 
mixture was then heated in a microwave until agarose dissolved completely, stopping 
heating periodically to mix the solution. 2-5µl of Web Scientific web-green DNA 
stain was added to per 100mL of cooled agarose gel before it solidified. The samples 
were loaded and the gel was then run at 3-5V/cm in 1xTAE buffer for time required to 
resolve bands of interest, against a 100 bp DNA ladder (Life Technologies) used for 
determination of the PCR product size. 
Chapter 2: Materials and methods 
Page 57 
 
2.6.6 RNA quality control by agarose gel electrophoresis 
An aliquot of neat total RNA was loaded onto a 1% w/v agarose gel prepared as 
described above and run under non-denaturing conditions to assess sample quality. 
Good quality mouse RNA should present two crisp bands at ~5kb and 2kb 
corresponding to the 28S and 18S subunits of the rRNA, with band intensity ratio of 
~2:1 (see Appendix 9.6). 
 
2.6.7 RNA hybridisation to RNAstable™ matrix 
Room temperature storage and delivery of isolated RNA was achieved with the use of 
a thermo-stable dissolvable RNA stabilization method. RNA of known concentration 
was added into and dried overnight within individual wells of a 96-well plate coated 
with Biomatrica® RNAstable. The plate was then sealed in a foil bag containing a 
desiccant. 
 
2.7 Histological and immunostaining procedures 
2.7.1 Muscle collection and storage 
For histology and immunolocalisation, hind limb muscles including the tibialis 
anterior (TA) and gastrocnemius (GC) were used because of their well-established 
pathological expression profiles. Analysis of both of these muscle groups has been 
recommended in a recent standard operating procedure for the use of mdx mice in 
DMD pre-clinical research (Willmann et al., 2012). Other muscles collected included 
the diaphragm and the heart. 
Using a clean dissection kit, skin layers were peeled away and skeletal muscles were 
excised from tendon to tendon. Section sampling was always performed within the 
middle third of muscle samples, away from manipulation sites and in the mid-belly 
section of the muscle. 
Following collection, samples were placed onto ice-cold tin foil to minimise protease 
sample degradation or they were flash frozen in a 1.5mL Eppendorf tube placed in 
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liquid nitrogen if the downstream application was Western blotting. Dissected muscle 
intended for cryosectioning was arranged on a cork disk in a small amount of OCT 
medium in a longitudinal orientation, so as to eventually achieve transverse sections, 
and frozen in liquid nitrogen chilled 2-methylbutane and stored at -80ºC. 
 
2.7.2 Muscle tissue cryosectioning 
Frozen muscle was transferred to a cryostat chamber and allowed to equilibrate to -
20°C. Using OCT cryo-resin, the cork disk upon which the tissue sat, was affixed to a 
chuck. 5-10μm thick cryosections were then cut from the middle third of the sample 
and collected on poly-L-lysine coated glass slides. These sections were allowed to air 
dry for several hours before long term storage at -80°C. 
 
2.7.3 Haematoxylin and eosin staining 
Haematoxylin and eosin (H&E) staining was performed to assess sample quality and 
tissue pathology following cryosectioning. Frozen muscle sections were collected 
onto a glass slide, allowed to reach room temperature and to dry. Sections were then 
covered in Vector® Haematoxylin QS nuclear stain solution for 45 seconds and rinsed 
in running tap water before 1 minute incubation in 95% v/v ethanol. Alcoholic eosin Y 
solution was applied to sections for 1 minute. Sections were then dehydrated in an 
ascending alcohol series (ethanol 95% v/v x2, 100% v/v x2) placed in xylene for 1 
minute and finally mounted in DPX synthetic mounting medium with a glass 
coverslip. Slides were thoroughly dried before microscopic analysis. 
 
2.7.4 Masson trichrome staining 
The trichrome method employed here is the TREAT-NMD-recommended protocol 
(http://treat-nmd.eu/research/preclinical/dmd-sops/). Briefly, 10μm thick heart 
cryosections were fixed in 4% w/v  PFA, 0.1M PBS followed by Bouin’s fixative, 
stained with Biebrich Scarlet-Acid Fuchsin solution (Sigma HT151) for 20 minutes, 
washed in water and incubated in a phosphotungstic/phosphomolybdic acid solution 
(5% w/v phosphotungstic acid; 5% w/v phosphomolybdic acid; DDH2O) for 4x 3 
minutes, directly before incubation in Aniline Blue solution (2.5% w/v; 2% v/v acetic 
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acid; DDH2O) for 15 minutes. Subsequently, sections were washed in water and 
incubated in glacial acetic acid solution (1% v/v; DDH2O) for 1 minute. Finally, 
sections were washed, dehydrated, mounted and visualized using bright-field 
Axiozoom V.16 microscope (Zeiss). 
 
2.7.5 Immunohistochemical staining 
Frozen muscle sections on glass slides were allowed to reach room temperature and to 
dry. Individual sections to be incubated with primary antibody and the negative 
controls were delineated using a hydrophobic wax marker pen (Vector Labs). Samples 
were then fixed in a 2-4% w/v paraformaldehyde solution in TBSt for 15 minutes at 
4°C, followed by two washes in TBSt. Sections were blocked for 20-30 minutes in a 
10% v/v serum (in TBSt) from the species in which the secondary antibody was 
derived. The primary antibody solution in TBSt, containing 10% v/v serum, was then 
applied to sections for 2 hours at room-temperature or overnight at 4°C. Following 
incubation, antibody solution was removed, sections were washed by three 5 minute 
incubations in TBSt, and endogenous peroxidases were quenched by applying 0.3% 
v/v H2O2 (in TBSt) directly to the sections for 5 minutes. Following another three 5 
minute washes, Vector® labs ImmPRESS secondary antibody complex was added 
and incubation carried out for 30 minutes. Following two 5 minutes TBSt washes, 
sections were incubated with the Vector® labs colorimetric ImmPACT NovaRed 
substrate for 10 minutes, to visualise the signal. Sections were next rinsed with two 5 
minute washes in distilled water, followed by a nuclear counterstaining with a diluted 
Haematoxylin QS (30 second incubation). Finally, sections were passed through an 
ascending alcohol series (95% ethanol x2, 100% ethanol x2) and xylene - 1 minute 
incubation each, and mounted with DPX. 
 
2.7.6 Immunofluorescence staining 
Frozen muscle sections were allowed to reach room temperature and to dry. 
Individual sections were delineated using a hydrophobic wax marker pen. Samples 
were then fixed in a 2-4% w/v paraformaldehyde solution in TBSt for 15 minutes at 
4°C, followed by two washes in TBSt. At this stage, a 100mM NaBH4, 50mM NH4Cl, 
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incubation was applied to the sections for 30 minutes to help subdue autofluorescence 
that may be present in a sample by reducing aldehyde to hydroxyl groups. Following 
three 5 minute washes in TBSt, sections were blocked for 20-30 minutes in a 10% v/v 
serum in TBSt from the species in which the secondary antibody was derived. The 
primary antibody solution in TBSt, containing 10% v/v serum, was then applied to 
sections for 2 hours at room-temperature or overnight at 4°C. Three 5 minute TBSt 
washes were then performed before a 1 hour room temperature incubation with 
secondary antibody diluted in 2% v/v serum containing Hoechst nuclear counterstain.. 
Sections were finally washed three times for 10 minutes before mounting in Merk 
Millipore FluorSave™ fluorescence mounting media. 
Fluorescence images were captured using a Zeiss LSM 710 confocal microscope. For 
montage composition, multiple adjacent optical windows were captured with some 
overlap to aid joining. 
 
2.8 Muscle morphometric analysis 
From skeletal muscle tissue sections that have had individual muscle fibres delineated 
using an anti-collagen type IV fluorescent staining, an image processing sequence was 
used to measure morphometric variables in a semi-automated manner following the 
logical image processing steps, as described by Briguet et al. (2004). 
Individual x20 fields of view were captured on a Zeiss LSM 7.10 confocal 
microscope and montaged together using Fiji (Schindelin et al., 2012), a packaged 
version of American National Institutes of Health (NIH) open source image 
processing software ImageJ (Rasband, 1997-2012). A macro was created to facilitate 
the montage process (see Appendix 9.3). Image processing steps undertaken across 
whole montaged muscle cross-sections included i) subtracting background 
components to minimise background noise that could interfere with further analysis, 
ii) applying band-pass thresholds to differing colour components, iii) dilating borders 
to close inconsistent gaps, iv) skeletonising these borders, v) applying a convolution 
filter to translate pixels uniformly for border detection. The ‘analyse particles’ 
function was used to generate a mask of the muscle fibre borders, simultaneously 
eliminating stray ‘non-border’ signals. An image of the threshold delimited nuclei was 
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then overlaid on the border mask, before another ‘analyse particles’ command was 
used to measure morphometric variables including ‘area’ and ‘minimum Feret’s 
diameter’. A macro was created to perform all image processing operations with 
minimal user input. 
Central nucleation was also quantified across these analysed cross-sections by co-
opting a ‘holes’ measure; the ‘holes’ were introduced to delineated muscle fibres by 
overlaying the threshold defined nuclei onto the border mask. 
Internet videos describing our implementation of the above procedures are available 
from the following private links: http://youtu.be/GZVaRQYgGQU - macro defined 
muscle morphometric analysis using Fiji. http://youtu.be/oxyM7r7VYp0 - using the 
morphometric output to measure central nucleation frequency. 
 
2.9 Sarcolemmal integrity assay 
2.9.1 Mouse IgG staining 
When muscle sarcolemma is compromised, blood borne molecules that are normally 
excluded from the cell may be allowed to enter the cytoplasm. Immunoglobulins are 
one such example. Using a secondary antibody raised against mouse IgG, an 
immunofluorescence approach was used to delineate compromised sarcolemma as a 
percentage of IgG positive to total fibres in 4 week GC samples from C57, mdx, and 
Pfizer dKO mice. The immunofluorescence procedure was as described earlier. 
Quantification of IgG stained area was achieved using Fiji and this value was 
expressed as % of total cross-sectional area. 
 
2.9.2 Serum creatine kinase assay 
A common clinical diagnostic marker for DMD is the level of serum CK. CK is an 
important metabolic enzyme present within muscle cells (Wallimann et al., 2011). As 
it is normally restricted to the intracellular compartment, CK found in the serum is a 
measure of sarcolemmal break-down. 
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Whole blood was collected from recently killed mice by cardiac puncture using a 25 
gauge needle and syringe, then stored at 4ºC. Clotted blood was then heated to 37ºC in 
a water bath for 10 minutes just prior to centrifugation. To minimise the chance of 
induced haemolysis, two low-speed centrifugations were adopted over one longer 
spin. Firstly, blood was centrifuged at 2,300 x gav for 5 minutes. Serum supernatant 
was then removed to a new Eppendorf tube for a second 5 minute spin at 2,300 x gav. 
The serum fraction was again transferred to a new tube, this time for storage at -80ºC 
or immediate testing. 
5µl of each sample was mixed with 250µl of CK enzymatic assay reagent (BIOO 
Scientific), containing excess ADP, glucose, and NAD(P)+, as well as hexokinase and 
glucose-6-phosphate dehydrogenase (quantities unspecified by kit manufacturer ) in 
single wells of a 96-well optical plate (Nunc-96). A standard series, containing a set 
quantity of NADH serially diluted with a standard dilution buffer (equivalent standard 
CK concentrations of 800, 400, 200, 100, and 50 IU/L) and the CK reagent was 
included in another 5 wells. One well was reserved for a negative control, containing 
only CK reagent and standard dilution buffer (equivalent standard CK concentration 
of 0 IU/L). Light absorbance at 340nm was measured in all wells immediately 
following CK reagent introduction and after 5 minutes of incubation, using a 
microplate spectrometer (POLARstar OPTIMA, BMG LABTECH, GmbH, 
Germany). NAD(P)H, the final product of the coupled enzymatic reactions has a peak 
absorbance of light at 340nm wavelength. Absorbance value increase over 5 minutes 
was multiplied by the assay-defined constant 2,186 (conversion factor), to obtain CK 
activity in International Units per litre (IU/L). 
 
2.10 Protein isolation and analyses 
2.10.1 Protein extraction 
Skeletal muscles obtained from both left and right leg of the mouse were crushed 
under liquid nitrogen to generate a well-mixed powder that could be split for protein 
and RNA extractions. On ice, 500μl of Complete Lysis-M reagent (Roche Applied 
Science) was added per 100mg of crushed tissue. The Complete Lysis-M reagent 
contained an additional 1 Roche Mini Protease Inhibitor Cocktail tablet and 2 Roche 
PhosSTOP phosphatase inhibitor cocktail tablets per 10mL of reagent. The sample 
Chapter 2: Materials and methods 
Page 63 
was then titration mixed using a large bore pipette tip before further thorough mixing 
by syringe titration through 23 gauge and then 25 gauge needles. The resultant 
homogenate was then centrifuged for 20 seconds at 800 x gav to pellet debris. The 
protein-containing supernatant was kept at -80ºC for long-term storage or used 
immediately. 
 
2.10.2 Protein quantification by BCA assay 
 Protein reduces Cu2+ proportional to BCA chelation of Cu+, resulting in a colorimetric 
reaction that is the basis for the BCA protein assay (Nagaoka et al., 2006; 
Abou‐Khalil et al., 2013). The light absorbance at 550nm of BCA reagent containing 
protein extract at three dilutions was compared to a linear range of bovine serum 
albumin (BSA) standard concentrations between 1µg and 10µg. 
1 to 10µl of BSA (Sigma Aldrich, 1mg/ml) was added, in duplicate, to a 96 well 
optical plate (Nunc-96) as a standard. Test samples were added to separate wells at 1, 
3, and 5 µl, in duplicate. To each standard and test sample-containing well, 200µL of 
BCA working reagent (50 parts BCA, 1 part of 4% w/v CuSO4) was added. The plate 
was then placed in a shaking incubator at 55ºC for 15 minutes. Absorbance at the 
550nm was measured using a microplate reader spectrometer (POLARstar OPTIMA, 
BMG LABTECH, GmbH, Germany). Protein concentration was determined by 
comparing standards of known concentrations to test samples of a similar volume. 
 
2.10.3 SDS polyacrylamide gel electrophoresis (PAGE) 
Equal quantities of protein extracts (20-40μg) were mixed 1:1 with 2 x Laemmli 
sample buffer (65.8mM Tris-HCl, pH6.8, 2.1% w/v SDS, 26.3% v/v glycerol, 0.1% v/v 
bromophenol blue), containing 5% v/v β-mecaptoethanol and  heated at 95°C for 5 
minutes. The resultant samples were then added to individual lanes of a two-phase 
PAGE gel before electrophoresis. 
PAGE gels were made with a lower percentage stacking gel (4% w/v) overlaying a 
resolving gel (6-12% w/v). The resolving gel was composed of DDH2O, 30% v/v 
acrylamide/bis, 1% v/v of 10% w/v SDS, and 25% v/v 1.5M Tris-HCl (pH 8.8). The 
stacking gel comprised of 61% v/v DDH2O, 13% v/v of 30% acrylamide/bis, 1% v/v 
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10% w/v SDS, and 25% v/v 0.5M Tris-HCl (pH 6.8). Stacking and resolving gel 
components were mixed in separate 15 ml Falcon tubes and polymerising agents: 10% 
w/v APS (0.005[stacking]-0.01[resolving]% v/v) and TEMED (0.002% v/v) were added 
just prior to pouring the gels. Alternatively, PROTEAN® TGX™ (Bio-Rad 
Laboratories Ltd) pre-cast polyacrylamide gels were used. Gels were assembled in a 
Mini-PROTEAN 3 Gel Cassette and Electrophoresis Module (Bio-Rad Laboratories 
Ltd) and immersed in SDS-PAGE running buffer. Electrophoresis voltage was set to 
100V until the bromophenol blue had reached the resolving gel component. Proteins 
were separated through the resolving gel at 120V until proteins of interest had reached 
the middle of the gel, as determined against a 3-7 µl visible protein marker ladder 
(PageRuler™ Plus, Thermo Scientific) inserted into either or both flanking lanes. 
 
2.10.4 Western blotting 
Gels with separated proteins were placed within a Western sandwich set up (BioRad) 
containing a PVDF membrane. Proteins were then transferred using an electrophoresis 
rig containing a Western blot transfer buffer. Transfers were run at 100V for ~2 hours 
or at 40V overnight. 
Following transfer, PVDF membranes were removed and washed prior to a 1 hour 
blocking with 5% w/v non-fat milk in TBSt. Membranes were then cut into strips 
according to expected molecular weights of target proteins and using protein ladder as 
a guide to allow multiple antibodies raised in the same species to be used with one 
blot. The primary antibody incubation was carried out for ~2 hours at room 
temperature or overnight at 4°C, in 5% w/v milk in TBSt. Membranes were then 
washed three times for 5 minutes in TBSt before secondary antibody incubation in 5% 
w/v milk in TBSt for ~1 hour at room temperature. After three final washes, 
membranes were incubated with chemiluminescent substrates (Millipore) and protein 
bands were visualised using a Syngene G:Box equipped with GeneSnap image 
capture and processing software. Subsequently, membranes were washed and dried 
for storage or re-probing. 
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For protein band quantification and comparison, relative band densitometry was 
employed using Fiji image analysis and Microsoft Excel spread-sheet software. 
Protein bands of specific size were assigned percentage values proportional to their 
relative densities and this was divided by similarly appropriated percentage values for 
sample-specific actin or β-tubulin bands, to give a comparative level of target protein 
relative to a loading control (as described in:  
http://lukemiller.org/index.php/2010/11/analyzing-gels-and-western-blots-with-image-j/). 
 
Two strategies were employed to re-probe PVDF membranes. The first involved 
placing the membrane(s) in a Western stripping buffer (see Table 2.2) for 2 hours at 
50°C, with constant agitation. Membranes were then washed three times for 5 minutes 
in TBSt, before methanol reactivation, another wash series, and the standard antibody 
incubation procedure (as described above). The second approach involved quenching 
the horseradish peroxidase enzyme coupled to the secondary antibody on the 
membrane by incubating it in H2O2 (30% v/v) for 15-20 minutes at 37°C. Membranes 
were then washed three times for 5 minutes, before methanol reactivation and 
antibody incubations. The second approach can only work if the primary antibody is 
raised in different species, but this method is useful if expected protein bands are of 
very similar sizes. 
 
2.11 In vitro diaphragm tissue bath tetanic force measurements 
Whole diaphragms with ribs attached were excised from 4 week and 4 month C57 
BL/10, mdx, Glaxo, and Pfizer mdx/P2X7-/- mice and placed into a Krebs Ringer 
solution (composition in table 2.2), taking care not to handle the muscle, wherever 
possible. Sutures were then tied to two points on either side of a segment of attached 
rib, which were then connected to an immobile plastic clamp. A centrally derived 
triangular section of the diaphragm was used for testing. Contractile force was 
translated along another suture, tied to the central tendon apex of the approximately 
equilateral triangular section of muscle. This suture was, in turn, attached to a 
mechanical force transducer (ADInstruments), amplifier, and data acquisition setup. 
Excitation of muscle was achieved via local field potentials through platinum 
electrodes in an oxygenated (95% O2; 5% CO2) Krebs Ringer solution, at a constantly 
maintained temperature of 37°C. 
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Each diaphragm was stretched in very small increments from an initial resting state to 
establish the optimal excitation-to-force generation length (Lo). Diagnostic testing 
also confirmed that the voltage twitch stimulus of 140V (2msec width) was adequate 
to elicit a maximal twitch response (Pt). To achieve a maximal isometric tetanic force 
response (Po), diaphragm sections were subject to a 140V (2msec) stimulus train at 
100Hz frequency for 0.5-1 seconds. The test regime involved collecting 6 twitch 
responses, followed by 6 tetanic trains, with 2 minutes rest period between each. 
Maximal twitch and tetanic response was taken from the tallest of the respective force 
traces. All forces were normalised to muscle wet weight and expressed as Newtons 
per mg of tissue (N/mg). The utilised testing strategy was a close match for a method 
used by Gosselin et al., (2003), and followed recommendations presented within the 
TREAT-NMD standard operating procedures for the use of experimental animals: 
http://www.treat-nmd.eu/downloads/file/sops/dmd/MDX/DMD_M.1.2.002.pdf  
 
2.12 P2X7 inhibitor study 
A preliminary P2X7 inhibitor study was undertaken using Coomassie Brilliant Blue G 
(CBB). CBB (0.22μm in PBS, filter sterilised) was injected intraperitoneally (i.p.) 
daily at 125mg per kg of mouse body weight, from post-natal day 2 until collection at 
4 weeks of age. PBS injection regime run in parallel was used as a negative control. 
Blood was collected from all experimental animals for subsequent serum CK analysis. 
 
2.13 Tissue preparation for bone histomorphometry  
6 month old male mdx (n=4), C57 (n=4), Glaxo and Pfizer single (n=2, 5) and double-
mutant (n=3, 4) mice were killed and then quickly had their skin and internal organs 
removed before being placed into a 4% w/v paraformaldehyde fixative overnight. This 
bone and skeletal muscle specimen was then placed into 70% v/v ethanol (in 0.1M 
PBS) for 2 hours before a final incubation and storage in 80% v/v ethanol, to complete 
fixation and to preserve bone architecture for morphometric analysis. 
Micro-computed tomography (µCT) was undertaken by Dr. Andrea Del Fattore and 
Prof. Anna Teti of the University of L’Aquila, Italy. To determine bone mineral 
density and thickness the following parameters were analysed: Bone volume/total 
volume (BV/TV, %), trabecular thickness (Tb.Th, µm), trabecular space (Tb.Sp, µm), 
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and the trabecular number per mm2 (Tb.N, n.mm-2). This analysis was analogous to 
their previously published work (Rufo et al., 2011). 
 
2.14 Statistics 
Statistical tests were performed using Minitab™16 statistical analysis software. For 
comparison of one response variable from 2 independent groups, a Student T-test was 
preferred when sample values could be assumed, or determined, as normally 
distributed. The parametric equivalent for more than 2 groups was an ANOVA 
analysis, with Tukey-Kramer post-hoc test to determine individual pairs of 
differences. The non-parametric equivalent was the Kruskal-Wallis test, with no 
subsequent option for post-hoc analysis. For all analyses, an α-level of 0.05 was 
chosen. Vertical bars in graphical representations of data represent SEM, where 
significance is indicated by asterisks. 
A note on sample numbers per group 
For statistical comparisons, a minimum number of three bological replicates, i.e. each 
sample from a different mouse, were required. In many cases we have been able to 
include more than three samples per group to increase the power of comparisons. As 
the data spread from each group has been used to determine variance to be applied to 
an ideal distribution, it is not a requirement that there be equal N number per group 
for parametric comparison. It was attempted to keep N numbers similar within tests. 
Between tests, the N number can vary considerably due to inherent differences in the 
spread of data determined by one method over another. An example of this is serum 
CK comparisons (p. 173, Figure 5.1), which required higher N number per group than 
other studies before power was achieved to determine differences between groups. 
Serum CK level is a useful diagnostic marker in human and animal dystrophinopathy 
studies but as a more global measure of muscle membrane destabilisation, it is well 
acknowledged to present a high degree of data-spread variance over disease threshold 
level (http://treat-nmd.eu/research/preclinical/dmd-sops/). 
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2.15 Contributions by others 
 Not all data presented within this thesis are from studies undertaken solely by the 
main author. The following table details contributions by specific collaborators 
(Table 2.6) 
 
Method Contributor(s) Notes 
Animal husbandry and 
euthanasia 
Specialist technicians  
Nucleic acid procedures Thesis author  
Genotyping by PCR Thesis author  
Quantitative PCR Thesis author  and Prof. Pawel 
Kalinski and Dr. Ravikumar 
Muthuswamy, University of 
Pittsburgh, USA 
Collaborators prepared 
cDNA from RNA sent to 
them and performed qPCR. 
Data analysis undertaken by 
thesis author 
Histology and 
immunolocalisation studies 
Thesis author  
Muscle morphometry – 
method design, development 
and implementation 
Thesis author Based on Briguet et al., 2004 
Sarcolemmal integrity assays Thesis author  
Protein isolation and analyses 
by Western blotting 
Thesis author  
In vitro diaphragm tissue bath 
force measurements 
Thesis author  
P2X7 inhibitor study Thesis author and specialist 
technicians
Injections performed by 
animal technicians 
Bone histomorphometry Thesis author and Prof. Anna Teti 
and Dr. Andrea Del Fattore, 
University of L’Aquila, Italy 
Animal bones prepared by 
thesis author and sent to Italy 
for micro-CT. Data analysed 
by the author. 
  
Table 2.6. Table of collaborator contributions for data presented in the thesis.
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3 
Effect of P2X7 receptor ablation on muscle structure 
and growth at the acute and post-acute phases of 
mdx disease 
 
3.1 Introduction 
3.1.1 Histological profile of mdx mouse muscle 
Human DMD patients undergo chronic muscle degeneration and tissue remodelling 
that results in reduced muscle force generation, collapse of tissue ultrastructure 
necessary to efficiently translate that force, and the replacement of muscle with fat 
and fibrotic scarring (Mann et al., 2011; Klingler et al., 2012). Satellite cells that 
would normally activate to repair damaged muscle, or that merge to form new fibres, 
are thought to exhaust in response to significantly increased replication, in a process 
termed replicative senescence (Schultz & Lipton, 1982). This process is thought to be 
partly dependent on the reduction in telomere length over the repeated cycles of 
satellite cell activation and proliferation associated with chronically diseased muscle 
(Decary et al., 2000; Sacco et al., 2010). Mice possess longer telomeres than humans, 
and this has been suggested as one reason for the less severe form of the disease in the 
mdx mouse model compared to human DMD (Sacco et al., 2010). Satellite cells and 
myoblasts may also be more susceptible to cell death due to the increased presence of 
ATPe released from damaged fibres combined with an increased expression and 
activity of ionotropic purinoceptors, such as P2X7, which were found in dystrophic 
myoblasts and myotubes (Yeung et al., 2006; Martinello et al., 2011; Young et al., 
2012). 
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The majority of muscles in the dystrophic mdx mouse do not undergo chronic and 
continuous degeneration, instead going through cycles of degeneration and 
regeneration. The first degeneration period occurs at around 3-6 weeks in the mdx 
mouse (Dangain & Vrbova, 1984; Tanabe et al., 1986; Coulton et al., 1988; Roig et 
al., 2004; Yeung et al., 2004; Willmann et al., 2012).Within this period, muscle fibres 
undergo pronounced necrosis and apoptosis, also leading to enhanced clearance of 
cellular debris involving mononuclear cell infiltrations and sterile inflammation 
mechanisms. Another histological marker is an increase in the incidence of central 
nucleation as a product of enhanced muscle repair and myogenic precursor cell fusion 
events. 
Muscle regeneration is ultimately regulated by a set of myogenic regulatory factors 
(MRFs) that are differentially expressed in response to micro-environmental stimuli 
including mechanical stress, autocrine and paracrine chemical signalling, and 
extracellular matrix interactions. The major MRFs expressed during secondary muscle 
regeneration include c-met, myoD, myf5, myogenin, MRF4, and myocyte enhancer 
binding factor-2 (MEF2) (Grounds et al., 1992; Yun & Wold, 1996; Cornelison & 
Wold, 1997) (Figure 3.1). These factors have a sequential and contingent expression 
profile in a continuum from quiescent to activated, inducing proliferation and then 
differentiation of myogenic precursor cells. A graded expression of several of these 
factors means that individual myogenic precursor cells can express multiple MRFs at 
any time, dependent on their progression through the myogenic program (Figure 3.1: 
see Boldrin et al., 2010; Dilworth & Blais, 2011).  
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Figure 3.1. A map of myogenic regulatory factors (MRF) involved in myofibre regeneration. 
Satellite cells that are present between the sarcolemma and the basal lamina of muscle fibres 
are activated upon tissue injury, which leads to their proliferation, differentiation, and then 
fusion to repair or to form new myofibres. Each step of the regeneration process is marked by 
the expression of multiple MRFs, as indicated (from Boldrin et al., 2010). MPC (myogenic 
precursor cell). 
 
Another morphological parameter that is modified in the disease state is muscle fibre 
size. In DMD, following a greater than average growth up to five years of age, 
muscles progressively degenerate, regenerate, and split resulting in smaller than 
average fibres observed in adolescence and adulthood (Watkins & Cullen, 1982). In 
the mdx mouse, a well characterised pattern of muscle fibre size changes that differs 
from that of the human pathology is evident (Dangain & Vrbova, 1984; Tanabe et al., 
1986; Coulton et al., 1988; Roig et al., 2004). Within the acute period of muscle fibre 
degeneration-regeneration, fibres are on average smaller in the mdx mouse, mostly 
due to the increased presence of smaller, regenerating, centrally nucleated, fibres. 
After this degenerative period, mdx muscle partially recovers, a subset of muscle 
fibres hypertrophy to compensate for an inherent weakness, whereas specific muscle 
force (normalised to muscle fibre cross-sectional area), remains lower. Muscle 
necrosis persists, albeit at low levels (Lynch et al., 2001). Dystrophic muscle 
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therefore presents a greater variation in muscle fibre sizes than is present in non-
diseased control tissue. Finally, there is a late-phase atrophy, from around 62 weeks of 
age, whereby the persistent degeneration of muscle fibres is no-longer compensated 
for by regeneration (Pastoret & Sebille, 1995).  
Although DMD muscles generally have no dystrophin, in many DMD patients a small 
proportion of muscle fibres show strong dystrophin staining. These "revertant fibres" 
are thought to arise due to somatic mutations in individual cell nuclei that correct and 
restore the dystrophin reading frame. The frequency of such somatic mutations 
increases with each satellite cell division and therefore the number of revertant fibres 
increases with the number of degeneration-regeneration cycles. Therefore, the 
revertant fibre count has been used as a discrete disease progression marker (Yokota 
et al., 2006; Young et al., 2012) in addition to the central nucleation index or levels of 
expression of various myogenic proteins. Revertant fibres are a good indicator of total 
regenerative fibre turnover since they represent a cumulative record of all regenerative 
events, whereas levels of myogenic proteins have a transient expression profile and 
are restricted to particular phases of regeneration. 
Specific muscle fibres are differentially susceptible to disease progression. Naturally 
smaller muscle fibres, tend to be less susceptible to DMD-related damage (Karpati & 
Carpenter, 1986; Karpati et al., 1988a), perhaps related to the cellular mechanics of 
Ca2+ handling in smaller compared to larger cells (Khurana et al., 1995). Despite this 
observation, an entire branch of treatment strategies in the DMD field involves 
attempting to exogenously increase muscle fibre size, since it has been shown that 
artificially increased fibre size increases force production and reduces susceptibility to 
contraction-induced damage (Wagner et al., 2002; Peter et al., 2009; Gehrig et al., 
2010; Kim et al., 2011; Selsby et al., 2012; von Maltzahn et al., 2012).  
In the human disease, certain muscle groups are more severely affected than others 
with those of the limbs, the diaphragm, and the heart being more affected. Within 
affected muscle groups fast-type, glycolytic, fibres are preferentially affected over 
slow-type oxidative fibres (Webster et al., 1988). In the mdx mouse, this is also the 
case (Moens et al., 1993; Ljubicic et al., 2011) and there is even a fibre type 
switching from fast-to-slow type over the progression of the disease (Carnwath & 
Shotton, 1987). Based on this observation, different mouse muscles have been 
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prefered for pre-clinical testing (Willmann et al., 2012) with the TA and GC hind-
limb muscles classified as ‘appropriate’ and ‘particularly appropriate’ for down-
stream morphological or biochemical analyses (Figure 3.1).  
 
3.1.2 The P2X7 receptor and skeletal muscle regeneration 
The P2X7 receptor is expressed in a large number of cell types. Along with an 
upregulation in the disease state, our laboratory has previously shown P2X7 to be 
expressed on myoblasts and myotubes (Yeung et al., 2006; Young et al., 2012). Work 
by us and others has also confirmed its expression in an in vitro model of muscle 
resident satellite cells (Banachewicz et al., 2005), at the neuromuscular junction 
(Deuchars et al., 2001), and in inflammatory cells infiltrating mdx muscles (Yeung et 
al., 2004). 
One of the best characterised cell lineages in which P2X7 receptors are known to be 
expressed is the haematopoietic, including most cells of the innate and adaptive 
immune systems (Collo et al., 1997; Lister et al., 2007) and also osteoblasts and 
osteoclasts (Gartland et al., 2003; Ke et al., 2003; Panupinthu et al., 2007; 2008; 
Muscle  Type Morphology Biochemistry Function 
Diaphragma Fast    
Extensor digitorum longus (EDL)b Fast    
Gastrocnemius (GC)c Mixed   * 
Quadricepsd Mixed   X 
Biceps/tricepse Mixed   X 
Tibialis anterior (TA)f Fast **  * 
Soleus (SOL)g Slow    
Table 3.1. Mouse muscles used for pre-clinical morphological, biochemical, and functional 
studies. = particularly appropriate;  = appropriate; X = not suitable. a Severe 
phenotype, should be used as much as possible; b Small size, more suited for functional 
assays; c Large size, heterogeneous fibre composition, affected by exercise; d Large size, 
affected by exercise; eAs back-up if GC or quadriceps not sufficient; f Large size, accessible; 
g Small size. As a purely slow muscle, soleus is more preserved from dystrophic pathology. 
* Only in in situ. ** Less affected by standard exercise regimes that induce muscle damage 
and contraction-induced pathological injury but badly affected during onset of necrosis 
(Figure and legend from Willmann et al., 2012). 
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Orriss et al., 2010). An important component of mdx and DMD disease progression is 
chronic muscle inflammation (Tidball, 2009). Given the association of P2X7 with 
diseases with an inflammatory component (Chu et al., 2012; Kimbler et al., 2012; 
Murphy et al., 2012; Cieslak et al., 2011; Baroja-Mazo & Pelegrin, 2012; Chatterjee 
et al., 2012) and the aforementioned inolvement of inflammatory cells and mediators 
(Table 3.2) in muscle regeneration (Spencer et al., 1997; Spencer & Tidball, 2001; 
Nguyen & Tidball, 2003a) it is pertinent to consider its effect on regenerative 
processes in dystrophic muscles. It is particularly important as P2X7 receptor 
inhibition or ablation has been shown to reduce the release of several of these 
inflammatory markers including active IL-1β (Solle et al., 2001; Labasi et al., 2002) 
and TNFα (Chessell et al., 2005), while the level of the anti-inflammatory IL-10 has 
been shown to be reduced by P2X7 receptor activation (Rizzo et al., 2009). 
Moreover, there is data suggesting that P2X7 receptors, in addition to influencing 
immune cell functions, may regulate muscle regeneration directly. The P2X7 receptor 
has been shown to promote myoblast proliferation (Martinello et al., 2011) as well as   
myoblast-to-myotube differentiation (Araya et al., 2004).  
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Molecule Expressing cell Effect on muscle References 
IL-4  Regenerating 
myotubes 
 M2 macrophages 
 Th2 lymphocytes 
 IL-4 KO mice had reduced muscle 
diameter due to reduced NFATc2 
dependent myoblast to myotube 
fusion 
(Horsley et al., 2003) 
IL-10  Myoblasts 
 Myotubes 
 M2 macrophages 
 T-cells, mainly Th2 
and T-reg 
 Prevents IGF-1 resistance by 
inhibiting the IL-1β induced JNK 
pathway, resulting in myogenin 
expression in myoblasts 
(Strle et al., 2008) 
IL-6  Satellite cells 
 Myotubes 
 M1 macrophages 
 T-cells 
 Neutrophils 
 Applied to rat myoblasts in vitro 
leads to enhanced differentiation 
 
 An IL-6 Ab reduced muscle 
atrophy in mice overexpressing IL-6
 
 Muscle disuse atrophy was 
extended in IL-6 knockout mice 
coinciding with delayed 
differentiation markers 
 
 IL-6 induces myoblast proliferation 
via a STAT3 dependent pathway 
 
 IL-6 mAb did not improve mdx 
regeneration profile 
(Okazaki et al., 1996) 
 
(Tsujinaka et al., 1996)
 
(Washington et al., 
2011) 
(Serrano et al., 2008) 
 
 
 
(Kostek et al., 2012) 
IL-1β  Myoblasts 
 Myotubes 
 M1 macrophages 
 NK cells 
 Neutrophils 
 Physiological concentrations of IL-
1β block IGF-1 induced protein 
synthesis and myogenin expression 
(Broussard et al., 2004)
TNFα  Myotubes 
 M1 macrophages 
 Th1 lymphocytes 
 Neutrophils 
 Physiological concentrations of 
TNFα inhibits IGF-1 induced protein 
synthesis and myogenin expression 
in both mice and pigs 
 
 TNFα promotes the proteasome-led 
destabilisation of MyoD leading to 
delayed myoblast cell-cycle exit 
 
 TNFα inhibits myogenic 
differentiation via NF-κβ pathway 
 
 Prolonged recombinant TNFα 
application decreases total muscle 
proteins 
(Miller et al., 1988; 
Layne & Farmer, 1999; 
Broussard et al., 2003)
 
 
(Langen et al., 2004) 
 
 
 
(Langen et al., 2001) 
 
 
(Fong et al., 1989) 
Osteopontin  Osteoblasts 
 Myoblasts 
 Macrophages 
 T-cells 
 Immobile osteopontin promoted the 
fusion of myoblasts whilst soluble 
osteopontin promoted myoblasts 
proliferation and resulted in smaller, 
rounder, myotubes 
(Uaesoontrachoon et 
al., 2008) 
Table 3.2. Selected inflammatory cytokines and their influence on skeletal muscle 
regeneration. Expressing cells listed are limited to those populations that can be present within 
skeletal muscle. The colour coding represents the general impact of the effect on muscle 
regeneration, from pro-regenerative (blue), mixed (purple), to deleterious (red). 
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3.1.3 Chapter summary 
The P2X7 receptor has the potential to affect various aspects of DMD disease 
progression due to its expression on muscle precursor cells as well as infiltrating 
immune cells. The effect of P2X7 ablation in the mdx mouse muscles were analysed 
using morphological and biochemical methods in two mdx P2X7-/- dKO mouse strains 
developed specifically for this study. Morphometric analysis was performed to 
compare muscle fibre size variation, fibre size distribution and the central nucleation 
index between mdx and mdx/P2X7-/- muscles. The choice of mouse muscles for these 
analyses was based on published guidelines (Willmann et al., 2012). To account for 
potential involvement of P2X7 in myoblast proliferation and differentiation, satellite 
cell quantification was undertaken to compare mdx with mdx/P2X7-/-.  
Western blotting was used to compare the expressions of myogenic and regenerative 
markers: myogenin and eMyHC. These analyses were supported with a revertant 
dystrophin-expressing fibre count comparison in mdx compared to mdx/P2X7-/- 
muscles.  
The muscle expression of the dystrophin analogue, utrophin, was compared between 
mdx and Pfizer mdx/P2X7-/- mice to evaluate possible changes in compensatory 
upregulation  (Rafael et al., 1998) and as it is also linked with a shift to a slow-
oxidative myogenic program (Gramolini et al., 2001; Selsby et al., 2012). 
Finally, diaphragms at the age of ~20 months was chosen to observe changes in 
minimum Feret’s diameter and revertant fibre numbers in Pfizer mdx/P2X7-/- 
compared to mdx, as at this age pathology has progressed to a very advanced stage in 
one of the most severely affected muscles in this mouse model of DMD. 
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3.2 Results 
3.2.1 Characterisation of the mdx/P2X7-/- double-mutant mouse strains 
The mdx mouse has been identified by Bulfield et al. (1984) in C57 BL/10 strain and 
found to be a spontaneous point mutation in exon 23 of the mouse dystrophin gene 
(Figure 3.2; Sicinski et al., 1989). 
Using primers sets specific for each allele (Figure 3.2), regular genotyping was 
undertaken to identify the genetic status (Figure 3.3a). The status was also confirmed 
at the protein level by Western blotting method showing that Pfizer and Glaxo 
mdx/P2X7-/- animals lacked both dystrophin (Figure 3.3b and d) and P2X7 receptor 
(Figure 3.3b and c). Additionally, it was found that mdx/P2X7+/- heterozygous male 
mice had the P2X7 expression level qualitatively intermediate between the mdx and 
C57 mouse (Figure 3.3d). 
Immunofluorescence analysis of P2X7 protein expression was undertaken using the 
most specific and best characterised antibody (177 003 Synaptic Systems). Using this 
antibody, P2X7 expression was found to localise to regions of mononuclear cell 
infiltrations in and around areas of skeletal muscle fibre degeneration in the mdx 
mouse at 4 weeks of age (Figure 3.4a). P2X7 receptor mRNA and protein is 
expressed in normal and dystrophic myoblasts and myotubes in vitro (Yeung et al., 
2006) and here P2X7 receptor localisation in the muscle fibre cytoplasm and at the 
sarcolemmal border of muscles in the mdx mouse has been found (Figure 3.4b). In 
the 4 week old mdx/P2X7-/- mouse, no such P2X7 fluorescence signal was detected 
(Figure 3.4a) thus confirming its specificity in mdx samples. 
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Figure 3.2. DNA sequences of P2X7 receptor and DMD loci, along with diagnostic PCR 
primer alignment regions (blue). The Glaxo P2X7 KO mouse has a LacZ insertion following 
the ATG codon in exon 1 (The top section). WT primer pairs flank exon 1 and a KO specific 
reverse primer was complementary to LacZ (sequence not shown but insert location is 
indicated by the LacZ arrowhead). The Pfizer P2X7 KO mouse has a neomycin resistance 
cassette insertion replacing a sequence within exon 13, normally encoding Cys506 to Pro532 
(The middle section). A wild type (WT) primer pair flanks the insertion region, and the KO 
primer pair is neomycin specific (sequence not shown). (The bottom section) The mdx 
dystrophin mutation involves a nucleotide substitution from a cytosine (WT: larger font) to a 
thymine (mdx: Black, below the wild-type sequence) within exon 23. The reverse primer 
allows for discrimination between WT and mdx sequences, and the forward primer is shared 
(sequence data from blast.ncbi.nlm.nih.gov/).  
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Figure 3.3. PCR and Western blot characterisation of Glaxo and Pfizer mdx/P2X7-/- 
compared to C57 BL/10 and mdx mice. a) Example PCR product analysis to confirm KO 
status of Glaxo mdx/P2X7-/- (dKO), Pfizer mdx/P2X7-/- (dKO), and mdx compared to C57. 
Specific dystrophin WT bands (105 bp) were present in C57, with faint read through bands in 
the KO genotypes likely due to the primer poorly discriminating between one nucleotide 
substitution at the 3’-end. Dystrophin mdx mutant bands (also 105 bp) are shown only for 
Glaxo dKO, Pfizer dKO, and mdx. Pfizer P2X7 KO status was determined with multiplex 
PCR containing primers for the P2X7 WT sequence spanning the beginning of exon 13 and a 
neomycin resistance cassette. Neomycin bands (280 bp) were present in both P2X7 KO 
mouse lines as neomycin was used as a selective marker in both. Specific Pfizer P2X7 WT 
bands (363 bp) were present, as expected, for C57, Glaxo dKO and mdx. Glaxo P2X7 WT 
primers span exon 1, and specific bands (566 bp) were observed for C57, Pfizer dKO, and 
mdx. KO bands (393 bp), representing amplification between the shared forward primer to a 
reverse primer within the LacZ motif, were present in Glaxo dKO only. b) Western blotting, 
showing increased P2X7r expression in mdx compared to C57, and its absence in Pfizer 
P2X7-/- and mdx/P2X7-/- TA muscles. Also note, dystrophin (427kDa) is present in C57 and 
Pfizer P2X7-/-, but not in mdx and mdx/P2X7-/- tissues. c) Western blots showing P2X7 
receptor subunit bands (78 kDa) in mdx that are absent in both Pfizer and Glaxo dKO skeletal 
muscle. d) Western blot (top) showing a lack of full length dystrophin (427 kDa) in both mdx 
and Pfizer P2X7+/- F1 heterozygous dystrophic mice compared to C57 WT controls. Another 
blot (bottom) indicating the increased expression of P2X7 in dystrophic skeletal muscle 
compared to C57, and also highlighting an intermediate expression of P2X7 in a mdx/P2X7+/- 
heterozygous mouse compared to mdx mice. Right, a graphical representation of the Western 
densitometry data showing a significant decrease in P2X7 receptor protein in the F1 P2X7+/- 
heterozygous mdx mouse compared to mdx (T-test, T=-3.65, df=1, P=0.022, assuming equal 
variance). All western-blotting bands at expected weights (Table 2.3). 
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Figure 3.4. The P2X7 receptor is upregulated in mdx compared to C57 TA muscle, localised 
to regions of monocellular infiltration and at the periphery of centrally nucleated muscle 
fibres, and is absent from the mdx/P2X7-/- (dKO) mouse. Immunolocalisation of P2X7 
receptors in 4 week mdx TA compared to Pfizer mdx/P2X7-/- samples. a) Note the 
predominant endomysial localisation of P2X7 (green signal) particularly in the areas of 
pathological infiltrations of inflammatory cells (identifiable by concentrations of cell nuclei - 
blue) in mdx skeletal muscle and its near complete absence in Pfizer dKO tissue. In Pfizer 
dKO tissue, P2X7 signal may be found in a small subset of mononuclear cells infiltrating the 
muscle (e.g. arrows; and bottom inset). P2X7 signal is absent in the negative control 
(secondary antibody only: not shown). b) In 4 week mdx, P2X7 may also localise to the 
muscle sarcolemmal borders of regenerating fibres (arrows). Left images show magnified 
insert region from the total cross-section on the right. Also note, P2X7 is expressed in a nerve 
trunk innervating muscle (arrowhead, at same location in both channels and characteristic 
morphology in collagen IV staining (Hagg et al., 2001) and orange signal when co-localised 
with P2X7).  
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3.2.2 Histological examination of mdx and mdx/P2X7-/- muscle at 4 weeks and 4 months 
To monitor for the skeletal muscle damage present at the acute degenerative and post-
degenerative phases of the mouse disease, 4 week and 4-5 month C57 wild-type, mdx, 
and Pfizer mdx/P2X7-/- TA muscle sections were analysed histologically. Nuclei and 
cytoplasm were delineated using standard H&E staining.  
 At 4 weeks, coinciding with an acute period of muscle degeneration-regeneration in 
the mdx mouse (Dangain & Vrbova, 1984; Tanabe et al., 1986; Coulton et al., 1988; 
Roig et al., 2004; Yeung et al., 2004; Willmann et al., 2012), mdx and Pfizer 
mdx/P2X7-/- TA presented clear regions of mononuclear cell infiltrations, fibre size 
variation, and instances of hyalinated or necrotic fibres that were absent in C57 
controls (Figure 3.5). These regions of pathology were distributed sporadically across 
the whole spectrum of mid-belly muscle cross-sections. The heterogeneous 
distribution of pathological changes within a single muscle cross-section between 
contralateral muscles (Kobayashi et al., 2012), and between individual animals of the 
same genotype has previously been noted. Therefore, it was difficult to identify 
significant differences in histopathology between H&E stained 4 week mdx and Pfizer 
mdx/P2X7-/- TA muscles by sight. 
At 4 months, regions of inflammation were less pronounced in dystrophic samples 
than at 4 weeks. Fibre size variation was still evident and the incidence of central 
nucleation was greatly increased, indicative of the degenerative-regenerative history 
of these muscles (Figure 3.5). 
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Figure 3.5. H&E staining, showing comparable histological features in dystrophic 4 week 
(left) and 4 month (right) TA muscle from mdx (middle) and Pfizer mdx/P2X7-/- (dKO - 
bottom). Note, the highly characteristic increased muscle fibre size variation in dystrophic 
mdx and dKO groups compared to C57 (top). Also note, the increased central nucleation and 
numbers of interstitially located nuclei in dystrophic tissue compared to C57 controls. 
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3.2.3 Quantification of satellite cell markers in skeletal muscles of mdx and mdx/P2X7-/- 
mice 
Considering the previously identified P2X7 receptor expression in muscle precursor 
cells, myoblasts and myotubes in vitro and in vivo (Araya et al., 2004; Banachewicz et 
al., 2005; Martinello et al., 2011; Young et al., 2012), an immunological analysis was 
undertaken to determine if P2X7 ablation would have any effect on satellite cell 
number. 
Antibodies against collagen type-IV and Pax7 were used to identify quiescent or 
activated satellite cells in relation to extracellular matrix components representing the 
periphery of muscle fibres, in 4 month C57 and mdx TA tissue. As has been published 
before (Seale et al., 2000), Pax7 (considered the satellite cell marker) localised to 
extracellular regions of mononuclear cell aggregation and to central nuclei inside 
regenerating fibres, in addition to a typical localisation beneath the basal lamina on 
the myofibre periphery (Figure 3.6a). 
Pax7 immunostaining was then used in a cross comparison of C57 (wild type), mdx, 
and mdx/P2X7-/- TA muscles at 4 weeks and 4 months, ages coinciding with acute 
degenerative and post-degenerative phases of disease progression. At 4 weeks, Pax7 
marker expression was greatly increased in dystrophic muscles compared to C57 
(Figure 3.6b left panels). Pax7 was also more often found in extracellular regions of 
nuclear aggregation or coinciding with central nuclei in dystrophic tissue compared to 
C57 wild-type controls (Figure 3.6a). At both 4 weeks and 4/5 months, mdx Pax7 
immunofluorescence in mdx was similar in terms of expression levels and patterning 
compared to mdx/P2X7-/- samples. 
A Western blotting study was undertaken to compare total Pax7 expression levels in 4 
week old C57, mdx, Glaxo and Pfizer mdx/P2X7-/- TA and GC muscle lysates (Figure 
3.7). Total Pax7 expression levels were found not to differ significantly between 
dystrophic strains harbouring the wild-type or the mutated P2X7 genes. 
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Figure 3.6. Pax7 signal is visible in satellite cells (including activated), it is  more 
pronounced in dystrophic muscle relative to control but there are no differences between mdx 
and Pfizer mdx/P2X7-/- tissues at 4 weeks or 4/5 months. a) Example immunofluorescence 
images showing Pax7 (green), within nuclei in cellular interstitial regions of active myoblast 
recruitment (left, arrow), in typical sub-sarcolemmal positions (right, arrowhead) in mdx and 
C57 skeletal muscle sections, respectively. Also note Pax7 expression within centrally placed 
nuclei of mdx. b) Pax7 signal across C57 (top), mdx (middle), and Pfizer mdx/P2X7-/- (DKO: 
bottom) 4 week (left) and 4-5month (right) tibialis anterior (TA) muscles. Images of 4/5 
month samples also show collagen signal (red) over half of image capture area. Note the 
increased Pax7 signal in mdx and Pfizer mdx/P2X7-/- tissues at 4 weeks compared to C57. 
Also, typical satellite cell placement on the periphery of myofibres is more evident in C57 
than in dystrophic tissue.  
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Figure 3.7. Western blotting of Pax7 satellite cell marker levels across genotypes, 
showing no significant differences in Pax7 expression in TA or GC at 4 weeks between mdx, 
Glaxo mdx/P2X7-/-, or Pfizer mdx/P2X7-/-. a) Example Western blots showing the expression 
of Pax7 across all four genotypes in 4 week gastrocnemius (GC) muscles. b) Graphical 
representation of TA (left) and GC (right) muscle Western blot densitometry data, showing 
no significant difference between any of the experimental groups at this time point (TA: 
ANOVA, F=2.34, df=2, P=0.136, N=3, 7, 6; GC: ANOVA, F=0.58, df=2, P=0.58, N=4, 4, 4). 
All western-blotting bands at expected weights (Table 2.3). 
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3.2.4 Morphometric comparisons between mdx and mdx/P2X7-/- skeletal muscles 
A systematic study was undertaken to determine the effect of P2X7 ablation on the 
morphology of dystrophic muscle fibres in vivo. To accomplish this, a semi-
automated form of morphometric image analysis was developed using Fiji. Previous 
logical operations necessary to complete such an analysis have been described 
(Briguet et al., 2004). Using this study as a methodological template, macros were 
written that sequentially translated an immuno-labelled image into a binary 8-bit 
format, dilated borders to close illogical border gaps and which measured threshold-
delimited areas, finally reporting their spatial properties (see Figure 3.8a and 
Appendix 9.3). Using this method, thousands of individual muscle fibres comprising 
a whole skeletal muscle cross-section, were analysed simultaneously. Results obtained 
from the whole cross-sectional analysis therefore negate the issue of the heterogeneity 
generated by random field sampling, which has the potential to unrepresentatively 
skew data. The accuracy of the semi-automated method was further confirmed 
qualitatively by overlaying a mask-output of the ‘analyse particles’ function of Fiji-
ImageJ upon the original immunofluorescence image (Figure 3.9a). Furthermore, a 
more systematic manual versus semi-automatic count was employed to compare 
analyses of the same image (Figure 3.9b). Using an additional ImageJ plugin 
(Ferreira, 2009-2012), a fibre cross-section was colour-coded according to 
morphometric variables. Using this tool, fibre size heterogeneity was evident across 
muscle cross sections (Figure 3.8b). In line with previous observations, fibre size 
heterogeneity was more pronounced in mdx than in C57 skeletal muscles in these 4 
month example animals (Briguet et al., 2004). 
Using this validated semi-automated method, several morphometric variables were 
compared in 4 week and 4 month old mdx and Pfizer mdx/P2X7-/- TA mid-belly cross 
sections. Indicative of many factors influencing muscle re-modelling processes, the 
level of muscle fibre size heterogeneity can be quantified and compared using a 
measure of the ‘coefficient of variation’ (CoV). The coefficient of variation is defined 
as the fibre size standard deviation divided by the mean, then multiplied by a constant 
x1000 (Briguet et al., 2004). Fibre size inconsistencies can be introduced due to the 
cryosectioning of tissue at variable oblique angles. To compensate for this, the fibre 
size unit of ‘minimum Feret’s diameter’ was adopted, as recommended by Briguet et 
al. (2004). Using the measure of fibre size variability across whole muscle cross-
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sections, an average CoV of 370 was determined for 4 week mdx compared to 400 for 
Pfizer mdx/P2X7-/-. At 4 months, mdx TA had an average CoV of 535 compared to 
548 for Pfizer mdx/P2X7-/-. This qualitative increase in the CoV for Pfizer dKO 
compared to mdx at both monitored ages was not statistically significant (Figure 
3.10b). 
Paracrine signalling cues and myogenic fusion events influence myofibre size 
following muscle tissue damage or mechanical stretch. Over the progression of the 
disease in the mdx mouse, myofibre sizes change according to the influence of these 
multiple factors leading to well-characterised differences between wild-type and 
dystrophic tissues (Roig et al., 2004). Comparing average fibre size using the semi-
automated morphometric method, Pfizer mdx/P2X7-/- muscle had a significantly 
greater minimum Feret’s diameter than mdx at 4 weeks of age (Figure 3.11a). At 4 
months, there was no significant difference in fibre size between Pfizer mdx/P2X7-/- 
and mdx TA muscle. 
To separate fibres that had undergone active regeneration from those that had not, a 
sub-level analysis of the morphometry data was run to determine the difference in 
minimum Feret’s diameter (fibre size) between centrally nucleated and non-centrally 
nucleated mdx and Pfizer mdx/P2X7-/- TA muscle at 4 weeks. This analysis showed 
that the difference in muscle fibre size found between these genotypes was mainly an 
effect of an increase in the size of centrally nucleated Pfizer mdx/P2X7-/- fibres. 
Across a fibre size distribution histogram, this increase in centrally nucleated 
minimum Feret’s diameter is represented by the right shift of the data plot for Pfizer 
mdx/P2X7-/- relative to mdx (Figure 3.11b). This translates to an increase in the 
maximal modal myofibre size grouping from 18.75-21.25µm for centrally nucleated 4 
week mdx TA fibres to 28.75-31.25µm for Pfizer mdx/P2X7-/-. The shallower peak in 
the percentage distribution of fibres, coupled to an extended upper range in overall 
distribution of fibre size, also helps to explain the slight qualitative increase in the 
coefficient of variation data for Pfizer dKO compared to mdx at this age (Figure 
3.10b). 
In accordance with Briguet et al. (2004), an image analysis method was integrated 
into the current Fiji macro to allow the quantification of centrally nucleated muscle 
fibres. Specifically, a mask of the filtered blue-Hoechst-nuclei channel was overlaid 
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onto an ‘analyse particles’ output, with the subsequent centrally nucleated fibres being 
recognised according to the presence of ‘holes’. The presence of central nuclei in 
post-mitotic muscle fibres indicate previous regeneration events and is used as a 
measure of pathological severity (Spurney et al., 2009). Loss of P2X7 did not result in 
a significantly different level of central nucleation in dystrophic muscle at either 4 
weeks or 4 months (Figure 3.10a). 
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Figure 3.8. Summary of image processing steps used to perform a semi-automated 
morphometric image analysis and confirmation of global differences between disease and 
control tissue. a) Example images showing an original Collagen type-IV immunostained 
muscle section (top-left), followed by conversion to 8-bit grayscale (top-right), binary band-
pass filtration before several pixel dilation and erosion steps (bottom-left) and software 
plugin particle analysis with a labelled mask output (bottom-right). b) Example fibre-size 
colour coded TA cross-sections from a C57 and an mdx mouse, derived from applying a ‘ROI 
colour coding’ plugin (Ferreira, 2009-2012) to a mask output from the semi-automated Fiji 
morphometric analysis of merged muscle cross-sections. 
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Figure 3.9. Comparison of semi-automatic versus manual morphometry, showing similar 
muscle fibre de-lineation and morphometric value outputs. a) An image of a collagen-IV 
(red) immunolabelled mdx skeletal muscle cross-section overlaid with the Fiji-ImageJ 
“analyse particles” mask, demonstrating a very high degree of muscle-boundary overlap. 
Nuclei (blue). b) Box plots and a histogram of morphometry data from 3 separate analyses, 
also showing a high degree of similarity between manual and automatic approaches. 
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Figure 3.10. The percentage of central nucleation and the coefficient of variation for 
minimum Feret’s diameter is not different between TA muscle fibres from mdx and Pfizer 
mdx/P2X7-/- at 4 weeks or 4 months. a) Average percentage of centrally nucleated muscle 
fibres in mdx and Pfizer mdx/P2X7-/- showed no significant difference in central nucleation 
(2-way ANOVA, F=1.18, df=1, P=0.299). b) Average coefficient of variation showed no 
significant difference between mdx and Pfizer mdx/P2X7-/- at 4 weeks or 4 months (2-way 
ANOVA, F=2.93, df=1, P=0.113). 
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Figure 3.11. Minimum Feret’s diameter is increased in 4 week TA from Pfizer mdx/P2X7-/- 
compared to mdx, and is not significantly so at 4 months. a) Graphical representation of 
average minimum Feret’s diameter of TA muscle fibres, showing a significantly greater fibre 
size in Pfizer mdx/P2X7-/- (dKO) compared to mdx at 4 weeks (T-test, T=-3.55, df=5, 
P=0.016) and no statistically significant difference at 4 months (T-test, T=-1.5, df=5, 
P=0.193). b) Histogram of minimum Feret’s diameter of centrally nucleated 4 week TA 
muscle fibres showing a right shift in the fibre size distribution of Pfizer mdx/P2X7-/- 
regenerated fibres compared to mdx.  
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3.2.5 Analysis of myogenic and regenerative markers in mdx and mdx/P2X7-/- 
skeletal muscles 
To assess the effect of P2X7-receptor ablation on candidate MRFs, myogenin and 
embryonic myosin heavy-chain (eMyHC) expressions were analysed in TA muscle 
extracts from 4 week old mice by Western blotting. Both of these markers have been 
used to describe changes in muscle fibre turnover correlating with dystrophic severity 
(Chen et al., 2000). The late differentiation-associated myofibre transcription factor, 
myogenin, was found to be significantly up-regulated in Pfizer and Glaxo P2X7-/- 
samples compared with mdx, with no difference in the expression between the two 
mdx/P2X7-/- strains (Figure 3.12). As expected, C57 showed little myogenin 
expression (data not shown). At 4 weeks, levels of eMyHC were reduced in Pfizer 
mdx/P2X7-/- TA muscles compared to mdx and similar between both mdx/P2X7-/- 
mouse strains (Figure 3.13). C57 TA muscle showed no detectable eMyHC 
expression (not included in statistical comparison due to low N number). 
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Figure 3.12. Western blotting, showing increased myogenin protein expression in Glaxo 
and Pfizer mdx/P2X7-/- muscle compared to mdx at 4 weeks. a) Representative Western blots 
from 3 different animals each for myogenin (~34 kDa), in mdx, Glaxo mdx/P2X7-/-, and 
Pfizer mdx/P2X7-/- (dKO), compared to β-tubulin loading control. b) Graphic representation 
of the quantitative analyses of the expression of myogenin relative to β-tubulin based on the 
densitometry values of the Western blot data, showing significantly greater myogenin 
expression in Glaxo dKO and Pfizer mdx/P2X7-/- muscle compared to mdx (ANOVA, 
F=33.38, df=2, P<0.001, Tukey post-hoc). All western-blotting bands at expected weights 
(Table 2.3). 
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Figure 3.13. Western blotting, showing reduced embryonic myosin heavy chain (eMyHC) 
protein expression in Pfizer mdx/P2X7-/- muscle compared to mdx at 4 weeks. a) 
Representative Western blot images of eMyHC and actin used as a protein loading control 
(Each lane contains protein from a different animal). b) The graphical representation of 
densitometric data derived from these immunoblots, showing significantly lower eMyHC 
expression in Pfizer mdx/P2X7-/- compared to mdx (Mann Whitney, W=27.0, α=0.04, 
P=0.0187 adjusted for ties). eMyHC expression was not detectable in C57 samples. All 
western-blotting bands at expected weights (Table 2.3).  
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3.2.6 Immunolocalisation and analysis of revertant fibre numbers in mdx and mdx/P2X7-/- 
muscle at 4 months 
A major feature of the dystrophic pathology in both mdx mice and DMD is the 
turnover of regenerating myofibres (Tanabe et al., 1986; Wallace & McNally, 2009). 
One indication of an improved disease profile is the reduction in the number of 
degeneration-regeneration cycles. Analysis was undertaken to compare the number of 
these cycles in Pfizer and Glaxo mdx/P2X7-/- muscles to that of mdx. 
Muscle fibres that gain dystrophin due to the restoration of the open reading frame of 
its transcript are known as revertant. The chances of somatic mutation or alternative 
splicing event responsible for such restoration increase with age and, particularly, the 
number of degeneration-regeneration events. Therefore, revertant fibre number have 
been used as an index for the numbers of such events that any skeletal muscle has 
suffered (Hoffman et al., 1990; Yokota et al., 2006; Young et al., 2012). Analysis of 
anti-dystrophin labelled 4 month TA cryosections (Figure 3.14) showed that there 
was a decrease in the mean percentage of revertant fibres relative to total fibres, 
particularly in Pfizer mdx/P2X7-/- (0.997%) compared to mdx (1.306%). However this 
difference failed to reach statistical significance.  
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Figure 3.14. Immunofluorescence analysis, showing no difference in revertant muscle fibre 
numbers in Glaxo or Pfizer mdx/P2X7-/- TA muscle compared to mdx at 4 months. a) 
Example images of 4 month TAs from all genotypes immunostained for dystrophin (green 
signal), highlighting revertant fibres (arrows) present in dystrophic genotypes. b) Graphical 
representation of revertant fibre counts, showing no significant difference in average values 
between genotypes at these N numbers (ANOVA, F=1.57, df=2, P=0.274).  
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3.2.7 Analysis of utrophin expression in mdx and mdx/P2X7-/- skeletal muscles at 4 
weeks 
We have previously identified an increase in centrally nucleated fibre size in 
mdx/P2X7-/- muscles. Gross morphological changes have been correlated with 
oxidative shift of fibre-types and utrophin overexpression (Ekmark et al., 2003). 
Therefore, utrophin protein expression in GC muscles at 4 weeks was compared 
between Pfizer mdx/P2X7-/- and mdx mice (Figure 3.15). There was no significant 
difference in utrophin expression levels relative to β-tubulin between these genotypes 
at this age. C57 BL/10 samples were not included in the analysis because utrophin is 
known to be expressed at much lower levels in healthy muscles (Helliwell et al., 
1992; Pons et al., 1994). 
 
 
Figure 3.15. Western blotting, showing no difference in Utrophin protein expression 
between mdx and Pfizer mdx/P2X7-/- GC muscle at 4 weeks of age. a) Western blot image for 
utrophin (400kDa) and β-tubulin (43kDa) loading control. b) Graphical representation 
comparing average utrophin band intensity relative to β-tubulin, showing no significant 
difference between the genotypes (T-test, T=-0.87, df=3, P=0.446). All western-blotting 
bands at expected weights (Table 2.3). 
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3.2.8 Mimimum Feret’s diameter and revertant fibre comparisons between aged, 20 
month, mdx and mdx/P2X7-/- diaphragms 
Mdx diaphragm muscle undergoes continuous degeneration. The immuno-histological 
comparisons of skeletal muscle regeneration indices were extended to see if 
improvements suggested at earlier time points translate into this more severely 
affected tissue. Using a semi-automated method of morphometry, it was confirmed 
that average minimum Feret’s diameter of diaphragm muscle fibres was increased in 
Pfizer-mdx/P2X7-/- compared to mdx at ~20 months of age (Figure 3.16a). The 
morphometric method could be adapted to work in even highly fibrotic old-dystrophic 
tissue (Figure 3.16b), and was employed to measure all muscle fibres in cross-section 
simultaneously (Figure 3.16c). 
Moreover, through immuno-histological comparisons, significantly fewer revertant 
fibres in aged Pfizer-mdx/P2X7-/- compared to mdx were confirmed (Figure 3.16d). 
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Figure 3.16. Immunological and histological markers of regeneration are improved by 
P2X7 receptor ablation in aged dystrophic diaphragms. a) Graph showing increased average 
minimum Feret’s diameter of ~20 month diaphragm muscle fibres in WT (C57) and Pfizer-
mdx/P2X7-/- compared to mdx (ANOVA, F=40.72, P<0.001, df=3, n=3; Tukey post-hoc). b) 
An image depicting the method of semi-automated morphometry applied here, which could 
be used to measure all muscle fibres in an entire cross-section of a rolled diaphragm 
simultaneously (c, C57 shown in this example). d) There were also significantly fewer 
revertant fibres in Pfizer-mdx/P2X7-/- compared to mdx ~20 month diaphragms (T-test, 
T=5.12, P=0.036, df=2, n=3).  
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3.3 Discussion 
3.3.1 Generation and characterisation of mdx/P2X7 -/- double mutant mice 
The Glaxo P2X7 KO (Glaxo P2X7-/-) mouse was developed by using homologous 
recombination to disrupt the open reading frame by insertion of a promoterless lacZ 
construct into exon 1 of the mouse P2X7 gene and then backcrossed onto a C57 BL/6 
wild-type background (Chessell et al., 2005). The Pfizer P2X7 KO (Pfizer P2X7-/-) 
mouse was made by insertion of a neomycin resistance cassette within exon 13 of the 
P2X7 gene, which caused an out-of-frame replacement within the C-terminus of the 
receptor sub-unit (Solle et al., 2001). Pfizer KO mice were also bred onto a C57/BL6 
background. Both Glaxo P2X7-/- and Pfizer P2X7-/- mice were found viable but with 
slightly altered immune responses (see Chapter 4). 
Using PCR and Western blotting the creation of two types of P2X7 mdx dKO animal 
strains was confirmed. The Glaxo dKO animal has a disruption in exon 1 of the P2X7 
gene. The Pfizer dKO mouse was confirmed dystrophic, testing positive for the mdx 
mutation DNA by PCR and harbouring a neomycin resistance cassette displacing a 
region of exon 13 of the P2X7 receptor, resulting in the loss of P2X7 protein 
expression in Western blotting of muscle tissue extracts (Figures 3.2 and 3.3c). 
However, by immunolocalisation of cryosectioned TA tissue, a drastically diminished 
but still detectable expression of a P2X7 positive signal was evident in the double KO 
animal (Figure 3.4). The most likely cause for this signal is the previously identified 
splice variant of the P2X7 protein that can escape inactivation in the Pfizer KO strain 
(Taylor et al., 2009a). Thought only to be expressed in the T-cell subset of 
haematopoietic-derived immune cells, this variant was also found to be non-functional 
(Taylor et al., 2009a). 
Perhaps more important as potential disease mediators are the other reported P2X7 
splice variants, especially one describe in the Glaxo P2X7 KO mouse. First described 
by Nicke et al. (2009) with contribution from our laboratory, the P2X7k variant, 
possesses an altered N-terminal region that can actually enhance canonical large pore 
opening and subsequent cell death processes in response to ligand-receptor; ATP-
P2X7 interactions. However, it has been found that the Glaxo mdx/P2X7-/- animal has 
no detectable P2X7 protein in muscle tissue extracts (Figure 3.3c). 
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There is also some controversy over the presence of functional splice variants 
preferentially expressed in regions of the central nervous system that may escape 
deletion in one or either of the two P2X7 KO mouse strains (Masin et al., 2012). The 
currently employed genetic PCR strategy for determining KO status does not 
discriminate between individuals likely to possess these alternative receptor 
transcripts. However, it may be possible that the P2X7 antibody used to confirm the 
absence of the full receptor from the dKO strains (Figure 3.3b) would recognise the 
K variant P2X7 receptor. In terms of suspected antibody-peptide interactions, it would 
be expected that the Synaptic Systems antibody (177 003), targeting a C-terminal 
region, may also recognise an N-terminally modified P2X7 peptide sequence. The 
antibody used therefore has the potential to recognise the two major functional P2X7 
isoforms. The predominant ‘a’ and the gain of function ‘k’ splice variant differ by the 
substitution of the first 42 amino acids in the N-terminal domain of the P2X7 receptor 
(Nicke et al., 2009). The dominant negative-like 13b and 13c splice variants have also 
been shown to be expressed in Pfizer P2X7 KO tissues by us and others. The 13b and 
13c isoforms are C-terminal truncated variants and were not expected to be recognised 
using the current antibody (Masin et al., 2012). 
Another biological variable that could systematically affect disease phenotype and 
potentially bias further pre-clinical experimental testing is the differing background 
genetics of the experimental animals. For example, P2X7 genetic polymorphisms can 
influence key receptor functions. The common C57 BL/6 mouse strain has been 
shown to contain a proline to leucine amino acid substitution at position 451 of the 
P2X7 sequence that substantially reduces receptor activity (Adriouch et al., 2002). 
For this reason Adriouch et al. (2002) have warned against neglecting this variable 
when constructing pre-clinical experimental animal studies that involve the testing of 
the role of the P2X7 receptor. By being forced to use mdx and two P2X7 KO strains 
of mice, which are derived from C57 BL/10 and C57 BL/6 background strains 
respectively, we have introduced the potential for a systematic background mediated 
influence of P2X7 receptor polymorphisms contributing to an experimental bias. The 
proline 451 to leucine substitution is common to both strains (Adriouch et al., 2002). 
Therefore, by using these strains of mice, it is likely that we are underestimating the 
role of P2X7 in the pathogenic progression of muscular dystrophy. Interestingly in 
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humans, P2X7 polymorphisms that reduce receptor pore formation also shift immune 
cells to a lesser inflammatory state (Denlinger et al., 2005). 
The C57 BL/10 strain of mouse is derived from the BL/6 type, minimising the 
chances for genetic background effects. Nevertheless, to address the issue of genetic 
heritage potentially influencing P2X7 function or mdx disease phenotypes, a control 
dystrophic P2X7+/- heterozygote (F1) heterozygote was used for comparison with the 
P2X7+/+ homozygous and mdx mouse strains. Since the F1 het mice were the resultant 
litter from an mdx female and a Pfizer P2X7 KO male, all males were expected to be 
dystrophic and to possess a fully functional P2X7 receptor on a mixed C57 BL/10 and 
BL/6 background. Subsequent differences between this control litter and the mdx 
mouse, according to key functional disease diagnostic tests including the level of 
serum CK (see Chapter 5), would therefore likely represent the effect of the mixed 
background influence. However, as shown in this section, the F1 het mouse possesses 
a significantly reduced expression of the P2X7 receptor compared to the mdx mouse 
(Figure 3.3c) that would ultimately alter the P2X7 influence on disease progression. 
Such an unexpectedly reduced expression of P2X7 on the heterozygous background 
has been previously reported for heterozygous immune cells (Chen et al., 2011). 
Clearly, the F1 heterozygotes could not be used as a positive control for the 
mdx/P2X7-/- KO mice but they serve as a good control for analyses of the effects of 
reduction of P2X7 levels in the dystrophic muscle. This could also explain the greater 
minimum Feret’s diameter of mdx/P2X7+/- muscle fibres compared to mdx (Appendix 
9.4). 
Moreover, the results from the Glaxo mdx/P2X7-/- mice could be used as a proof that 
the effects observed are due to P2X7 receptor knockout and not due to genetic 
background variation: both Glaxo and Pfizer are on the C57/Bl6 background but 
Pfizer mdx/P2X7-/- mice lacking all functional receptors showed significantly stronger 
effects than the Glaxo mdx/P2X7-/- mice, which retain one functional P2X7 isoform. 
The present study shows that the P2X7 receptor localises to regions of monocellular 
infiltration, in the peripheral nervous system including nerve bundles, and at the 
sarcolemmal border of regenerating myotubes in mdx muscle (Figure 3.4). 
Sarcolemmal staining of P2X7 protein is consistent with previous lab findings for this 
receptor subunit (Yeung et al., 2006), for other P2X subunits (Jiang et al., 2005), and 
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the notion that P2X receptors may be necessary for, at least phases of, skeletal muscle 
myotube formation (Ryten et al., 2002; Araya et al., 2004). These latter groups have 
also shown P2X receptor localisation to developing and regenerating rat skeletal 
muscle in vivo (Ryten et al., 2001). However, our finding that myogenin expression 
may be upregulated upon the loss of P2X7 receptor activity in the mdx mouse model 
of DMD also partly contradicts the latter studies, in which P2X5 and P2X7 were 
shown to positively mediate skeletal muscle differentiation (Ryten et al., 2002; 2004). 
Myoblast to myotube terminal differentiation requires an increase in intracellular 
Ca2+. ATP is a stimulus that can induce this rise in intracellular Ca2+ in muscle cells 
(Collet et al., 2002; Cseri et al., 2002) but it must be possible for mouse skeletal 
muscle to achieve this Ca2+ threshold without the P2X7 receptor since no studies have 
reported a specific myogenesis defect in either Glaxo or Pfizer P2X7 KO animals. 
 
3.3.2 Histology and regeneration marker comparisons between mdx and mdx/P2X7-/- 
dKO muscles 
Myogenesis is a recurring feature of mdx muscle, along with muscle fibre 
degeneration due to both apoptotic and necrotic processes, and the influx of 
inflammatory cell types. All these features are evident in histological preparations of 
dystrophic muscle. There was an obvious qualitative difference in representative H&E 
staining between mdx and C57 BL/10 TA muscle sections at both 4 weeks and 4 
months (Figure 3.5). However, according to a qualitative assessment of these images, 
there was no clear difference between mdx and Pfizer mdx/P2X7-/- dKO muscles at 
both ages. This early stage analysis also highlighted an important experimental 
concern, primarily related to two observed mdx disease factors. Firstly, there is 
consistent pathological heterogeneity within even a single muscle section in 
dystrophic mice, such that one area of muscle may appear healthy, whilst an adjacent 
area presents massive degeneration or immune cell infiltrations. Secondly, and 
consistent with the described differences between human and mouse pathology, there 
are often very few major areas of degeneration within a single muscle cross-section. 
Exercise, or direct muscle intervention resulting in induced regeneration, is often used 
to exacerbate disease pathology in the mdx mouse model of DMD (Spurney et al., 
2009; Kobayashi et al., 2012; Willmann et al., 2012). Since the mdx mouse does not 
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present disease symptoms as severe as DMD patients, mouse muscle challenge is an 
experimental attempt to evaluate therapies or probe pathways during extreme phases 
of the disease pathology, perhaps more similar to the general human condition. The 
substantial central nucleation and general lack of widespread degeneration in even 4 
week TA muscles from the mdx mouse (Figure 3.5) attests to a potential draw-back 
with using unchallenged mice in this study. 
 
Pax7, satellite cells, and muscle precursor cells 
Upon satellite cell self-renewal, Pax7 expression may increase coincident with a 
reduction in later stage myogenic progression. For instance, activation of the MRF, 
myostatin, may result in a reduced muscle fibre size via an ERK1/2 mediated 
enhancement of the Pax7 self-renewal pathway (McFarlane et al., 2008). 
Inflammatory second messengers might also increase the proliferation of muscle 
precursor cells at the expense of muscle fibre growth. IL-6 promotes satellite cell 
proliferation via a STAT3 signalling pathway (Toth et al., 2011). Satellite cells have 
traditionally been considered a quiescent muscle precursor cell type, with the 
transcription factor Pax7 becoming down-regulated inversely proportional to the 
differentiation status of the cell and the expression of a series of major MRFs, MyoD 
and Myf5 (Seale et al., 2000; Olguin & Olwin, 2004). It has been subsequently shown 
that Pax7 is expressed in satellite cells even into differentiation (Zammit et al., 2004; 
2006; Collins et al., 2005), localising to centrally placed nuclei within muscle fibres 
and extracellular regions of muscle precursor cell fusion (Seale et al., 2000). This was 
confirmed here with the use of Pax7 immunofluorescence in 4 month mdx muscles 
(Figure 3.6). Using a now validated antibody, it was thus decided to compare levels 
of the satellite cell marker, Pax7, between mdx and both mdx/P2X7 dKO TA and GC 
muscles at 4 weeks (Figure 3.7). 
P2X7 has been implicated as a STAT3-related survival receptor in mouse embryonic 
stem cells (Thompson et al., 2012). Within undifferentiated E14tg2a cells, P2X7 
receptor variants including the full-length ‘a’ and gain of function ‘k’, were found to 
mediate cell proliferation upon basal ATP stimulation but cell necrosis after chronic, 
or high-dose exogenous, ATP activation. In dystrophic muscle, local levels of ATP 
can reach very high levels and is persistently increased in extracellular spaces 
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consistent with chronic sarcolemmal instability. We have failed to identify a 
difference in the levels of Pax7 between mdx and mdx/P2X7-/- dKO mice at the 
acutely degenerative 4 week period (Figure 3.7). This may indicate that there is no 
phenotype associated with the loss of P2X7 on satellite cell numbers in the mdx 
mouse, may reflect the counterbalance between reduced proliferation/self-renewal and 
the cell death of muscle precursor cells, or might reflect localised changes in small 
muscle regions that are not translated to significant quantitative differences when 
tested at the level of whole muscle. To further probe for an effect of P2X7 ablation on 
muscle regeneration in the mdx mouse, more MRFs were considered along with a 
histological analysis of fibre size. 
Enhancing muscle fibre size can increase resistance to contraction-induced damage 
and the deleterious effects of the dystrophic pathology (Gehrig et al., 2010). It is 
therefore interesting that we have seen an increase in the size of centrally nucleated 
muscle fibres in mdx/P2X7-/- dKO compared to mdx 4 week old animals (Figure 
3.11). Since an increase in fibre size is generally considered beneficial in relation to 
the dystrophic pathology (Wagner et al., 2002; Gehrig et al., 2010; Vidal et al., 2012), 
a parallel qualitative increase in fibre size variation (CoV: Figure 3.10) should not 
necessarily be interpreted as negative, despite this also having been described as a 
marker correlated with disease severity (Briguet et al., 2004). Any derived marker of 
disease progression or amelioration should be evaluated within the context of the 
particular study. That our reported CoV values were similar to those reported by 
Briguet et al. (2004) for mdx muscles has reaffirmed the accuracy of the derived semi-
automated morphometry method used here, something we have further confirmed 
visually, using an overlay of a analyse particles output mask upon the original image, 
as well as with an example manual versus automated analysis of the same tissue 
(Figure 3.9). 
An increase in muscle fibre size can be mediated via multiple mechanisms. One of the 
best known muscle hypertrophy pathways involves the IGF-1/PI3K/Akt/mTOR 
cascade (Bodine et al., 2001b; Rommel et al., 2001). Indeed, experimental Akt 
overexpression was found to promote muscle myogenesis and improve disease 
outcome in the mdx model of DMD (Kim et al., 2011). The PI3/Akt/mTOR pathway 
is usually directly opposed by the atrophy related transcription factor FoxO3 and the 
genes atrogin-1, MuRF-1, and cathepsin-L (Bodine et al., 2001a; 2001b; Rommel et 
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al., 2001; Sandri et al., 2004; 2006). These atrophy factors negatively regulate the 
differentiation-inducing myogenic regulatory factors (Kitamura et al., 2007; 
Lokireddy et al., 2012). Without pinpointing the exact interaction, we can therefore 
conclude that loss of P2X7 promotes enhanced muscle fibre growth, possibly by 
enhancing the MRF myogenin (Figure 3.12), a marker for myoblast differentiation 
and fusion (Grounds et al., 1992; Dedieu et al., 2002; Vidal et al., 2012). A possible 
controversy relates to a recently published link between P2X7 receptor induction and 
PI3K/AKT in tumour cells (Bian et al., 2013), which, if translated into muscle, would 
be inconsistent with P2X7 loss and resultant muscle fibre growth. 
Quiescent satellite cells do not express the MRFs MyoD or myogenin (Grounds et al., 
1992). During differentiation of muscle precursor cells, Pax7 expression is inversely 
correlated with that of myogenin. Furthermore, an overexpression of Pax7 results in a 
downregulation of MyoD, and a subsequent reduction in myogenin (Olguin & Olwin, 
2004). In a 9 time-point microarray and corroborative RT-PCR study focusing on 
regeneration-associated genes expressed in the mdx mouse from age 1-20 weeks, it 
was shown that the proliferation gene, Notch2, was persistently overexpressed in 
dystrophic hind-limb compared to wild-type control muscle (Turk et al., 2005). 
Myogenin was expressed at very similar levels between mdx and C57, until the 8 
week period when dystrophic tissue showed an upregulation concomitant with a 
reduction in the wild-type animal. Altogether, these observations confirm the 
contingent nature of myogenic regeneration, with myoblast differentiation and fusion 
events following satellite cell activation, and myoblast proliferation. This result also 
indicates the enhanced therapeutic potential of modulating muscle myoblast 
differentiation, which is episodically regulated, over proliferation, which seems to be 
chronically activated in dystrophic muscle. Therefore, an increase in late-
differentiation upon a reduction in P2X7 receptor activation, as indicted here by the 
increase myogenin expression in the mdx/P2X7-/- dKO compared to the mdx mouse, 
could be deemed an improvement in disease parameters. 
Also important here is a consideration of the interaction of muscle precursor cells to 
their micro-environment and the interplay between one regenerative process and 
another. Using an in vitro model of myofibre myogenic regulatory factor expression, 
myogenin expression was shown to be inversely correlated with the level of pro-
inflammatory cytokine TNFα (Szalay et al., 1997; Perdiguero et al., 2011). 
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Environmental stimuli that promote the proliferation of myogenic precursor cells, 
including myoblasts, seem to be generally antagonistic to signals that eventually 
promote the differentiation and fusion of these cells to (re)build muscle tissue. For 
instance, the pro-inflammatory cytokine TNFα has been demonstrated to promote the 
proliferation of satellite cells in vitro (Li, 2003; Tidball & Villalta, 2010), whereas it 
may inhibit later stage differentiation and fusion of these cells (Langen et al., 2001; 
2002; 2004; Perdiguero et al., 2011). The cytokine IL-4 preferentially promotes the 
myoblast to myotube fusion (Horsley et al., 2003). The state of muscle precursor cells 
along a transition from proliferation, to differentiation, to fibre integration, is 
described via the expression of many other specific basic helix-loop-helix proteins 
and MRFs (see Boldrin et al., 2010; Dilworth & Blais, 2011). 
Although it is not an MRF, the protein eMyHC is linked with skeletal muscle 
regeneration (Schiaffino et al., 1986), where it is transiently expressed in newly 
regenerated muscle fibres and has been associated with the maturation or fusion 
potential of muscle fibres (Martinello et al., 2011; Vidal et al., 2012). In this sense, 
the reduction of eMyHC in 4 week old mdx/P2X7-/- dKO muscle compared to mdx 
(Figure 3.13) is contradictory to the increase in myogenin expression and their similar 
levels of central nucleation. However, in many published articles eMyHC expression 
has been correlated with disease severity at acute phases of muscle regeneration. For 
instance, eMyHC-positive small regenerating muscle fibres are more common in 
mdx/utrophin double KO TA muscle than in mdx, especially at the 4 week phase of 
disease progression (also used here), and concurrent with a more severe pathology in 
the mdx/utrophin dKO mice (Grady et al., 1997). Additionally, despite the association 
of eMyHC with myotube maturation, other more directed studies have shown eMyHC 
expression to be limited to proliferating myoblasts (Rodgers, 2005) with a nuclear 
downregulation observed during myoblast differentiation (Silberstein et al., 1986). 
These latter studies comfortably marry the increase in myogenin expression in 
mdx/P2X7-/- dKO muscle to the decrease in eMyHC observed here. 
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Revertant fibres 
A complementary analysis for monitoring muscle regeneration in relation to DMD 
disease severity is a histological measure of muscle dystrophin revertant fibre 
expression. Dystrophic muscle has the potential to re-express truncated dystrophin 
isoforms via random mRNA splicing events during regeneration. The numbers of 
these revertant fibres is therefore directly proportional to the amount of degeneration 
and regeneration events that has occurred in a single muscle tissue. Yokota et al. 
(2006) proposed the use of a histological measure of revertant fibre number, showing 
that reduced revertant fibre numbers was associated with improved disease features, 
including the stabilisation of a key DAPC binding partner, nNOS. Our current data 
failed to identify a significant decrease in total revertant fibre numbers between mdx 
and either mdx/P2X7-/- dKO mouse in 4 months old TA muscle (Figure 3.14), 
although a qualitative decrease in mean revertant fibre percentage was evident for the 
Pfizer dKO mouse compared to mdx. Base level revertant fibre comparisons could not 
be made between this study and the Yokota et al. (2006) paper on the basis that we 
studied 4 month old mice whilst Yokota et al. (2006) looked at a maximum age of 3 
months. Additionally, we have presented revertant fibre numbers as a percentage of 
total fibres to maintain equivalency between individuals, whilst Yokota et al. (2006) 
instead presented their results as the mean of maximum revertant fibres. It is unclear 
how Yokota et al. (2006) normalised revertant fibre numbers between individuals, but 
a standard experimental approach would be to report mean number per a constant unit 
of area. 
Our laboratory has previously used the measure of mean revertant fibre percentage to 
evaluate the effect of a P2X receptor antagonist, Coomassie-Brilliant Blue (CBB), on 
regeneration potential in the mdx mouse at 4 months of age after a prolonged 
treatment schedule (125mg/kg every three days between 3 and 14 weeks of age) 
(Young et al., 2012). In that study, Young et al. (2012) successfully identified a 
reduction in mdx mean revertant fibre percentage after CBB treatment (~2.4% in 
saline treated mice compared to ~1.5% in CBB treated mice). This result provided 
extra impetus to evaluate revertant fibre numbers in P2X7 dKO muscle compared to 
mdx. However, despite recording revertant fibre numbers at the same 4 month period 
and adopting the same percentage method for reporting mean revertant fibre numbers 
between groups, our reported mean revertant fibre percentage for the mdx animal is 
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~1.3% compared to ~2.4% for the saline treated group in the Young et al. (2012) 
paper. This difference could be for several reasons. Firstly, i.p. saline treatment could 
adversely affect DMD disease measures. This is unlikely, especially given a recent 
report that dietary sodium chloride supplementation may actually improve mdx 
disease outcome (Yoshida et al., 2006). Secondly, and more likely, Young et al. 
(2012) adopted a different sampling strategy, using a random microscope field-of-
view approach to normalise between individuals, instead of a whole cross sectional 
analysis adopted here, likely to generate systematic differences in basal reported 
values. 
Apart from experimental artefact leading to systemic differences in basal reported 
values, a more important observation is the reported significant difference in the 
Young et al. (2012) paper between saline and CBB treated mdx animals that we have 
failed to recapitulate at 4 months in a genetic model. In our study, the mdx/P2X7-/- 
dKO mouse only presented a qualitative decrease in revertant fibre number compared 
to mdx (Figure 3.14). The reason for this is unknown but is most likely related to not 
including enough individuals to reasonably achieve significance at the current N 
numbers of 3 and 4. The P2X7 inhibitor used in the Young et al. (2012) study, CBB, 
is selectively efficient at blocking rat P2X7, separate from other P2X receptors 
including P2X4 (Jiang et al., 2000), which may be co-assembled with P2X7 subunits 
(Yeung et al., 2004; Guo et al., 2007). Therefore, if a discrepancy does exist, it is 
unlikely to be related to a contribution of P2X4 to the dystrophic phenotype. 
 
Utrophin expression 
Utrophin is the structural analogue of dystrophin that is thought to provide partial 
functional replacement in the mouse model of DMD (Pons et al., 1994; Rafael et al., 
1998; Baban & Davies, 2008). Utrophin is also thought to be differentially expressed 
across muscle fibre-types. Predominantly oxidative or glycolytic muscle fibres are 
also differentially distributed across muscle groups. Slow oxidative type muscle fibres 
express and retain more utrophin than fast type fibres (Gramolini et al., 2001; 
Chakkalakal et al., 2008). Notably, fast glycolytic type fibres have been shown more 
susceptible to dystrophic damage and death (Webster et al., 1988). Since utrophin 
expression is positively correlated with the expression of DAPC members including 
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β-dystroglycan, and endogenous utrophin downregulation at ~2 weeks of age 
coincides with the onset of necrosis in the mdx mouse (Roma et al., 2004), it may be 
that utrophin has an ability to stabilise the sarcolemma via DAPC binding or, at least, 
is positively correlated with preferential sarcolemmal stabilisation in slow-type 
muscle fibres of the mdx mouse. There is also some evidence for an association of 
slow-type muscle fibre development from myogenin mediated terminal 
differentiation, as opposed to the MRF myoD (Hughes et al., 1993; Talmadge, 2000). 
We have shown an increase in myogenin expression in P2X7 deficient muscle mdx 
skeletal muscle (Figure 3.12). Partly for these reasons, we chose to compare utrophin 
levels between mdx and mdx/P2X7-/- dKO hindlimb muscles at the 4 week acute 
degenerative period. From this analysis, we failed to identify a differing utrophin 
protein level between mdx and Pfizer mdx/P2X7-/- dKO GC muscles at 4 weeks of age 
(Figure 3.15). 
Utrophin has previously been defined as upregulated in mdx mouse muscle compared 
to healthy controls, where an elevated expression is deemed compensatory and 
beneficial (Tinsley et al., 1998). From our data showing no difference between mdx 
and Pfizer dKO utrophin expression levels, it could therefore be suggested that we 
have maintained this level of successful and endogenous compensation with the loss 
of the P2X7 receptor. Moreover, we have earlier shown an increase in centrally 
nucleated average muscle fibre diameter in mdx/P2X7-/- dKO muscle compared to 
mdx perhaps indicating an enhanced muscle regenerative potential in the mdx mouse 
upon the loss of P2X7 receptor activation. One important molecular pathway via 
which enhanced fibre growth could be effected is the Akt/mTOR cascade. In their 
study into the effects of valproic acid mediated α7 integrin upregulation on the mdx 
pathology, Gurpur et al. (2009) showed that Akt activation was linked to enhanced 
fibre diameter and a reduced susceptibility to apoptosis. Akt overexpression has also 
been shown to ameliorate disease features in the mdx mouse coincident with an 
increase in the utrophin-glycoprotein complex (Kim et al., 2011). Similar to results 
presented here, Kim et al. (2011) showed an increase in muscle fibre size without a 
statistically significant difference in numbers of centrally nucleated fibres. However, 
we have failed to find a related increase in utrophin expression between mdx and 
mdx/P2X7-/- dKO muscle as their study found with improved pathology upon Akt 
overexpression. This may indicate that this is not the primary pathway effecting the 
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muscle fibre size increase in this study, with an increased utrophin-glycoprotein 
complex compensating by contributing an enhanced sarcolemmal stability to 
regenerating muscle. 
It should also be noted that in several key measures of biological function, utrophin 
differs from dystrophin, with clinical implications regarding its compensatory effects. 
For instance, it has recently been shown that supra-physiological levels of forced 
utrophin expression did not increase the anchoring of otherwise delocalised nNOS to 
the sarcolemma in the mdx mouse (Li et al., 2010a). 
 
Analysis of diaphragm from aged mice 
In preceding analyses, two dystrophic age points were used in the mouse, 4 week and 
4 month, to represent regenerative/degenerative and post-regenerative tissues 
respectively. These time points are relevant for pre-clinical and proof-of-principle 
studies into the effects of P2X7 ablation on the dystrophic background using 
recommended hindlimb muscles, in vivo (Table 3.1). However, it has been 
acknowledged that diaphragm represents a very suitable tissue for experimental pre-
clinical testing, and perhaps more similar to the general human DMD pathology due 
to the enhanced severity of histologically-evident pathology in this dystrophic tissue 
compared to others (Table 3.1; Stedman et al., 1991). Furthermore, from a biological-
mechanistic perspective, mdx diaphragm tissue undergoes continuous degeneration 
and tissue reorganisation relevant to observe longer-term effects of P2X7 ablation on 
muscle regenerative pathways and histological markers of disease progression, 
especially in aged mice. Therefore, comparing diaphragms from ~20 months old mice, 
at an age well-into the late-term whole body atrophy phase of mdx disease progression 
(Figure 1.5b), it was confirmed that the minimum Feret’s diameter of muscle fibres 
was significantly larger in Pfizer-mdx/P2X7-/- compared to mdx and intermediate in 
size between C57 and mdx (Figure 3.16). This result agrees with that obtained using 4 
week TA muscles. With the inclusion of the Pfizer single-KO P2X7-/- diaphragm, we 
can now also state that removing P2X7 activity in vivo does not affect muscle fibre 
size under non-dystrophic conditions. Because the aged dystrophic diaphragm 
uniquely represents a severe model of perpetual degeneration and regeneration in the 
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mdx mouse, we can confidently apply this conclusion to less severely affected 
muscles and at younger ages. 
Since revertant dystrophin-positive fibres arise through chance somatic reversions, 
their numbers in dystrophic tissue are positively correlated with time and, more 
specifically, the number of preceding cycles of degeneration and regeneration. In a 
severely disease-affected muscle like the diaphragm, and especially in aged animals, it 
may therefore be expected that inherent biological differences should be exaggerated 
with respect to underlying dystrophic severity. Significantly fewer revertant fibres 
were found in Pfizer-mdx/P2X7-/- compared to mdx ~20 month diaphragms (Figure 
3.16). This result is consistent with previous reports published by our laboratory, 
using 4 month hindlimb muscle (Young et al., 2012), and lends further support to the 
notion that P2X7 receptor over-activity may be negatively influencing muscle 
regeneration in the mdx mouse. This is especially evident given the enhanced 
diaphragm-muscle fibre sizes from these ~20 months old Pfizer-mdx/P2X7-/- 
compared to mdx mice and the later mentioned other histological pathological markers 
measured in these same tissues and in heart (Chapter 4). 
 
3.3.3 Conclusions 
DNA and protein analysis techniques confirmed the generation of two mdx/P2X7-/- 
dKO mouse strains. The Pfizer mdx/P2X7-/- variant was preferred for most subsequent 
comparisons to mdx. This was primarily based upon a previously reported splice 
variant of P2X7, the K variant, which is known to escape inactivation in the Glaxo 
P2X7-/- KO mouse (Nicke et al., 2009). The background effect of differing wild-type 
mouse origins between both P2X7 KO strains and the mdx mouse was also deemed 
unlikely given the similarities between C57 BL/6 and BL/10, including the shared 
proline to leucine P2X7 amino acid substitution that renders the receptor substantially 
less active. While mdx/P2X7+/- heterozygous mouse was found to be unsuitable as a 
true haplo-sufficient control based upon an intermediate expression of P2X7, in 
between mdx and C57, it was a good control for the impact of P2X7 expression levels 
on the mdx pathology. 
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P2X7 expression is greatly increased in dystrophic mdx mice and localised to regions 
of mononuclear cell infiltrations and at the sarcolemma of regenerating muscle fibres. 
Without exacerbating disease features through exercise or exacerbation of muscle 
damage by other means, for instance, we have failed to identify obvious gross 
qualitative histological differences in pathology between mdx and mdx/P2X7-/- dKO 
muscles at either 4 weeks of age, representing an acute phase of muscle degeneration 
in the mdx mouse, or at 4 months, in post-degenerative skeletal muscle. However, a 
more detailed histological analysis using a semi-automated form of morphometry 
revealed that Pfizer mdx/P2X7-/- mice had a greater average minimum Feret’s 
diameter of centrally nucleated muscle fibres compared to mdx, without significantly 
increased total central nucleation or a variation in fibre sizes across a whole cross-
section. This was coupled to an increase in the levels of myogenin but not the satellite 
cell marker, Pax7. That the two could be normally negatively correlated relates to the 
observation that the cell cycle progression, necessary for myoblast proliferation, is 
usually directly opposed to the growth arrest, necessary for differentiation (Rodgers, 
2005). 
Irrespective of the mechanisms in play, it was clearly presented that these improved 
histological parameters also extended into the most severely disease-affected muscle 
in the mdx mouse, the diaphragm, a tissue advised for use in pre-clinical and basic 
research studies because of its continuous degenerative profile. That it was also shown 
the increased minimum Feret’s diameter of mdx/P2X7-/- compared to mdx was 
concurrent with fewer dystrophin-revertant fibres from this muscle, serves to highlight 
a potential link between the number of cycles of regeneration and muscle fibre size. 
Whilst larger muscle fibres are not necessarily beneficial in mdx disease pathology, 
larger fibres have been shown to be more resistant to mechanical stresses in the mdx 
mouse (Schertzer et al., 2007; Gehrig et al., 2010).  
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4 
Effect of P2X7 receptor ablation on the immune cell 
phenotype in mdx muscles 
 
 
4.1 Introduction 
4.1.1 Inflammation in DMD 
Inflammation is an important aspect of DMD. For example, in a meta-analysis of 
microarray studies from a wide age range of DMD muscle biopsies, immune response 
genes were found consistently up-regulated (Kotelnikova et al., 2012). Large immune 
cell infiltrations are found in DMD patients as well as in the mdx mouse (Evans et al., 
2009), leading to the notion that the currently employed corticosteroid treatment in 
humans may be having at least some beneficial effect by reducing the cytotoxicity and 
inflammation in diseased muscles (Villalta et al., 2009). Furthermore, treatments that 
limit immune cell activity have proven beneficial in ameliorating disease symptoms in 
mdx mice (Spencer et al., 2001). Mouse studies have shown steroids to be effective at 
reducing mdx disease severity over short-term (Keeling et al., 2007; Sali et al., 2012) 
and longer term (Keeling et al., 2007) treatments. In other longer term studies, 
however, it has also been observed that some features of mdx pathology, like reduced 
muscle strength and heart fibrosis, may be worsened with regular steroid treatments 
(Sali et al., 2012). It is currently difficult to dissociate these longer-term effects from 
the non-immune-modifying effects of steroid treatments, especially as these may 
differ in exercised and non-exercised muscles and with disease progression (Lim et 
al., 2004). Moreover, it has been recently shown that nonsteroidal anti-inflammatory 
treatments in the mdx mouse decreased levels of inflammatory cytokines concurrent 
with increases in muscle strength and reduced serum CK levels but, unlike steroids, 
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without negatively affecting key myogenic regulators (Huynh et al., 2013; 
Uaesoontrachoon et al., 2014). This suggests that anti-inflammatory treatments 
specifically targeting mechanisms involved in the pathological arm of the 
inflammatory response could modify the disease while avoiding the negative effects 
of long-term steroid treatment. However, some beneficial effect of steroids might be 
independent of immune response regulation. In the C. elegans model of DMD, 
prednisone reduced numbers of degenerating muscle cells (Gaud et al., 2004), while 
the worm possesses only a very primitive innate immune system that would not 
respond to prednisone in the same way as a mammalian does. Interestingly, when 
steroids were first used in DMD, the precise rationale for their supposed biological 
effect was not offered (Drachman et al., 1974). 
As explained earlier, the form of inflammation in DMD is sterile, caused by danger 
signals and DAMPs, attracting and activating innate immune cell types, including 
macrophages and neutrophils. Due to the chronic nature of the degenerative process 
and the perpetual presentation of DAMPs human and mouse muscular dystrophy 
present features akin to autoimmune diseases (Tidball & Wehling-Henricks, 2005). In 
DMD carriers, this chronic inflammatory response can also occur and has led to 
misdiagnosis as polymyositis or viral hepatitis (Yoon et al., 2011). 
A mix of innate and adaptive immune cells infiltrating dystrophic muscles contribute 
to cell debris clearance but also cell death and reparative processes. Macrophages 
make up the bulk of inflammatory cells in dystrophic muscle, with as many as 50,000 
cells per mm3 (Wehling et al., 2001). Another major component of the inflammatory 
milieu are granulocytes and T-cells. CD8+ cytotoxic T-cells contribute to muscle 
degeneration via a perforin-mediated cytolysis. Increased T-cell numbers are also 
consistent with an autoimmune-like phenotype existing in DMD patients (Spencer et 
al., 1997). 
The phenotype of infiltrating macrophages changes over the course of disease 
progression (Figure 4.1). As found in the mdx mouse, at an acute degenerative period 
around 4 weeks of age, M1 macrophages responsible for the cytolysis of muscle fibres 
and for T-cell activation predominate (Villalta et al., 2009). Later on, M2 (CD163 
positive) macrophages responsible for reducing inflammation (Gordon, 2003; 
Martinez et al., 2008; Villalta et al., 2009) and inducing muscle regeneration but also 
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promoting scarring (Vidal et al., 2008) increase in numbers (Tidball & Villalta, 2010). 
In DMD, there is a continuum of M1 and M2 macrophages, with these phenotypes 
expressed at the same time in various regions of the continuously, albeit 
heterogeneously, degenerating muscle. 
  
Figure 4.1. Schematic representation of macrophage phenotypic transitions in relation to T-
cell and MRF (myogenic regulatory factor) induction following muscle injury in mice. 
(Image adopted from Tidball & Villalta 2010). PMN (polymorphonuclear leukocytes: 
neutrophils); MEF2 (myocyte enhancer binding factor-2). 
In summary, reducing total immune cell infiltrates may be problematic, since it also 
carries the potential to interfere with regenerative processes. However, interventions 
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that can change the ratio of competing immune cells towards pro-regenerative may 
benefit host health, ultimately reducing the severity of the disease pathology.  
The P2X7 receptor presents an interesting target, potentially able to regulate the 
beneficial shifts in immune cell sub-types. 
 
4.1.2 The P2X7 receptor and immune cell responses 
ATP is now recognised as an important autocrine and paracrine signalling factor, 
influencing functions of inflammatory cells (Corriden & Insel, 2010). An example of 
this is ATPe enhancing IL-6 release by macrophages, via P2X- and P2Y-mediated 
Ca2+ currents (Hanley et al., 2004). 
P2X7 is capable of inducing ATP-mediated cell death in macrophages via a Ca2+-
induced caspase/calpain activation (Hanley et al., 2012). In a flow cytometry study, 
P2X7 has been localised to most major immune cell populations. A predominant 
P2X7 protein surface expression was in monocytes, with weaker B-lymphocyte, T-
lymphocyte, and natural-killer (NK) cell expressions (Gu et al., 2000). Neutrophil 
P2X7 surface expression was reported as negligible in this report (Gu et al., 2000) and 
deemed absent in another, more recent, study (Hanley et al., 2012) but identified by 
Christenson et al. (2008). 
The induction of IL-1β release via P2X7 receptor activation is well established in a 
variety of infectious (Lee et al., 2012) and chronic inflammatory conditions 
(Arulkumaran et al., 2011). Although the canonical induction of IL-1β via P2X7 
stimulation occurs in lipopolysaccharide (LPS)-primed macrophages, a model of 
pathogen-induced rather than sterile inflammation, it is known that P2X7 receptors 
can trigger IL-1β and TNFα release via alternative activation routes such as by contact 
with microvesicles containing phospholipid secondary signalling mediators (Thomas 
& Salter, 2010), interaction with the ECM component biglycan (Babelova et al., 
2009), or following phagocytosis of autophagic cells (Ayna et al., 2012). As a part of 
its general pro-inflammatory function, IL-1β has been shown to increase the 
expression of Th1-associated molecules including COX-2, IL-6, and osteopontin 
(OPN) (Uaesoontrachoon et al., 2008). Il-1β is also integral to the conversion of 
immunosuppressive T-reg into Th17 type cells participating in inflammation and 
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autoimmunity (Acosta-Rodriguez et al., 2007; Chung et al., 2009). TNFα, is an 
important inflammatory mediator in DMD (Lundberg et al., 1995; Grounds & Torrisi, 
2004; Hodgetts et al., 2006; Pierno et al., 2007) and an elevated level of plasma TNFα 
has also been associated with cachexia (Nagaoka et al., 2006). TNFα was shown to 
inhibit the differentiation of muscle (Miller et al., 1988; Szalay et al., 1997; Layne & 
Farmer, 1999; Langen et al., 2001; 2002; 2004). TNFα and IL-1β significantly 
reduced the expression of myogenin in both murine and porcine myoblasts (Broussard 
et al., 2003; 2004).  
With regard to the aforementioned macrophage sub-populations, P2X7 receptors may 
be differentially expressed across the M1 to M2 macrophage polarization gradient. 
Although protein levels and receptor membrane localisation appeared similar between 
M1 and M2 macrophages in vitro, P2X7 receptor gene expression was shown to be 
down regulated in M1 compared to M2 macrophages. However, in response to ATP, 
M1 macrophages preferentially release mature IL-1β (Pelegrin & Surprenant, 2009), 
which might be important in pathological progression of DMD.  
 
4.1.3 Chapter summary 
In summary, DMD muscle is chronically inflamed (Haslett et al., 2002; Porter et al., 
2002), and treatments aimed at reducing this inflammation have ameliorated disease 
features in model organisms. The P2X7 receptor has been linked to the induction of 
inflammation pathways. It is known to be expressed on many immune as well as on 
dystrophic muscle cells (Ferrari et al., 1996; 1997; Gu et al., 2000; Di Virgilio et al., 
2001; Gudipaty et al., 2001; Lenertz et al., 2009; Wewers & Sarkar, 2009). The P2X7 
receptor can respond to DAMPs, including ATP, to shape the inflammatory response 
through release of pro-inflammatory cytokines such as IL-1β and TNFα or via 
influencing immune cell subtype selection. Therefore, we have used immunodetection 
methods to determine the expression of P2X7 protein in relation to major immune cell 
types in mdx and mdx/P2X7-/- skeletal muscle and to identify any potential shift in cell 
populations including between M1 and M2 macrophage subsets. qPCR analysis was 
undertaken to identify immunophenotype shifts resulting from P2X7 ablation, 
followed by immunodetection of key identified targets in mdx and mdx/P2X7-/- muscle 
samples. Finally, we extended our immunohistological analysis into aged dystrophic 
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diaphragms and hearts, to see if positive modulation of inflammation by P2X7 
ablation continued into later phases of disease progression, or whether disease 
features were in fact worsened. 
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4.2 Results 
4.2.1 P2X7 co-immunolocalisation with immune cell subtypes in 4 week old mdx muscles 
Specific antibodies have been used to detect CD11b, CD68, Ly6G, and OPN in C57, 
mdx, and Pfizer mdx/P2X7-/- muscle from 4 week old mice. These protein targets may 
be used to distinguish between major inflammatory cell types. CD11b is a protein 
subunit of αMβ2 integrin expressed on a variety of leukocytes including monocytes, 
granulocytes, macrophages, and NK cells (Ward et al., 2006). CD68, is a scavenger 
receptor type transmembrane glycoprotein expressed on monocytes and tissue 
macrophages (Ward et al., 2006). OPN, also known as secreted phosphoprotein 1 
(SPP1), is a glycoprotein expressed by many cell types including macrophages, 
neutrophils, T-cells, dendritic cells, osteoblasts, and osteoclasts (Ashkar et al., 2000; 
O'Regan & Berman, 2000) (Suzuki et al., 2002). Lymphocyte antigen 6 complex 
[locus G] (Ly6G), also-known-as Gr-1, is expressed predominantly on bone marrow 
granulocytes and neutrophils. Ly6G has recently been linked with neutrophil ability to 
migrate to regions of tissue inflammation in vivo (Wang et al., 2012). The 4 week 
time point has been chosen as it is the period of active tissue 
degeneration/regeneration and major mononuclear cell infiltrations in the mdx mouse 
and, as such, closely resembles the human disease. 
P2X7, in agreement with previous studies, localised definitively with two of these 
four immune markers, CD11b and CD68, in dystrophic mdx muscles in vivo (Figure 
4.2: top two rows). A lesser degree of co-localisation was found between P2X7 and 
Ly6G (Figure 4.2: bottom row).  The P2X7 receptor signal co-localised with OPN in 
a subset of cells but these two proteins appeared to have a mutually-exclusive pattern 
of expression in the cytoplasm and the nucleus (Figure 4.2 and Figure 4.4). Further 
higher magnification immunological analysis confirmed P2X7 co-localisation with 
CD68-positive monocytes (Figure 4.3).  
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Figure 4.2. Immunofluorescence, showing the P2X7 receptor (middle column) co-
expressed with immune cell markers CD11b, CD68, and Ly6G in mdx TA muscle at 4 weeks. 
Note the inset image in the OPN panel showing strong P2X7 signal in the cytoplasm and 
OPN predominantly in cell nuclei. 
  
Chapter 4: Effect of P2X7 ablation on mdx inflammatory phenotype 
 
Page 123 
 
Figure 4.3. P2X7 and CD68 co-localisation in 4 week mdx skeletal muscle. Z-stack slices 
highlight total co-localisation between P2X7 and macrophage marker, CD68. 
  
Chapter 4: Effect of P2X7 ablation on mdx inflammatory phenotype 
 
Page 124 
 
Figure 4.4. P2X7 and OPN co-localisation in 4 week mdx GC muscle. Top image: OPN 
(red) heavily expressed in strongly P2X7-positive (green) areas of cellular infiltration. 
Bottom image: most interstitial P2X7-positive cells exhibit nuclear OPN expression (arrows). 
Orthogonal views provide Z-stack confirmation along the yellow intersect. The strongest 
OPN signal was associated with the myonuclei of small regenerating myofibres (yellow 
asterisks). Inset image showing co-localisation of the Hoechst (blue) signal with the OPN 
staining in some myonuclei (myofibres outlined in white) and interstitial immune cells. 
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4.2.2 Comparisons of immune cell subtypes infiltrating mdx and mdx/P2X7-/- muscles 
Total GC cross-sections were immunohistochemically stained for a pan immune-cell 
marker CD11b. Generally, single areas of monocellular CD11b+ immune-cell 
aggregation were greater in 4 week mdx hind-limb tissue compared with Pfizer 
mdx/P2X7-/- (Figure 4.5). C57 control GC samples had only a slight CD11b+ signal in 
locations corresponding with blood vessels at the perimysium borders. 
To confirm the location and co-localisation prior to quantification, the pan 
macrophage markers CD68 and CD163, predominantly labelling all and M2 type 
macrophages respectively, were used for an immunofluorescence study. As observed 
by others (Deng et al., 2012), both CD68 and CD163 antibodies labelled the 
cytoplasm of immune cells in the interstitial space of mdx muscles (Figure 4.6). 
CD163 immunofluorescence was present in a subset of CD68 positive cell bodies in 4 
week GC (Figure 4.6). 
In an attempt to characterise and compare the major immune cell infiltrate profiles in 
these two types of dystrophic muscles, mdx and mdx/P2X7-/- samples were stained 
using macrophage specific CD68 and F4/80 antibodies for immunofluorescence 
detection. Applying a colour pixel intensity analysis, no difference was found between 
mdx and Pfizer mdx/P2X7-/- for CD68 or F4/80 expression levels at 4 weeks (Figure 
4.7). Individual cell bodies were inconsistently defined by either antibody, making the 
quantification of discrete cell numbers in cryosectioned tissue implausible. 
Additionally, the anti-F4/80 antibody from Abcam (ab74383) did not label interstitial 
cell bodies that define the traditional macrophage infiltrations in dystrophic mouse 
muscle tissue. F4/80 positive signal was evident in areas of obvious muscle 
degeneration, providing an indication that the anti-F4/80 antibody could be used as a 
macrophage associated marker for the semi-quantitative Western blotting and 
immunolocalisation pixel intensity distribution analysis. 
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Figure 4.5. Example immunohistochemical staining of CD11b-positive immune cells 
highlighting focal pathology in the GC mdx and Pfizer mdx/P2X7-/- at 4 weeks. Note, an 
absence of CD11b signal (red/brown) in C57 (WT: top) compared to both dystrophic samples 
(middle and bottom). Also note, the enhanced area of monocellular infiltration in mdx versus 
Pfizer mdx/P2X7-/- (dKO). Areas of disease-related inflammation were often heterogeneous 
across single muscle cross-sections and between individuals within the same genotype. 
Nuclear counterstaining was deliberately light to avoid masking primary signal in these 
images. 
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Figure 4.6. Immunofluorescence microphotographs, showing M2 macrophage sub-type 
marker CD163 expressed in a sub-set of CD68 positive cells in dystrophic skeletal muscle in 
vivo. The CD163 signal (green), predominantly found on the M2 subtype of macrophages, 
co-localises, with varying intensity, with a subset of CD68 expressing cells (yellow: bottom-
right arrows and insert; orange: bottom-right arrowhead). Additional CD68 signal (red) that 
does not spatially coincide with CD163 agrees with the pan macrophage nature of this marker 
that may also be expressed on monocytes and fibroblasts. Cell nuclei are labelled with 
Hoechst (blue). 
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Figure 4.7. Immunofluorescence analysis, showing no difference in CD68 or F4/80 
protein expression between mdx and Pfizer mdx/P2X7-/- TA muscle at 4 weeks (also see 
Appendix 9.1; 9.2). Pixel intensity distribution of: a) CD68 and b) F4/80 showed no 
difference in average CD68 (T-test, T=-0.16, P=0.884, df=2, N=3) or F4/80 (T-test, T=1.04, 
P=0.406, df=2, N=3) fluorescence levels between 4 week mdx and mdx/P2X7-/- TA muscles. 
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4.2.3 Western blotting analysis of immune cell markers between mdx and mdx/P2X7-/- 
muscles 
Due to the complex staining pattern with the macrophage-specific antibodies and 
because of the inherent limitation of a method involving sampling at only a cross-
sectional level, a Western blot assay was used to compare immune cell infiltrates in 
protein extracts from the whole 4 week TA or GC muscles of C57, mdx, and 
mdx/P2X7-/- mice.  
The available antibodies recognizing CD4, CD8a, and Foxp3 antigens did not work 
under denaturing conditions used for Western blotting (data not shown). Using the 
F4/80 pan macrophage marker (~130 kDa), significantly lower intensity bands were 
found in GC from C57 and both mdx/P2X7-/- strains when compared to mdx, relative 
to the actin loading control (Figure 4.8). This indicates that total macrophage 
infiltrations may be reduced in mdx/P2X7-/- mdx muscle compared to mdx, at 4 weeks. 
The Western blotting analysis showed a significant reduction in the levels of F4/80, 
total macrophage marker, relative to CD163 in Pfizer mdx/P2X7-/- strains compared to 
mdx (Figure 4.8). There was no significant difference in this parameter between the 
hypomorph Glaxo mdx/P2X7-/- and mdx samples. 
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Figure 4.8. Western blotting, showing lower levels of F4/80 and F4/80 to CD163 protein 
expression in mdx/P2X7-/- and C57 4 week GC muscle compared to mdx. a) Representative 
immunoblots for F4/80, CD163, and actin (protein loading control). b) Graphical 
representation of the average F4/80 expression relative to actin (left) and F4/80 relative to 
CD163 (right), showing significantly less F4/80 protein in Pfizer, Glaxo, mdx/P2X7-/- and 
C57 compared to mdx (ANOVA, F=9.93, P=0.001, df=3, N=4, Tukey post-hoc). F4/80 to 
CD163 protein ratio was significantly lower in C57 and also reduced in Pfizer but not Glaxo 
mdx/P2X7-/- compared to mdx (ANOVA, F=4.05, P=0.033, df=3, N=4, Tukey post-hoc), 
(Mann Whitney, W=26.0, P=0.0304). All western-blotting bands at expected weights (Table 
2.3). 
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4.2.4 qPCR analysis of immune response gene expressions in skeletal muscles from mdx 
and mdx/P2X7-/- dKO mice 
Numerous genes have been linked with the chronic inflammatory phenotype of the 
dystrophic mdx mouse. To address the question of the potential impact of P2X7 
ablation on the key mediators of inflammatory responses in mdx skeletal muscles, a 
qPCR analysis was undertaken on C57, mdx, Glaxo mdx/P2X7-/- and Pfizer 
mdx/P2X7-/- muscle at the acute degenerative period of 4 weeks of age. mRNA 
samples were extracted, converted into cDNA and analysed by TaqMan qPCR 
method. This latter part of analysis was completed in collaboration with Prof. Pawel 
Kalinski and Dr. Ravikumar Muthuswamy, at the University of Pittsburgh, USA. 
The quantitative PCR study included primer sets for the following transcripts: 
interferon-gamma (IFNγ), TNFα, CD4, CD8, perforin-1 (PRF1), granzyme-B 
(GZMB), Foxp3, retinoic acid related orphan receptor-C (RORC), granulocyte 
receptor-1 (GR-1; also known as subunit Ly-6G), COX2, indoleamine 2,3-
dioxygenase 1 (IDO1), natural killer cell p46-related protein (NKP46), IL-12, IL-27, 
IL-17A, IL-10, chemokine [C-C] motif ligands: 5 (CCL5), CCL22, CXCL10, 
CXCL12, CX3CL1, and XCL1. The resulting qPCR data was analysed using 
ANOVA. The C57 values were not statistically analysed at ‘n=2’, and their mean is 
only reported for a general reference to the dystrophic groups. As expected, the levels 
of inflammatory marker mRNAs were lower in samples from C57 animals than in 
mdx animals. 
Following statistical analysis of the qPCR data sets, Glaxo and Pfizer mdx/P2X7-/- 
mice showed a general trend towards a decreased inflammatory profile, compared to 
mdx samples (Figure 4.9). Four genes emerged as being of particular interest because 
of their statistically significant reduction in expression levels in mdx/P2X7-/- TA 
compared to mdx. Specifically, CX3CL1 and RORC mRNA levels were significantly 
reduced in both Glaxo and Pfizer mdx/P2X7-/- compared to mdx. TNFα mRNA was 
significantly reduced but only in Pfizer mdx/P2X7-/- 4 week TA compared with mdx. 
Finally, in Glaxo and Pfizer mdx/P2X7-/- 4 week TA tissue, Gr-1 mRNA expression 
was significantly reduced compared to mdx. 
The general gene expression patterns for many of the other gene markers analysed 
correlated well with the potential shift away from a pro-inflammatory phenotype upon 
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P2X7 ablation (Figure 4.9). The pro-inflammatory prostaglandin-related COX-2 
transcript had a lesser average expression value for Glaxo and Pfizer mdx/P2X7-/- TA 
muscle compared to mdx samples. The same pattern was observed for PRF-1 gene 
expression. For FOXP3 and XCL1, there was a qualitative increase in gene product 
expression in Pfizer mdx/P2X7-/- TA muscle compared to Glaxo mdx/P2X7-/- and mdx. 
 
  
Chapter 4: Effect of P2X7 ablation on mdx inflammatory phenotype 
 
Page 133 
 
Figure 4.9. Graphical representation of qPCR data comparing relative gene expression 
levels (2-ΔCT) normalised to HPRT1, showing a reduced inflammatory mRNA profile in 
mdx/P2X7-/- TA muscle compared to mdx. The results indicate a general trend towards a 
reduction of pro-inflammatory gene expression upon P2X7 receptor ablation with 
significantly lower expression levels of TNFα, CX3CL1, RORC, and GR-1 in P2X7 
mdx/P2X7-/- mice compared to mdx (ANOVA, F=8.19, 8.78, 6.39, 14.68, P=0.029, 0.010, 
0.022, 0.002, df=2, respectively). Note: gene labels are above each graph. 
Legend: Interferon-γ (IFNG), tumour necrosis factor-α (TNFA), perforin-1 (PRF1), 
scurfin/forkhead box P3 (FOXP3), retinoic acid related orphan receptor-C (RORC), 
granulocyte receptor-1 (GR1), cycloxygenase-2 (COX2), indoleamine 2,3-dioxygenase 1 
(IDO1), natural killer cell p46-related protein (NKP46). 
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4.2.5 Comparison of Ly6G neutrophil marker and IL-1β expression in mdx and 
mdx/P2X7-/- muscles 
Neutrophils make up an important component of the innate immune response in 
dystrophic muscle (Hodgetts et al., 2006), and P2X7 receptor has been linked with 
pro-inflammatory cascades leading to local neutrophil accumulations (Christenson et 
al., 2008; Kawamura et al., 2012; da Silva et al., 2013). Since the Gr-1 (also known as 
Ly6G) gene was identified by the qPCR study as a factor reduced in both mdx/P2X7-/- 
mice compared to mdx, it was decided to compare levels of the encoded protein 
subunit, Ly6G, between genotypes using immunological methods. IL-1β is also 
closely linked to P2X7 activation and neutrophil migration and therefore IL-1β was 
included in this comparison. 
Using immunofluorescence detection, it was found that an anti-Ly6G antibody 
labelled cells within regions of mononuclear infiltrations in mdx and Pfizer 
mdx/P2X7-/- 4 week TA muscles, consistent with it being expressed mainly on 
neutrophils but also on macrophages (Figure 4.10). The staining patterns indicated 
that Ly6G expression was more prevalent in mdx than in mdx/P2X7-/- muscle. To 
quantifiably confirm this, a Western blot comparison method was adopted. Ly6G 
protein expression was found to be significantly reduced in 4 week Pfizer mdx/P2X7-/- 
GC compared to mdx muscle (Figure 4.11).  
The immunofluorescence experiments also showed increased IL-1β in mdx compared 
to Pfizer mdx/P2X7-/- muscle (Figure 4.10) but the experiment to confirm by Western 
blotting was not attempted. Finally, P2X7 co-localisation with Ly6G was undertaken 
and showed that this receptor is expressed in regions where neutrophils were present. 
(Figures 4.2 and 4.11b), which was contrary to one recent study (Hanley et al., 2012). 
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Figure 4.10. Example immunofluorescence images of Ly6G neutrophil marker (red) and 
IL-1β (green) in mdx and mdx/P2X7-/- TA muscles at 4 weeks. Within similarly located 
regions of mononuclear cell infiltrations, strongly Ly6G positive bodies appear more often in 
mdx (top) than in mdx/P2X7-/- (bottom). IL-1β cytoplasmic signal (green) was more evident 
in mdx than in Pfizer mdx/P2X7-/- muscle fibres. In the mdx sample, higher numbers of 
infiltrating cells were also less intensely Ly6G positive (e.g. yellow arrows), maybe 
presenting labelled myeloid cells. Also evident in the Pfizer mdx/P2X7-/- sample is a region of 
muscle fibre regeneration with less pronounced mononuclear cell infiltrations (line delineated 
area adjacent to asterisks). Cell nuclei (blue). See Appendix 9.6 for more examples. 
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Figure 4.11. Western blotting comparison and immunofluorescence staining, showing 
reduced neutrophil marker, Ly6G, expression in Pfizer mdx/P2X7-/- GC muscle compared to 
mdx at 4 weeks. a) Western blot image for Ly6G and β-tubulin (loading control) in 4 week 
GC muscle. b) Graphical representation of average Ly6G band density relative to β-tubulin, 
showing significantly greater Ly6G protein levels in mdx compared to Pf mdx/P2X7-/- tissue 
(T-test, T=4.14, P=0.006, df=6, n=4). c) Example Ly6G immunofluorescence comparison, 
illustrating P2X7 and Ly6G co-immunofluorescence in mdx, lack of P2X7 signal and reduced 
total Ly6G staining in Pfizer mdx/P2X7-/- muscle compared to mdx. Cell nuclei (blue). All 
western-blotting bands at expected weights (Table 2.3). 
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4.2.6 Evaluation of inflammation and fibrosis in aged dystrophic diaphragm and heart 
upon P2X7 ablation 
By reducing inflammation at earlier stages of the disease, including potentially 
shifting macrophage sub-populations to the pro-regenerative M2 phenotype, we have 
created the potential to exaggerate fibrosis at later stages of mdx disease progression. 
To address this issue, we have monitored overall inflammation and measures of 
fibrosis, in aged dystrophic diaphragm and heart tissues. Both of these tissues, and 
especially diaphragm, are severely affected by the dystrophinopathy. They are thought 
to undergo continuous degeneration and enhanced fibrosis, more akin to the general 
human condition (Figure 1.5b). 
Using collagen type-Ia immunofluorescence, trichrome staining, and CD11b 
immunolocalisation, we have confirmed the pathological increase in fibrosis in 
diaphragms and hearts as well as CD11b-positive immune-cell infiltrations in mdx 
tissues compared to WT (C57). Despite the above concerns, it was found that, with 
P2X7 ablation, inflammation was reduced even in aged dystrophic diaphragms and 
hearts (Figure 4.12a and Figure 4.13b, respectively). Moreover, collagen type-Ia 
deposition in diaphragms was not different from mdx (Figure 4.12b) and fibrosis in 
the heart was actually reduced (Figure 4.13a) in ~20 month Pfizer mdx/P2X7-/- mice 
compared to mdx. The diaphragm inflammation at ~20 months was also analysed in 
WT and Pfizer mdx/P2X7-/- using the anti-CD68 but at n=1 it could only be assessed 
qualitatively. 
In aged diaphragms, similar collagen type-Ia depositions were also confirmed in 
Pfizer P2X7-/- compared to C57 (Figure 4.12b). Inflammation is qualitatively similar 
between Pfizer P2X7-/- and C57, using anti-CD68 immunology (Figure 4.12a, n=1).
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Figure 4.12. An immuno-histological comparison of diaphragms from aged (~20 month) 
mice, showing continued reduced inflammation in Pfizer mdx/P2X7-/- versus mdx, without 
enhanced collagen type Ia deposition. a) Representative immunofluorescence of CD68 (right) 
with quantification and analysis in Pfizer mdx/P2X7-/- and mdx (left), showing reduced CD68 
immune-cell infiltrations into diaphragms upon P2X7 ablation (T-test, T=4.73, P=0.042, 
df=2, n=3). A single WT (C57) and Pfizer-P2X7-/- tissue are presented for non-disease 
reference. b) Representative immunofluorescence of collagen type-Ia (right) with 
quantification and analysis of Pfizer mdx/P2X7-/-, mdx, WT, and Pfizer-P2X7-/- (left), 
showing reduced collagen deposition in WT and Pfizer-P2X7-/- compared to mdx, and no 
difference between mdx and Pfizer mdx/P2X7-/- (ANOVA, F=19.39, P<0.001, df=3, n=3; 
Tukey post-hoc). 
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Figure 4.13. An immuno-histological comparison of hearts from aged (~20 month) mice, 
showing reduced inflammation and fibrosis in Pfizer mdx/P2X7-/- versus mdx. a) 
Representative Masson’s trichrome staining (left) with quantification and analysis of WT 
(C57), mdx, and Pfizer mdx/P2X7-/- (right), showing reduced fibrosis in aged heart (blue 
staining in the heart tissue) from WT and Pfizer mdx/P2X7-/- compared to mdx (ANOVA, 
F=166.29, P<0.001, df=2, n=3; Tukey post-hoc). b) Representative immunofluorescence of 
CD11b (left) with quantification and analysis of WT, mdx, and Pfizer mdx/P2X7-/- (right), 
showing reduced CD11b immune-cell infiltrations into heart tissue upon P2X7 ablation, and 
in WT compared to mdx (ANOVA, F=19.65, P=0.002, df=2, n=3; Tukey post-hoc). 
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4.3 Discussion 
4.3.1 P2X7 receptor expression in immune cells 
In this study, P2X7 receptor expression has been analysed within the acute period of 
dystrophic muscle degeneration/regeneration and compared to expression of cell 
markers for specific immune cell subpopulations. 
The general pattern of P2X7-receptor expression and the coincidence with immune 
cell marker expression observed in this study was consistent with published 
observations. 
CD11b 
P2X7 receptor expression was found to be coinciding with the CD11b subunit of the 
αMβ2 integrin receptor (Figure 4.2). CD11b, also known as integrin αM, is a protein 
subunit of the larger αMβ2 integrin complex expressed on a variety of leukocytes 
including monocytes, granulocytes, macrophages and NK cells and is a key receptor 
involved in phagocytosis, cell mediated cytotoxicity, chemotaxis, and cell activation 
leading to production of multiple pro-inflammatory cytokines, including TNFα. In 
mice with altered αMβ2 integrin-fibrinogen interactions in leukocytes, acute 
inflammatory responses were significantly diminished (Kitagawa et al., 2013). 
Another established function of the αMβ2 integrin is in promoting adhesion of 
neutrophils via its interaction with intercellular adhesion molecule-1 (ICAM-1) 
(McDonald et al., 2010). Interestingly, in clear relevance to this study, the sterile 
inflammation initiator used in this study was ATP and it was found acting through 
P2X7 receptor-mediated Nlrp3 inflammasome activation (McDonald et al., 2010).  
CD68 
P2X7 protein also localised to tissue regions expressing CD68 (Figure 4.2), a marker 
specific for the monocyte and macrophage subpopulations of leukocytes (Tidball & 
Villalta, 2010). True co-localisation was further confirmed by Z-stack analysis of 
immunolocalised CD68 and P2X7 by confocal microscope analysis (Figure 4.3). 
P2X7 receptor expression in macrophages and their CNS equivalent, microglia, has 
been previously described (Collo et al., 1997; North, 2002). Considering that ATPe 
acts as a danger signal helping to establish a state of chronic inflammation (Hanley et 
al., 2004), it is noteworthy that ATP can actively inhibit IL-1β release from 
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macrophages lacking the P2X7 receptor, even when these macrophages are presented 
with agents that normally elicit an IL-1β release-independent of P2X7 activation 
(Pelegrin & Surprenant, 2009). Similarly, ATP acting via the P2X7 receptor has been 
shown to reduce tolerogenic histocompatibility antigen class-1-G in human 
monocytes (Rizzo et al., 2009), reinforcing the notion of P2X7 as a predominantly 
pro-inflammatory receptor coupled to cells of the myeloid lineage. 
Osteopontin (OPN) 
OPN is a glycoprotein expressed by several activated immune cell types where it is an 
important mediator of chemotaxis, adhesion, and differentiation to pro-inflammatory 
phenotypes (Ashkar et al., 2000; Denhardt et al., 2001; Renkl et al., 2005). OPN 
expression is upregulated upon macrophage and T-cell activation but is not 
recognisably present in circulating monocytes (Krause et al., 1996). Furthermore, 
OPN expression has been shown to be upregulated in a wide range of dystrophic 
mouse muscles (Porter et al., 2002) and also in DMD patients (Vetrone et al., 2009), 
in agreement with its link to other chronic inflammatory conditions (O'Regan & 
Berman, 2000; Denhardt et al., 2001; Yumoto et al., 2002; Comabella et al., 2005; 
Agnholt et al., 2007; Kariuki et al., 2009). Perhaps most importantly, it has also been 
shown that P2X7 receptor inhibition can reduce the expression of OPN in LPS-
stimulated macrophages in vitro (Hu et al., 1998). A potential decrease in OPN 
expression in mdx muscle as a function of the loss of P2X7 receptors may produce an 
anti-inflammatory immunophenotypic shift. Moreover, it may also affect muscle 
regenerative processes as OPN is expressed by myoblasts and can affect their 
proliferation (Uaesoontrachoon et al., 2008; Paliwal et al., 2012). The co-localisation 
study undertaken here showed P2X7 and OPN expression in close proximity but not 
clearly colocalising in many cells within regions of active mdx muscle pathology 
(Figure 4.2). This apparent lack of co-localisation in some cells was however 
restricted to, what appeared to be, myonuclei of small regenerating fibres (Figure 
4.4). This is in agreement with aforementioned myonuclear OPN expression in 
regenerating muscle fibres (Uaesoontrachoon et al., 2008; Paliwal et al., 2012). 
Moreover, some of this apparent mis-localisation was due to a clearly different 
distribution of these two proteins in leukocytes as OPN signal was found in cell nuclei 
whereas P2X7 signal was present in the cytoplasm.  This result therefore agrees with 
both OPN and the P2X7 receptor having a known expression in immune cells.  
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Nucleus-localised OPN has been reported previously in human embryonic kidney 
cells, where, interestingly it has been linked to cells in mitosis (Junaid et al., 2007).  
Ly6G 
The final marker that was monitored for its spatial expression relative to P2X7, was 
Ly6G, the protein product of the gene Gr-1. Ly6G is predominantly expressed on 
bone marrow granulocytes and neutrophils. Neutrophils represent an important 
component of the initial inflammatory infiltrate in acutely damaged or diseased 
muscle. In DMD, neutrophils contribute to the cytotoxic environment (Nguyen & 
Tidball, 2003b). This effect is, at least partly, mediated by myeloperoxidase released 
by neutrophils (Tidball & Villalta, 2010). The immunolocalisation study performed 
here showed that P2X7 may be expressed by at least some Ly6G-expressing cells 
(Figures 4.2 and 4.12c). Further work is needed to confirm to what extent Ly6G and 
P2X7 receptors are expressed in macrophages and neutrophils, respectively. 
The overall level of P2X7 immunofluorescence shown here agrees with the existing 
literature describing the purinoceptor as predominantly expressed on cells linked with 
chronic states of immune responses. Having established the background expression 
profiles in the mdx samples and wishing to further explore the potential changes in 
these immune cells subpopulation in the absence of P2X7 receptor, comparisons of 
immune cell markers were made between the mdx and the mdx/P2X7-/- mouse. 
 
4.3.2 Comparisons of macrophage subpopulations in mdx and mdx/P2X7-/- muscles 
Used in other studies as a histological marker for disease severity (Spencer et al., 
1997; Kim & Lawler, 2012), areas of CD11b aggregation, corresponding to immune 
cell infiltrates including monocytes, granulocytes, macrophages, and NK cells, were 
often smaller in area in P2X7 dKO muscle than in mdx (Figure 4.5). This qualitative 
observation was corroborated in the Western blotting using F4/80 macrophage 
marker, showing that these most numerous of immune cell infiltrating dystrophic 
tissue are reduced by P2X7 ablation (Figure 4.8). Since macrophages represent a 
major component of the CD11b-positive cellular infiltrate in dystrophic tissue, 
analysis was extended into immunolocalisation using the CD68 and F4/80 
macrophage markers. While immunofluorescence intensity comparisons did not show 
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significant differences (Figure 4.7), the more directly quantitative Western blotting 
confirmed that total macrophage loads were reduced in P2X7-/- double-knockout 
muscle compared to mdx (Figure 4.8). 
A reduction in the total macrophage number has been shown to improve mdx disease 
manifestation independent of other factors. For instance, mdx soleus muscle depleted 
of macrophages using an i.p. injection of anti-F4/80 antibody administered from 1 to 4 
weeks of age, reduced mdx muscle cell lysis by over 75% in vivo (Wehling et al., 
2001). However, the possible impact of a long-term macrophage depletion is more 
complicated when one considers that macrophages are also important for reparative 
processes in injured muscle. 
Depletion of macrophages at 4 days following muscle damage, decreased numbers of 
regenerating fibres, myoD expression, and caused a reduction in myofibre cross-
sectional area in mice (Tidball & Wehling-Henricks, 2007). The population of 
macrophages present at later periods of muscle tissue regeneration may effect a shift 
towards myoblast proliferation over differentiation (Merly et al., 1999). This raises an 
interesting possibility that the increase in muscle fibre size in mdx/P2X7-/- muscle 
described earlier (Chapter 3: Figure 3.11) may be a result of increased myogenic 
differentiation or fusion events (Chapter 3: Figure 3.12) over proliferation and that 
this is, at least partly, mediated by a change in inflammatory phenotypes. 
Macrophage population sub-types have been defined in terms of their activation, as 
either classical, M1, or alternative, M2. In the mdx mouse model of DMD, the 
cytolytic M1 type macrophage is known to be the major form expressed in acutely 
damaged tissue at the 4-6 week period, whilst the M2 type, although co-expressed at 
the 4-6 week period, is upregulated during the subsequent, predominantly 
regenerative, phases of disease progression (Villalta et al., 2009). By depleting 
macrophages at this later stage, Tidball & Wehling-Henricks (2007) may have 
preferentially depleted the M2 type macrophages, linked to repair. In another study by 
this group it has been shown that the increased activation of this subtype, via IFN-γ 
knock-out in vivo or by exogenous increase of IL-10 in vitro, also improved mdx 
disease outcome (Villalta et al., 2011a; 2011b). Because IL-10 production has been 
shown to be reduced by ATP acting on P2X7 (Rizzo et al., 2009) and because this 
receptor knockout has been linked to the reduction of active IL-1β (Mutini et al., 
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1999; Solle et al., 2001; Labasi et al., 2002) and TNFα (Chessell et al., 2005) this 
purinoceptor ablation could alter macrophage phenotypes. Within the M2 lineage in 
muscle there is also an established sub-division into M2a and M2c macrophages. Both 
of these M2 type cells produce the reparative cytokines IL-4 and IL-10 but the M2a 
type has been specifically linked to fibrosis in dystrophic mouse muscle (Vidal et al., 
2008; Villalta et al., 2009) whilst the M2c type is especially linked with the 
regenerative phase (Tidball & Villalta, 2010). 
Using markers for the M2c subtype of macrophage, CD163, and total macrophages, 
CD68, we have confirmed that CD163 labels a subset of CD68 positive cell bodies in 
4 week mdx tissue (Figure 4.6). A Western blotting analysis of F4/80 to CD163 ratio 
was undertaken and a small shift towards the M2 phenotype was observed in 
mdx/P2X7-/- muscle compared to mdx, indicating a potential for a beneficial shift in 
macrophage composition in these muscles. However, such a shift could still lead to 
increased fibrosis (Zhang et al., 2012), a pathological implication we later address. 
P2X7 receptor KO may influence the function of macrophages in addition to changing 
their phenotype. For instance, whereas M2 type macrophages tend not to activate 
caspase-1 in response to ATP stimulation, this activation pathway is otherwise 
important for the release of active IL-1β and the induction of macrophage pyroptosis, 
an apoptosis-independent form of cell death (Pelegrin & Surprenant, 2009). In sterile 
inflammation, IL-1β may be released upon caspase-1-induced Nlrp3 inflammasome 
activation, following tissue damage and the release of DAMPs like ATP (Iyer et al., 
2009). In the mdx mouse, IL-1β is upregulated compared to control animals (Huang et 
al., 2009) while in another sterile inflammation study, monocyte infiltrations were 
reduced in IL-1β KO animals (Kono et al., 2012). In our study, P2X7 receptor 
ablation reducing the level of active IL-1β in the mdx mouse is consistent with the 
reductions in total macrophage numbers seen here. 
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4.3.3 Effect of P2X7 receptor ablation on inflammatory genes expression in mdx 
muscle 
To measure key pro-inflammatory genes, which might be transcriptionally regulated 
upon P2X7 disruption, a qPCR study to compare relative mRNA levels in TA from 4 
week old C57, mdx, Glaxo and Pfizer mdx/P2X7-/- animals was undertaken. 
There was a general trend of decreased expression of pro-inflammatory genes 
noticeable even with a low sample number and several genes were differentially 
regulated across genotypes. It should be noted that the low number of biological 
replicates allows identification of major differences by qPCR analyses while small but 
still biologically significant differences may not be detected. Therefore, further qPCR 
analyses are being carried out in our laboratory to extend the preliminary findings of 
this study into both larger sample number and further inflammatory genes (see Future 
Studies). Of the differentially regulated genes TNFα, CX3CL1, RORC, and GR-1 
(also known as Ly6G), were significantly lower in Pfizer mdx/P2X7-/- compared to 
mdx. 
TNFα 
Downregulation of this pro-inflammatory cytokine in the absence of P2X7 agrees 
with the known role of this receptor in TNF signalling. 
TNF has been strongly linked with the chronic inflammatory component of DMD 
pathology (Lundberg et al., 1995; Grounds & Torrisi, 2004; Hodgetts et al., 2006; 
Pierno et al., 2007). In an mRNA study of human muscle biopsies it was shown that 
levels of TNFα were higher in DMD patients than in another inflammatory myopathy, 
juvenile dermatomyositis (De Pasquale et al., 2012). Additionally, an anti-TNFα 
treatment in the mdx mouse resulted in a substantial reduction in muscle breakdown 
(Grounds & Torrisi, 2004). Furthermore, TNFα was inversely correlated with the anti-
oxidant heme-oxygenase-1 expression in a myoblast cell culture model, showing the 
degenerative effects of oxidative stress in skeletal muscle (Vercherat et al., 2009).  
CX3CL1 
The chemokine CX3CL1 is expressed in a membrane bound form on a variety of 
tissue infiltrating monocytes where it has been linked to the trafficking of these cells 
and their interactions with cytotoxic lymphocytes in muscle-specific chronic 
Chapter 4: Effect of P2X7 ablation on mdx inflammatory phenotype 
 
Page 146 
inflammatory disorders (Suzuki et al., 2005; 2012). Lymphocytes, including NK and 
CD8+ T-cells express CX3CR1, the native receptor for CX3CL1. In inflammatory 
conditions, it has been hypothesised that CX3CL1 could act as a major migration and 
recruitment factor (Nishimura et al., 2002). In patients with polymyositis, a muscle- 
specific chronic inflammatory disorder, levels of serum CX3CL1 were shown to 
positively correlate with disease activity and with reduced muscle strength (Suzuki et 
al., 2012). Similarly, CX3CL1 depletion in mice was shown to reduce several disease 
markers of an experimental autoimmune myositis, including TNFα, IFNγ, perforin 
levels, and the numbers of necrotic muscle fibres (Suzuki et al., 2005). 
RORC 
The orphan nuclear receptor RORγt, encoded by the gene RORC, is expressed in 
CD4+CD8+ cells where it is thought to induce their differentiation into the pro-
inflammatory Th17 type, also downstream of IL-1β (Ivanov et al., 2006; Acosta-
Rodriguez et al., 2007). RORC was upregulated along with numbers of IL-17 positive 
cells in a mouse model of experimental autoimmune encephalomyelitis, also 
coinciding with the induction by myeloid-derived suppressor cells and of Th17 from 
naïve CD4+ T-cells (Yi et al., 2012). This is another instance in which IL-1 may be 
inducing pro-inflammatory conditions, at least partly via the upregulation of a 
CD11b+/Gr-1+ myeloid cell population.  
Gr-1 (Ly6G) 
Granulocyte receptor-1 is expressed in bone marrow-derived granulocytes and tissue-
infiltrating neutrophils. Neutrophils are an important cytotoxic cell type contributing 
to ROS generation and muscle degeneration in dystrophic tissue (Hodgetts et al., 
2006). It was noted that in macrophages exposed to ATP released from dying 
autophagic cells there was activation of the NACHT, LRR, and PYD domains-
containing protein 3 (NALP3) inflammasome, ultimately contributing to tissue 
recruitment of neutrophils (Ayna et al., 2012). 
 
Many of the other gene expression levels reflected the shift to a lesser inflammatory 
state upon P2X7 receptor ablation. These included IFNG, encoding IFNγ, involved in 
a Th1 T-cell induction profile and the activation of macrophages (Villalta et al., 
2011a).  
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PRF-1 is the gene encoding the enzyme, perforin-1 in cytotoxic T-cells (Trapani & 
Smyth, 2002). Perforin and granzyme-B are major enzymes effecting the apoptotic 
function of cytotoxic lymphocytes. COX-2 is responsible for the eicosanoid 
inflammatory signalling. Knock-out of this gene reduced macrophage invasion into 
injured muscle and also lowered myoblast proliferation (Bondesen et al., 2004) and 
recent evidence has localised COX-2 expression to necrotic and fibrotic lesions in 
mdx muscle (de Oliveira et al., 2013a). The chemokine XCL1 has been shown to 
enhance the regulatory function of CD4+CD25High T-reg cells in allergic asthma 
(Nguyen et al., 2008). The increase in the mRNA expression profile for the XCL1 
gene in Pfizer mdx/P2X7-/- TA compared to mdx is therefore consistent with the 
similarly patterned expression of Foxp3. Foxp3 is a transcription factor involved in 
the specification of immunosuppressive T-cells (Hori et al., 2003).  IL-6 was shown 
to potentiate the Th17 pro-inflammatory cell population through the negative 
regulation of T-reg Foxp3 via P2X7 receptor (Schenk et al., 2011). Th17 cells are a 
common feature of the autoimmune inflammatory milieu and are also found 
upregulated in DMD (De Pasquale et al., 2012; Marwaha et al., 2012). As mentioned 
previously, RORγt (encoded by RORC), promotes the induction of the Th17 T-cell 
population while Foxp3 can directly inhibit RORγt target transcription and subsequent 
Th17 induction (Zhou et al., 2008). CXCL12 is a small protein involved in 
chemotaxis and a pro-inflammatory cytokine cascade. From even a pre-symptomatic 
phase of DMD, several CC- and CXC- class chemokines, including CXCL12, have 
been found to be upregulated in this disease (Pescatori et al., 2007). During sterile 
inflammation CXCL12 is thought to complex with high mobility group box 1 
(HMGB1), released from damaged and necrotic cells, to interact with its native 
receptor, CXCR4, expressed on a variety of leukocytes (Venereau et al., 2012). In 
injured muscle, this CXCL12-HMGB1 heterocomplex was found to promote 
inflammatory cell recruitment (Schiraldi et al., 2012). 
P2X7 activation has also been linked to pro-inflammatory T-cell activation 
(Tsukimoto et al., 2009) and the negative selection of tolerogenic CD25+ T-regulatory 
cells in vivo (Daniel et al., 2010). Importantly, there is evidence of auto-immune 
disease features in DMD and mdx muscles (Karpati et al., 1988b; Tidball & Wehling-
Henricks, 2005). Pharmacological inhibition of P2X7 has limited autoimmune T-cell 
activation and proliferation (Lang et al., 2010) and P2X7-mediated T-regulatory cell 
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selection in a heart muscle rejection model has recently been shown (Vergani et al., 
2013). It is, therefore, interesting to consider whether P2X7 blockade could have 
similar beneficial effect in mdx muscle. 
 
4.3.4 Neutrophils and the P2X7 receptor 
Altered GR-1-gene expression indicated reduced neutrophil infiltrations, which are 
known to contribute to the dystrophic muscle pathology, into mdx/P2X7-/- muscle 
compared to mdx muscle. These cells induce muscle cell lysis but, unlike 
macrophages, are not thought to aid in regenerative processes (Pizza et al., 2005). It 
is, therefore, unsurprising that muscle necrosis was reduced upon depletion of 
neutrophils in the mdx mouse (Hodgetts et al., 2006). Decreased GR-1/Ly6G 
expression in mdx/P2X7-/- mice could contribute to the alleviation of disease features 
described here. Consistent with these data, neutrophil numbers were also reduced in 
bronchoalveolar lavage samples from smoke-challenged P2X7-/- KO mice compared 
to wild-type controls (Eltom et al., 2011).  
Mechanisms connecting P2X7 receptor ablation to reduced neutrophil numbers may 
include reduced macrophage to neutrophil co-operation, lower levels of active IL-1β 
and TNFα, and reduced neutrophil lifespan due to a lower resistance to apoptosis. 
Furthermore, ATP-induced macrophage ROS production can trigger macrophage 
inflammatory protein-2 synthesis, leading to neutrophil migration (Kawamura et al., 
2012). IL-1β is also important for recruitment of neutrophils into inflamed tissues, 
including in sterile inflammation (Netea et al., 2010; Kono et al., 2012), and IL-1β is 
a known downstream product of P2X7 receptor activation. Therefore, P2X7 ablation 
would have a potential to modify neutrophil as well as macrophage functions. 
Macrophages and neutrophils together are more efficient at cell lysis than either cell 
population alone by using a NO-dependent, superoxide-independent, mechanisms 
(Nguyen & Tidball, 2003a). Therefore, due to this interdependency, treatment 
strategies that can reduce either neutrophil or cytotoxic macrophage numbers may be 
beneficial for the amelioration of DMD progression.  
Immunolocalisation analysis presented here suggests that P2X7 expression could co-
localise with neutrophils, which agrees with some previous data (Christenson et al., 
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2008). Furthermore, in rheumatoid arthritis, P2X7 stimulation has been shown to 
impart an anti-apoptotic property to neutrophils (Christenson et al., 2008).  In another 
study, receptor expression could not be confirmed in human neutrophils using a 
variety of experimental approaches, including RT-PCR, Western blotting, 
immunostaining, and patch-clamp electrophysiology (Martel-Gallegos et al., 2010). 
Therefore, it is unclear whether P2X7 receptor ablation could impact neutrophil 
functions directly.  
Because the presence of one immune cell type can influence the proliferation and 
activation of another, it is difficult to predict, but also important to know, the precise 
effect of P2X7 ablation on the mdx inflammatory cascade.  
The dual effects of low (tonic) and high (toxic) P2X7 receptor activation may also be 
important for inflammatory cells. Amoroso et al. (2012) showed a link between P2X7 
function and the induction of aerobic glycolysis in fast-growing cells, also linked to 
hypoxia inducible factor 1α. Immune cells would directly benefit from the alternative 
energy source provided under conditions of acute hypoxia in areas of tissue damage.  
 
4.3.5 Effect of P2X7 receptor ablation on inflammation and fibrosis in aged mdx 
diaphragm and heart 
Further studies were undertaken to confirm the positive effects of P2X7 ablation on 
dystrophic muscle and to exclude the possibility that a skewed macrophage population 
might have a negative impact on DMD pathology through enhanced fibrosis. The data 
presented earlier as well as results showing reduced myofibroblast number and 
collagen deposition in the absence of P2X7 in a mouse model for tubulointerstitial 
disease (Goncalves et al., 2006) were encouraging. This effect was coincident with a 
reduction in the pro-fibrotic cytokine TGFβ. TGFβ and collagen type-I deposition 
were significantly attenuated in mdx mice diaphragms in which TNFα was blocked 
(Gosselin & Martinez, 2004). Since we have evidence of a reduction in TNFα gene 
expression in the mdx/P2X7-/- mouse at 4 weeks, it seems plausible that TGFβ and 
collagen expression may be limited via this same pathway. 
While TGFβ analysis was not undertaken as part of this study, we could otherwise 
confirm that reducing P2X7 activation did not exacerbate fibrosis in either aged ~20 
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month mdx diaphragms or hearts (Figures 4.12b, 4.13a). In fact it reduced fibrosis in 
mdx/P2X7-/- compared to mdx aged heart tissue (Figure 4.13a). Furthermore, 
inflammatory cell infiltrations were reduced in both diaphragms (Figure 4.12a) and 
hearts (Figure 4.13b) from mdx/P2X7-/- mice, consistent with results for the 4 week 
hindlimb muscles presented earlier. These data are also consistent with published 
findings indicating the positive correlation between general immune-cell infiltrations 
and cardio-fibrosis in the adult mdx mouse. Fibrosis was significantly reduced in 
hearts from 10-12 month mdx mice in which the adapter molecule myeloid 
differentiation primary response gene 88 (myd88) was knocked-out (Henriques-Pons 
et al., 2013). Myd88 expression is positively correlated with macrophages and is 
involved in their full-scale activation in response to cytokines like IFN-γ (Shi et al., 
2003). In another study with a direct relevance for P2X receptor mediation of this 
response, the pan P2 receptor antagonist, suramin, was used in 11 month old mdx 
mice to reduce cardiac fibrosis concomitant with reduced inflammatory cell 
infiltrations (de Oliveira Moreira et al., 2013b). In another similar study, but in 6 
month mdx mice, suramin reduced serum CK and fibrosis in TA, biceps brachii, and 
diaphragm muscles but not heart, following a daily 1 hour down-hill exercise regime, 
for a period of 7 weeks (Taniguti et al., 2011). 
 
4.3.6 Conclusions and further studies 
Corroborating published observations, we have shown that P2X7 expression is co-
localised with a variety of immune cell sub-types in dystrophic mouse muscle in vivo. 
Furthermore, the loss of P2X7 receptors resulted in the reduction of pro-inflammatory 
macrophages and neutrophils, coincident with a reduction of expression of pro-
inflammatory genes. 
This study therefore represents the first known analysis of an effect of P2X7 ablation 
on chronic inflammation in skeletal muscle. Outside of skeletal muscle, this 
association has already been established for brain (Sharp et al., 2008; Chu et al., 
2012; Kimbler et al., 2012), alimentary tract (Schenk et al., 2011), kidney (Goncalves 
et al., 2006), salivary gland (Woods et al., 2012), and heart (Vergani et al., 2013). 
Macrophages make up the majority of infiltrating immune cells in dystrophic muscle 
such that their modulation has great potential to influence disease parameters. Another 
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myeloid cell type recruited to muscle during early stages of inflammation and 
collaborating with macrophages to effect tissue damage are neutrophils.  Neutrophil 
numbers were also significantly decreased in mdx/P2X7-/- muscles and this effect can 
be a direct as well as indirect one. However, the P2X7 receptor has been linked with 
many more aspects of innate and adaptive immune response than we have tried to 
monitor. For instance, based on the known function of the P2X7 receptor in T-cells, a 
proper analysis of lymphocyte populations is required. 
Also interesting in this regard, is work on P2X7 in dendritic cells, where receptor 
activation resulted in dendritic cells with lower potential to activate T-helper cells 
through antigen presentation (Mutini et al., 1999). Therefore, quantification of T-cell 
subtypes is lacking. Attempts were made to determine CD4 and CD8 numbers by 
immunohistochemistry and flow-cytometry but were unsuccessful due to low 
antibody specificity. 
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5 
Functional analysis of mdx and mdx/P2X7-/- dKO 
mice 
 
5.1 Introduction 
DMD is characterised by a loss of muscle integrity, leading to reduced muscle force 
generation. Other major symptoms include a mild to severe cognitive impairment in 
many patients and an osteopenic, bone resorption, phenotype. The primary aetiology 
that leads to impaired learning capacity (Hinton et al., 2004) may be contributing to 
cognitive impairment but it is now known that the loss of dystrophin may lead to 
neuronal and blood brain barrier dysfunction directly, due to the specific roles for 
dystrophin and the associated DAPC in the CNS (Man et al., 1991; Gorecki et al., 
1992; Austin et al., 2000; Aleman et al., 2001; Lien et al., 2012). Osteopenia is a far 
less studied feature of DMD despite a high penetrance and the severe clinical 
implications for patients. 
Although the loss of P2X7 receptor activation in the mdx mouse has so far seemed to 
ameliorate disease pathology through anti-inflammatory and pro-myogenic effects, 
functional pre-clinical measures are required to assess the effective outcomes of 
molecular pathway changes on some of the major symptoms of DMD. 
Sarcolemmal breakdown leading to muscle fibre degeneration and the enhanced 
release of immune-stimulating cytoplasmic components is a primary dysfunction 
downstream of dystrophin absence. The DAPC effectively mechanically stabilises the 
sarcolemma by coupling the intracellular cytoskeleton to extracellular matrix 
components, such that the loss of dystrophin function will directly compromise 
myofibre viability (Petrof et al., 1993; Dudley et al., 2006). Second messenger led 
Chapter 5: Functional analysis of mdx and mdx/P2X7-/- dKO mice 
Page 153 
pathways, including proteolytic and apoptotic pathways downstream of elevated 
intracellular Ca2+, are now also considered integral to membrane destabilisation. 
Weakening of muscle force is a primary symptom of DMD. It is a factor representing 
the convergence of multiple cellular and molecular dysfunctions inherent to the 
disease, including the exaggerated degeneration and leakiness of muscle fibres.  
 
5.1.1 Muscle force in DMD and mdx 
Muscle force production is a single functional output measure of organism health, 
directly relevant as a clinical therapeutic measure of treatment efficacy in muscular 
dystrophy studies. The reduction of muscle force in DMD patients is mainly related to 
the loss of muscle fibres over time. Muscle fibres reduce in number and are replaced 
by fatty-fibrous deposits, resulting in few capable force-producing elements and a 
tissue ultrastructure less optimal at translating or sustaining that force. In the mdx 
mouse, total muscle force is remarkably well maintained across the life span of the 
animal due to very successful compensatory regeneration. When muscle force is 
adjusted relative to muscle size, it has been established that there is a ‘specific’ 
muscle-force deficit in different muscle groups (Lynch et al., 2001; Goldstein & 
McNally, 2010). For example, WT extensor digitorum longus muscle showed a 
recorded maximum specific isometric tetanic force of ~250 kN/m2 compared to ~220 
kN/m2 for mdx at 6 months, with the soleus muscle also presenting similar values 
(Lynch et al., 2001). In other studies, the C57 diaphragm presented a maximum 
specific isometric tetanic force of ~195 kN/m2 compared to ~150 kN/m2 for mdx at 6 
months (Schertzer et al., 2007; Gehrig et al., 2012). Typical maximum specific force 
values for isolated diaphragm have not been published.  
Another feature of dystrophic muscle is a susceptibility to stretch-induced damage. In 
mdx mouse studies, this feature of the disease can be tested and compared using an 
eccentric contraction assay. Following the stretching of muscle past a maximum 
tetanic length, subsequent excitation-force traces can be mapped, usually resulting in 
more pronounced healthy versus diseased tetanic force differences, in vivo or in vitro, 
as the dystrophic muscle characteristically worsens over repeated eccentric stretches 
(e.g. Blaauw et al., 2008). Eccentric contraction assays are particularly useful when 
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testing therapies hypothesised to improve the mechanical stability of the sarcolemma, 
for instance following pharmacological or genetic approaches to reinstate functional 
dystrophin (Gilbert et al., 2003). Their sensitivity to intermediate differences in 
muscle function along a continuum of disease severity means that eccentric 
contraction assays are useful to map functional improvements following most 
treatment strategies. 
In addition to structural protein factors, the specific force deficit of the mdx mouse, 
derived through either tetanic or eccentric force experimentation, also attests to a 
fundamental metabolic aspect of disease biology, which is also likely shared by 
human DMD patients. In addition to the loss of muscle fibres, several cellular-
biochemical mechanisms can contribute to reduced muscle force production in DMD. 
These include an altered energy handling capacity, a shift in muscle oxidative 
phenotype, an increase in ROS/RNS generation, and a systematic change in 
neuromuscular innervation. All of these phenomena could involve purinoceptor signal 
transmission via P2X7, as shall be discussed below. 
 
Energy handling and fibre-type shifting in muscular dystrophy 
Skeletal muscle is an important site of glucose metabolism and glycogen storage. In 
DMD, skeletal muscle has been shown to contain significantly less glucose than in 
non-dystrophic subjects (Sharma et al., 2003). This seems to indicate a fundamental 
energy handling deficit in DMD that could affect muscle function. Muscle metabolic 
potential is also reflected in oxidative capacity or muscle fibre-type, a parameter also 
known to be compromised in DMD. 
Using an exercise mimetic compound, AICAR, to exogenously activate the 
ATP:AMP cellular sensor, AMPK, in the mdx mouse has been shown to shift 
myofibres to the type I oxidative phenotype, more resilient to dystrophic challenge 
(Jahnke et al., 2012). Part of this effect was mediated by a reduction in Foxo1 
transcription. Inversely, it has been shown that Foxo1 over-expression resulted in 
fewer type I fibres and smaller type I and II fibres (Kamei et al., 2004). If P2X7 is 
contributing to autophagic induction in DMD muscle, this could result in reduced 
muscle force potential and may also help to explain the earlier defined increased 
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average minimum Feret’s diameter values for the mdx/P2X7-/- dKO hindlimb muscle 
compared to mdx. 
Larger muscle fibres tend to produce greater force, but this effect is also normally 
correlated with muscle fibre-type. Fast-glycolytic muscle fibres tend to be larger and 
to produce greater maximum force. For instance, mdx mice treated long-term with an 
aptamer inhibitor for all IGF-binding proteins, NBI-31772, resulted in larger muscle 
fibres capable of producing more specific force, less susceptible to contraction 
induced sarcolemmal breakdown, and shifted to a fast-glycolytic, type-IIb, fibre-type 
(Schertzer et al., 2007). 
 
Increased ROS/RNS production 
Persistently increased intracellular Ca2+ causes muscle damage and muscle force 
reduction via activation of Ca2+-dependent calpain proteases. Recent work suggests 
that this may be heavily influenced by an accompanying increase in ryanodine 
receptor S-nitrosylation affecting sarcoplasmic reticulum Ca2+ handling (Bellinger et 
al., 2008a; 2008b; 2009). Others have also reported a decrease in specific muscle 
force production upon increased ROS/RNSgeneration (Li et al., 2011b). 
The origin of these enhanced levels of detrimental ROS/RNS is multi-focal. Recent 
evidence suggests that above normal iNOS expression, associated, for instance, with 
increased immune cell infiltration, may not represent a major cause for reduced 
muscle force in DMD, or even the majority of nitrotyrosination in dystrophic muscle 
(Li et al., 2011a). Instead, the intracellular location of native nitrogen and oxygen 
donors may be more important than their total absence or presence. At the cell 
membrane, NO donated by nNOS is thought essential for promoting satellite cell 
activation and fusion but when delocalised it may contribute to overall nitrosative 
stress leading to nitrosylative protein modifications and the loss of muscle force (Eu et 
al., 2003; Bellinger et al., 2008a; 2008b; 2009). 
A link to enhanced cellular ROS/RNS with P2X7 over-activation in muscle is not 
immediately obvious but has been described for at least two forms of P2X7-mediated 
neuronal cell death (Nishida et al., 2012; Apolloni et al., 2013). In both cases, P2X7 
activation was described as mediating increased ROS generation via activation of 
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NADPH oxidase. Moreover, recent work has also identified the P2X7 receptor as 
responsible for ROS generation in an erythroid cell line (Wang & Sluyter, 2013). That 
P2X7-dependent ROS generation in these cell types is shared with macrophages 
(Martel-Gallegos et al., 2013) perhaps indicates the ubiquity of this cellular cascade. 
 
Neuromuscular synaptic transmission 
P2X receptors, including P2X7, have been shown to be linked to ACh co-release at 
synapses (Sun & Stanley, 1996; Hong & Chang, 1998; Salgado et al., 2000) and this 
is a means by which the receptor may affect muscle force generation. It has also been 
shown that this co-release may be a mechanism by which inactive heterosynaptic 
inputs may be protected from an imposed loss of synaptic efficacy (Jia et al., 2007). 
In this latter study, P2 receptors were considered the likely ATP targets effecting this 
protection since the P2 blocker, suramin, promoted substantial activity-dependent 
neuromuscular synaptic losses. Of particular note, 100μM ATP, instead of protecting 
synapses, reduced synapse strength (Jia et al., 2007). This activation level threshold 
behaviour is characteristic of the P2X7 receptor and may be related to the multiple 
open states this receptor is known to possess, including the large pore formation 
(Rassendren et al., 1997; Browne et al., 2013). 
 
5.1.2 Dystrophic bone phenotype 
Given the clear musculoskeletal interactions, bone structure abnormalities found in 
DMD patients and mdx mice were believed to have muscle origins. However, rather 
than being an effect of asymmetric loss of muscle force alone, these abnormalities 
have recently been found to be independent disease manifestations. 
Bone is a plastic tissue, able to adapt its structure in reaction to age-related biological 
changes (Hamrick et al., 2006), metabolic disorders, and animal immobility (Kaneps 
et al., 1997). In DMD patients, long-term steroid therapy may contribute to the loss of 
bone mineral density (Bianchi et al., 2003; Mayo et al., 2012). 
Muscle weakness can influence bone mineralisation by reducing shear stress forces 
necessary to activate osteoblasts (Hillam & Skerry, 1995; Yan et al., 2012), although 
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it is likely that other intrinsic factors, different in dystrophic compared to healthy 
organisms, also greatly contribute to osteopenia in the disease state. For instance, 
Nakagaki et al. (2011) found a characteristic bone phenotype in the femur of 3 week 
old mdx mice without evidence of accompanying quadriceps pathology. Similarly, 
osteoblasts from healthy humans did not mineralise bone after contact with serum 
from DMD patients, indicating the presence of inhibitory paracrine factors in DMD 
serum (Rufo et al., 2011). 
Hormonal imbalance linked to chronically lower testosterone levels and 
hypogonadism are thought to heavily propagate lower bone mineral density in DMD 
patients (Cruz Guzman Odel et al., 2012). Based on available literature evidence, it is 
also likely that inflammatory cytokines significantly influence the osteopenic 
phenotype of DMD patients. For instance, IL-6 was found to enhance 
osteoclastogenesis and to be increased in DMD and mdx serum. In the Pfizer P2X7-/- 
KO mouse, IL-6 was one cytokine initially found to have a more limited expression 
compared to wild-type controls (Solle et al., 2001). 
However, perhaps the best reason for studying the effects of P2X7 ablation on the 
osteopenic phenotype of the mdx mouse is to determine if there is a compound 
exacerbation in bone resorption. P2X7 function has been previously positively linked 
to activity-dependent bone formation, whilst loss-of-function polymorphisms have 
been linked to increased fracture risk in humans and bones of lower density in mice 
(Gartland et al., 2003; Ke et al., 2003; Orriss et al., 2010; Syberg et al., 2012; 
Wesselius et al., 2013). Therefore, P2X7 gene disruption could affect mdx bone 
positively by changing the dystrophic phenotype but also negatively by impacting on 
bone resorption. 
 
5.1.3 Chapter summary 
The DMD pathology is multi-facetted. Humans and mice share many disease 
symptoms including a compromised sarcolemmal stability, reduced muscle force and 
endurance potential, as well as osteopenia. 
To test the therapeutic potential of targeting P2X7 receptors to treat DMD, we have 
sought to test several basic parameters of muscular dystrophy pathology in the mdx 
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compared to the mdx/P2X7-/- dKO mouse. To do so, we have followed established 
methods of pre-clinical study, including an analysis of the levels of serum CK across 
dystrophic genotypes at 4 weeks, a complimentary histological IgG study in GC 
muscle at 4 weeks, an in vitro diaphragm tissue-bath study measuring maximum 
isometric tetanic force at 4 weeks, and a μCT analysis of trabecular bone 
morphometry across 6 month mdx, mdx/P2X7-/- dKO, and Pfizer KO mice. μCT 
samples have been prepared by the candidate and analysis was performed by 
collaborators, Prof. Anna Teti and Dr. Andrea Del Fattore, University of L’Aquila, 
Italy. 
Serum CK level is an indication of muscle protein extravasation following 
sarcolemmal compromisation. Serum CK is a standard clinical diagnostic marker for 
DMD, also used in mouse model studies (Hess et al., 1964; Coulton et al., 1988). 
Mouse IgG immunohistochemistry was used to determine sarcolemmal instability by 
measuring the levels of blood borne immunoglobulins that are normally excluded 
from the muscle cytosol. In this sense, IgG staining could be correlated with serum 
CK data, although the latter is a more global measure of membrane compromisation. 
For a preliminary analysis, it was also decided to test the potential of using a drug-
based P2X7 antagonist for therapeutic intervention. Mdx mice were injected i.p. with 
the P2X7 antagonist CBB (125mg/kg) or saline negative control every day from 
postnatal day 2 (P2) until collection at 4 weeks. Serum CK analysis was then 
performed.  
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5.2 Results 
5.2.1 Serum CK comparisons between mdx and mdx/P2X7-/- dKO mice 
Mouse serum was collected and using a commercial enzymatic CK detection kit, it 
was confirmed that the mdx mouse had a much higher level of serum CK compared to 
the non-dystrophic C57 at 4 weeks of age. The C57 and Pfizer mdx/P2X7-/- dKO 
mouse had a significantly lower average serum CK level than age-matched mdx 
(Figure 5.1). There was a large spread in the data about the mean for each dystrophic 
group, necessitating large ‘n’ numbers before statistical significance could be attained. 
The Pfizer mdx/P2X7-/- dKO mouse presented an average serum CK, 796.9 IU/L, 
almost half that of mdx, 1461.6 IU/L. The spread of individual scores about the mean 
was also greater for mdx (StDev=848) than for Glaxo dKO (StDev=591) or Pfizer 
dKO (StDev=561) mice. Glaxo mdx/P2X7-/- dKO mouse serum CK was qualitatively 
intermediate but not significantly different from either mdx or Pfizer mdx/P2X7-/- dKO 
serum CK levels. 
 
Figure 5.1. Serum CK levels are significantly lower in both C57 and Pfizer mdx/P2X7-/- 
dKO serum relative to mdx at 4 weeks. Mouse serum CK levels showed significantly lower 
average values for C57 and Pfizer P2X7-/- dKO compared to mdx at 4 weeks (ANOVA, 
F=6.94, P<0.001, df=3, Tukey post-hoc). 
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5.2.2 Muscle membrane permeability in mdx and mdx/P2X7-/- dKO muscle 
Serum CK analysis gives an indication of total muscle fibre damage. To assess 
individual fibre membrane damage within specific muscles a histological measure of 
fibre permeability was used to quantify and compare mdx and mdx/P2X7-/- dKO GC 
muscles. As a corollary for serum CK a tracer was employed that can only enter 
muscle fibres when sarcolemma integrity is compromised. 
An anti-mouse IgG antibody conjugated to a fluorophore was used to label blood-
derived immunoglobulins in GC cryosections at 4 weeks. Based on a pixel density 
distribution of the immunolocalisation signal as a percentage of total cross-sectional 
area, significantly lower values were found in Pfizer mdx/P2X7-/- dKO GC (1.47% 
±0.9) compared to mdx (6.34% ±2.5) (Figure 5.2). Whilst not statistically 
significantly different from either genotype, Glaxo mdx/P2X7-/- dKO GC muscle 
presented an intermediate average IgG percentage value (3.1% ±2.08). Non-
dystrophic controls did not present IgG infiltration (Figure 5.2a), so were not 
measured. 
Using the IgG antibody, muscle fibres present one of two main forms of infiltration, 
differentiated by the levels of tracer intensity, either low or high. 
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Figure 5.2. Immunofluorescence analysis, showing absent infiltrating mouse IgG in C57 
and a significantly reduced IgG in Pfizer mdx/P2X7-/- dKO GC muscle fibres compared to 
mdx at 4 weeks. a) Example whole 4 week GC muscle cryosections presenting mouse IgG 
Immunofluorescence (red: indicative of individual muscle fibre membrane being 
compromised) in C57, mdx, and Pfizer dKO mice. Note, insert showing higher and lower 
tracer intensity within a single cluster of permeable membranes. b) Graphical representation 
of average mouse IgG signal as a percentage of total muscle area for mdx, Glaxo dKO, and 
Pfizer dKO, showing a signifcant difference in mouse IgG positive signal between mdx and 
Pfizer mdx/P2X7-/- tissues (ANOVA, F=5.52, P=0.031, df=2).  
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5.2.3 Analysis of isometric tetanic force in mdx and mdx/P2X7-/- dKO diaphragms in 
vitro  
Significantly reduced absolute muscle force is a hallmark of DMD; a symptom also 
shared with the mdx mouse (Lynch et al., 2001; Goldstein & McNally, 2010). Using 
an in vitro diaphragm organ bath setup to measure isometric tetanic force evoked by 
electrical field stimulation, muscle force was compared between C57, mdx, Glaxo 
dKO, and Pfizer dKO mice at 4 weeks and 4 months. 
A triangular section of excised muscle was taken from the mid-section of the whole 
diaphragm (Figure 5.3a). A voltage stimulus required to elicit a maximal isometric 
twitch (Pt) response (Figure 5.3b) was determined during diagnostic testing (data not 
shown), with the value of 140V being chosen as being well within the plateau range. 
A stimulus frequency of 100Hz was used to achieve a maximal isometric tetanic force 
(Po) (Figure 5.3b). This value was based on published data and also confirmed during 
testing (data not shown). All tissue bath experiments were performed with the tissue 
in a Krebs buffer maintained at a physiological temp. of 37°C. After the stimulus-
response recording the tested muscle was wet-weighed for normalisation per 
milligram of tissue and force in Newtons derived by multiplication by 0.0098. 
At 4 weeks of age, average maximal isometric tetanic force per gram of tissue was 
significantly increased in the Pfizer mdx/P2X7-/- dKO diaphragm compared to mdx 
(Figure 5.3c).The mean value of 12.544 N/g force production for Pfizer dKO was 
intermediate between mdx, 5.1 N/g, and C57, at 32.34 N/g, and similar to that of the 
Glaxo dKO diaphragm. 
At 4 months of age, average maximal isometric tetanic force per gram of tissue was 
significantly increased in both Glaxo and Pfizer P2X7-/- dKO diaphragms compared to 
mdx (Figure 5.3d). The mean values of 17.5 N/g and 23.4 N/g force production for 
Glaxo dKO and Pfizer dKO, respectively, were again intermediate between mdx, at 
12.6 N/g, and C57, at 32.34 N/g. 
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Figure 5.3. Diaphragm tetanic muscle force is increased in mdx/P2X7-/- dKO muscle 
compared to mdx at 4 weeks and 4 months. Example experimental setup, stimulus-force trace, 
and graphical representation of in vitro diaphragm tissue bath data comparing average 
isometric tetanic force (N/g) between C57, mdx, Glaxo dKO, and Pfizer dKO at 4 weeks and 
4 months. a) Image depicting a setup used for measuring diaphragm muscle force in vitro. 
The triangular muscle segment has been secured to the plastic clamp via a rib attachment 
maintained in situ. b) An example force trace indicating maximal isometric twitch tension 
(Pt) and tetanic tension (Po), elicited by 140V stimuli applied singularly or in 100Hz trains, 
respectively. c) At 4 weeks, C57 presents a significantly greater average isometric tetanic 
force than mdx (ANOVA, F=7.79, P=0.002, df=3, Tukey post-hoc), with Pfizer dKO also 
presenting increased force compared to mdx via T-test (T=-2.4, df=8, P=0.043). d) At 4 
months, C57 and both Glaxo dKO and Pfizer dKO diaphragms present greater average 
isometric tetanic force upon electrical field stimulation at 100Hz (ANOVA, F=102.55, 
P<0.001, df=3, Tukey post-hoc).  
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5.2.4 Bone histomorphometry comparisons in mdx and mdx/P2X7-/- dKO mice at 6 
months 
6 month old C57 BL/10, mdx, Pfizer mdx/P2X7-/- dKO, and Pfizer P2X7 KO mice had 
their femurs removed after death and were prepared for μCT analysis. Four 
parameters, described as some of the basic minimum recommendations for 
quantitatively assessing trabecular bone morphology (Bouxsein et al., 2010), were 
then derived from micro-CT data (Figure 5.4). The ratio of bone volume to trabecular 
volume (BV/TV, %) is a measure of bone density. Interestingly, BV/TV was 
significantly higher in C57, Pfizer mdx/P2X7-/- dKO, and Pfizer P2X7 KO mice 
compared to mdx. Furthermore, the Pfizer mdx/P2X7 dKO mouse had a BV/TV % 
similar to C57 wild-type and Pfizer P2X7 KO animals. Trabecular thickness (Tb.Th) 
was again lower in mdx, although only Pfizer P2X7 KO presented a significantly 
higher average. Trabecular spacing/separation (Tb.Sp) is a measure of the distance 
between trabeculae. C57, Pfizer mdx/P2X7-/- dKO, and Pfizer P2X7 KO mice all 
presented lower average Tb.Sp compared to mdx. Trabecular number (Tb.N) is a 
measure of the number of trabeculae per unit of area or length. Mdx mice presented a 
lower average Tb.N than other genotypes, although only C57 and Pfizer P2X7 KO 
animals were significantly higher. Altogether, these measures indicate a rescued 
osteopenic phenotype in mdx/P2X7-/- dKO mice compared to mdx at 6 months. 
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Figure 5.4. Micro-CT bone histomorphometry comparisons, showing lower bone 
resorption in wild-type, P2X7-/- KO, and mdx/P2X7-/- dKO femurs compared to mdx at 6 
months. Four parameters were compared between genotypes, including bone volume/ total 
volume percentage (BV/TV %) (ANOVA, F=8.07, df=3, P=0.003, Tukey post-hoc); 
trabecular thickness (Tb.Th μm) (ANOVA, F=4.013, df=3, P=0.029, Tukey post-hoc); 
trabecular space (Tb.Sp μm) (ANOVA, F=49.59, df=3, P<0.001, Tukey post-hoc); and 
trabecular number (Tb.N/mm2) (ANOVA, F=6.7, df=3, P=0.006, Tukey post-hoc). All 
statistical comparisons are shown relative to mdx, with significantly different averages 
denoted by an asterisk. 
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5.2.5 P2X7 receptor pharmacological antagonism study in mdx mice 
Serum CK levels did not significantly differ between CBB injected, saline injected, or 
non-injected mdx mice following a 4 week treatment, at the current N numbers 
(Figure 5.5). The average serum CK value for CBB injected mdx, 883 ±481.6 IU/L, 
was qualitatively lower than that presented by mdx, 1462 ±847.9 IU/L, and similar to 
Pfizer mdx/P2X7-/- dKO, 797 ±560.8 IU/L. Similarly, saline injected mdx mice 
presented an increased average serum CK, 1506 ±1014.2 IU/L, which was not 
significantly different from CBB injected mdx (Figure 5.5b). There was a large 
spread in the injected mdx individual data points that was qualitatively similar to non-
injected mice (Figure 5.5a). Data from this CBB and saline treatment CK study was 
added to previous CK data for comparative purposes. 
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Figure 5.5. Preliminary P2X7 receptor antagonist study, showing qualitatively, but not 
significantly, lower serum CK levels in CBB injected compared to mdx and mdx saline 
injected mice at 4 weeks of age. a) Analysis of mouse serum CK, comparing 4 week mdx 
with C57 BL/10, both mdx/P2X7-/- dKOs, and Coomassie Brilliant Blue (CBB) injected mdx. 
Only C57 BL/10 and Pfizer dKO mice presented serum CK that was significantly different 
from mdx (ANOVA, F=5.99, P<0.001, df=4, Tukey post-hoc). Also note, saline treated mdx 
were added to the mdx group for this analysis. Individual value points for serum CK (red 
spots). b) Serum CK from 4 week CBB and saline injected mdx did not significantly differ 
(T-test, T=-1.41, P=0.208, df=6). 
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5.3 Discussion 
5.3.1 Sarcolemmal permeability differences between mdx and mdx/P2X7-/- dKO mice 
Lower average serum CK in Pfizer mdx/P2X7-/- dKO compared to mdx mice indicates 
reduced total muscle pathology related to P2X7 ablation (Figure 5.1). The fact that 
the Glaxo mdx/P2X7-/- dKO mouse did not present a significantly reduced serum CK 
at 4 weeks, perhaps reflects the hypomorph (incomplete P2X7 KO) status of this 
mouse (Nicke et al., 2009). This is also interesting as an explanation for the repeated 
qualitatively intermediate outcome for this genotype in multiple measures of disease 
pathology. As was the case for multiple inflammatory transcripts (see Chapter 4), the 
Glaxo mdx/P2X7-/- dKO mouse present an average serum CK intermediate between 
that for the Pfizer mdx/P2X7-/- dKO and the mdx mouse. 
Average serum CK levels were similar between mice at 4 weeks and 4 months (not 
shown). This observation is inconsistent with there being less muscle inflammation 
and degeneration at 4 months than at 4 weeks. However, CK is a metabolic enzyme 
and it should be expected that overall levels would vary as a function of age and size 
of muscle. Therefore, the similar levels of serum CK from 4 month old animals 
compared to 4 weeks, perhaps reflects the larger sizes of animals at 4 months 
compared to 4 weeks. In one recent example of an analysis of mdx serum CK, levels 
were actually higher in 6 month animals compared to 4 week (Baltgalvis et al., 2011). 
Also, the dystrophic animals in this study were not exercised; a method often used to 
exacerbate disease pathology for pre-clinical therapeutic testing (Spurney et al., 2009; 
Kobayashi et al., 2012; Willmann et al., 2012). Without exercising or challenging the 
muscle, natural conservative behaviours may be adjusting to limit disease 
expressivity, or metabolic and molecular disease pathways may be otherwise limited 
by natural controls. These compensatory factors may be beneficial for the well-being 
of affected animals but may also mask the sometimes subtle effects of altering an 
experimental variable, such as the removal of P2X7 receptor function, especially in 
vivo. The average CK values reported here for 4 week old mdx mice, 1461.6 
±848IU/L, is much less than published values for exercised mdx mice (Kobayashi et 
al., 2012) but similar to that shown in un-challenged animals, for example 1148±477 
IU/L in 8 week  old mice (Sacco et al., 2010). 
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Mouse-IgG 
Levels of GC fibre permeability using the anti-mouse IgG antibody, complemented 
the serum CK data by showing significantly less IgG signal in Pfizer mdx/P2X7-/- 
dKO myotubes compared to mdx (Figure 5.2). Also paralleling the findings of the 
serum CK assay, Glaxo mdx/P2X7-/- dKO mice again presented a disease marker 
severity qualitatively greater than that for the Pfizer mdx/P2X7-/- dKO mouse and less 
than mdx. In the IgG histological assay of fibre permeablisation it should also be 
noted that muscle fibres positive for tracer infiltration presented either a strong or a 
weak cytoplasmic staining. This experimental effect has been noted elsewhere (Straub 
et al., 1997; Wooddell et al., 2010), although the biological cause is as yet not fully 
understood. 
A total understanding of the biological consequences of sarcolemmal IgG 
permeability is difficult to ascertain from current literature but the association with 
muscle damage and a subsequent positive correlation with dystrophinopathy disease 
severity seems obvious from seminal papers (Straub et al., 1997; Wehling et al., 2001; 
Sacco et al., 2010; Wooddell et al., 2010). However, it should also be mentioned that 
a compromised or damaged sarcolemma does not always result in the loss of that cell. 
Muscle from healthy or dystrophic subjects can become damaged before a process of 
repair (for a recent discussions see Han and Campbell, 2007; Swaggart et al., 2014). 
Furthermore, in one correlative study in mdx mice, the authors could not establish a 
clear histological correlation between the dye, Evans blue, and H&E evident features, 
like necrosis (Straub et al., 1997). Whilst necrotic fibres always stained positively for 
Evans blue, dye positive skeletal muscle fibres sometimes co-localised with 
morphologically normal fibres in the corresponding H&E stain. 
 
5.3.2 Specific diaphragm force differences between mdx and mdx/P2X7-/- dKO mice 
Muscle force generation is mediated by multiple cellular and biochemical factors that 
are differentially regulated in the DMD disease state. Upon P2X7 ablation, we have 
shown an increase in diaphragm muscle specific force at 4 weeks, using a non-
multivariate analysis, and at 4 months, by standard ANOVA (Figure 5.3). Although 
the role of iNOS in reducing muscle force generation in the mdx mouse has been 
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contested (Li et al., 2011a), inflammatory infiltrate probably still influences force 
production. For instance, neutrophils are uniquely capable of rapidly releasing 
superoxide, which is cytotoxic (Toumi et al., 2006) and able to reduce muscle force 
production (Li et al., 2011b). In addition to this, we have previously also shown that 
mdx/P2X7-/- dKO mice have an increased centrally nucleated fibre size (Figure 3.11) 
and reduced sarcolemmal fragility (Figure 5.1; 5.2), which are obvious other factors 
that could contribute to an increased tetanic force production in mdx/P2X7-/- dKO 
mice compared to mdx. In the diaphragm an attempt was made to normalise muscle 
force to muscle mass between genotypes but muscle fibre size was not quantitatively 
appraised for comparison. A standard approach for inferring diaphragm cross-
sectional area requires applying the calculation CSA(cm2)=[diaphragm wet 
mass(g)/fibre length (cm) x 1.056 (g/cm3)], where 1.056 g.cm-3 represents the constant 
for a pre-determined average muscle density (see Staib et al., 2002). However, muscle 
fibre density may not be uniform along the length of a single diaphragm, especially in 
a DMD disease state. Another important consideration is that maximum specific force 
varies as a function of myosin heavy chain content in even the diaphragm, with slow-
type muscle fibres producing less force than the fast-type (Geiger et al., 2000). 
Considering that fibre-type can change as a function of disease severity, it may be 
possible that normalising muscle force to diaphragm cross-sectional area or weight 
would not adjust relative to this important factor. Despite this, it would still be 
expected that greater force producing muscle should be deemed healthier, even as a 
function of preserved fast-type fibre integrity. Finally, the normal approach for 
inferring diaphragm cross-sectional area uses a constant density-value (1.056 (g/cm3)) 
that has been shown to change as a function of aging processes, contributing to 
sarcopenia (Greising et al., 2013). P2X7 receptors may be involved in aging related 
cellular and molecular events and DMD otherwise involves similar forms of muscle 
atrophy, usually defined in terms of cachexia. 
In other studies, it has been shown that genetic ablation of TNFα production 
significantly improved maximal isometric diaphragm force in the mdx mouse 
(Gosselin et al., 2003) and TNFα application reduced diaphragm force due to the 
direct blunting of myofilament Ca2+ activation (Reid et al., 2002). These results are 
consistent with the increase in isometric tetanic force presented for the mdx/P2X7-/- 
dKO diaphragm compared to mdx (Figure 5.3), since we have also confirmed a 
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reduction in TNFα mRNA expression in 4 week TA muscle (Figure 4.9). It should be 
noted, however, that this comparison has been made between diaphragm force and 
hindlimb cytokine expression and thus is indirect. Nevertheless, all other parameters 
were constant in leg and diaphragm muscles and therefore it is justified on the basis of 
shared purinergic utilisation and basic musculoskeletal biology. 
It was mentioned in the general introduction (1.6) that the Glaxo and Pfizer P2X7-/- 
KO mice are similar, for instance related to absent mature IL-1β induction in 
macrophages following LPS-priming (Solle et al., 2001; Chessell et al., 2005) but 
they also differ, for instance related to the differing bone phenotypes observed in 
either strain (Ke et al., 2003; Gartland et al., 2003b). It is known that the Glaxo P2X7-
/- KO mouse possesses a gain-of-function splice variant, the P2X7 ‘K’ variant, that 
may be contributing to identifiable functional differences. However, it is prematurely 
speculative to expect an exaggerated disease severity in dystrophic mice carrying the 
gain-of-function ‘K’ variant of P2X7, even if the normal full-length purinoceptor can 
be linked to disease pathogenesis or progression. In this study, the Glaxo mdx/P2X7-/- 
dKO mouse also presents a qualitative increase in diaphragm tetanic force at 4 weeks 
(Figure 5.3a) and a significantly greater tetanic force at 4 month (Figure 5.3b) 
compared to mdx, and this may be consistent with other improved disease features, 
such as elevated myogenin protein levels (Figure 3.12) or reduced total macrophage 
infiltration (Figure 4.8) and immune marker mRNA (Figure 4.9) in 4 week hindlimb 
muscle. We have not otherwise attempted a systematic analysis of P2X7 K-variant 
influence. The wider significance of the qualitative pattern of intermediate Glaxo to 
Pfizer mdx/P2X7-/- disease marker presentation often repeated in this work shall be 
further mentioned in the general discussion section. 
 
5.3.3 Bone remodelling differences between mdx and mdx/P2X7-/- dKO mice 
Previous positive data, indicating a reduction in skeletal muscle inflammatory 
phenotype, a potential improvement in muscle regenerative potential, and the 
improvement in maximum isometric diaphragm muscle force generation coupled to a 
decreased muscle membrane permeability, may translate to an improved bone 
phenotype in the mdx/P2X7-/- dKO mouse compared to mdx. However, this must also 
be counter-balanced by a well-defined osteopenia phenotype associated with the 
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P2X7 KO mouse (Gartland et al., 2003; Ke et al., 2003; Orriss et al., 2010; Syberg et 
al., 2012; Wesselius et al., 2013). The P2X7 receptor is thought to be expressed on 
both osteoblasts and osteoclasts (for review see Orriss et al., 2010) but it has been 
described as having alternate functions in either cell population. In osteoblasts, the 
P2X7 receptor has been mainly described as promoting bone formation (Panupinthu et 
al., 2007; 2008), including a fluid-flow mediated ERK1/2 phosphorylation with 
subsequent osteogenic gene activation (Okumura et al., 2008). Additionally, one of 
these osteogenic genes was osteopontin (OPN), also a pro-inflammatory factor found 
to be chronically upregulated in DMD and linked with enhanced counter-productive 
fibrosis (Vetrone et al., 2009; Zanotti et al., 2011). In osteoclasts, the role of P2X7 is 
varied with a preference towards promoting the apoptosis of this cell type, effectively 
limiting bone resorption (Ohlendorff et al., 2007; Wesselius et al., 2013). 
Neither of the predominant effects on osteoblasts or osteoclasts fit our data (Figure 
5.4), except when we consider information, perhaps more relevant to complicated 
chronic diseases. In one study, it was found that P2X7 expressed by osteoclasts may 
also function to promote the formation of multinucleated osteoclasts, and that this 
may be inhibited by P2X7 receptor blockade (Gartland et al., 2003). Importantly, 
Gartland et al. (2003) showed that P2X7 activation had the potential to promote 
osteoclastogenesis in addition to the apoptosis of this cell type, as if helping to 
balance skeletal homeostasis. In healthy adult bone, osteoclasts are normally low in 
number. In the DMD disease state, in which skeletal homeostasis is already 
chronically perturbed by a host of factors, it is difficult to automatically assume that 
an over-expressed P2X7 receptor may still be predominately effecting bone formation 
over resorption, or that the removal of this receptor would not benefit bone turnover. 
In DMD, many factors will disturb bone homeostasis, including long-term 
glucocorticoid use (Bianchi et al., 2003), reduced bone stress contributed by more 
limited musculoskeletal movements (Hillam & Skerry, 1995; Yan et al., 2012), and 
chronic skeletal muscle inflammation. Focusing on this last factor, it was recently 
shown that IL-6 was one of several candidate proteins that adversely affected bone 
parameters in the mdx mouse (Rufo et al., 2011). That we have earlier indicated a 
reduction in the inflammatory phenotype of mdx/P2X7-/- dKO muscle compared to 
mdx, including a potential reduction in type-M1 macrophages known to preferentially 
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release IL-6, creates the further possibility that bone osteopenia may be reduced in the 
dKO mouse by this mechanism. 
Additionally important in terms of this study, is evidence that higher levels of free 
fatty acids have been found to promote P2X7 receptor expression via MAPK 
induction in PC12 neuroblastoma cells, leading to enhanced IL-6 release (Xu et al., 
2013). Perhaps more relevant in bone formation, P2X7 receptor activation was also 
found to promote IL-6 release in bone-joint located synoviocytes in a model of 
rheumatoid arthritis (Caporali et al., 2008). Finally, in an original analysis of the 
Pfizer P2X7 KO mouse, receptor ablation was found to reduce total levels of 
circulating IL-6 (Solle et al., 2001). 
Even if P2X7 ablation did rescue the mdx bone resorption phenotype, it is still 
difficult to explain our P2X7 KO data from animals without muscular dystrophy. Our 
data showed P2X7 KO mice to have BV/TV and Tb.N values very similar to C57 
mice, indicating no osteopenic phenotype in P2X7 KO mice according to these 
parameters (Figure 5.5). 
None-the-less, the current finding that P2X7 receptor ablation may also rescue the 
muscular dystrophy bone phenotype in addition to the aforementioned benefits to 
sarcolemmal stability, diaphragm muscle strength, reduced muscle inflammation, and 
an improved muscle regeneration potential, warrants further study because of the 
potential for P2X7 inhibitors to effect an holistic therapeutic intervention in DMD, 
acting on multiple aspects of disease pathology simultaneously. 
 
5.3.4 The effects of pharmacological antagonist CBB on serum CK levels (preliminary 
study) 
Administration of broad purinoceptor antagonists have shown some impact in the mdx 
model of DMD (Taniguti et al., 2011; de Oliveira Moreira et al., 2013b). A proof of 
principal study was carried out to look into the effects of the specific P2X7 antagonist 
CBB on the level of a standard pre-clinical diagnostic marker of DMD, serum CK.  
CBB is a non-competitive inhibitor of the P2X7 receptor, with around 1000-fold more 
potency at the rat-receptor than the most closely related subunit, P2X4 (Jiang et al., 
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2000). On this basis, CBB is a highly specific antagonist and information gleamed 
from its use may be used to support the involvement of the P2X7 receptor in the 
pathogenesis of DMD, even over the closely related and sometimes co-expressed 
P2X4 receptor. Furthermore, CBB has already been used in mouse studies to 
challenge the P2X7 receptor and to improve animal health (Gandelman et al., 2010). 
Using CBB to antagonise P2X7 receptor function in vivo, qualitatively lower serum 
CK levels were attained compared to mdx, and similar to the Pfizer mdx/P2X7-/- dKO 
mouse, that did not reach statistical significance. If more than the current number of 
10 animals were tested, it may have been possible to attain a significant difference 
between saline-injected or non-injected mdx and CBB-injected mdx mice. This claim 
is corroborated by a power analysis study, indicating a lower than required number of 
CBB injected animals to be confident in the outcome of determined difference 
between this and other groups (Appendix 9.10: with an assumed group standard 
deviation of 550 there is a ~56% chance that we can correctly identify a difference at 
N=10, if that difference exists). The pattern is none-the-less promising because of 
similar results obtained from the KO study. Moreover, CBB has a slow association 
rate and does not competitively block agonist activation (Michel et al., 2008). We  are 
currently testing new generation, increased affinity, competitive antagonists that block 
all P2X7-mediated functions, including Ca2+ influx, pore formation, and IL-1β release 
[36], which therefore are significantly more effective. 
If the P2X7 receptor is eventually recognised as a useful target in the treatment of 
DMD, it is likely that other drug-based compounds will be necessary to safely 
challenge receptor function in vivo. One of the current advantages of challenging the 
P2X7 receptor is that several highly-specific antagonists have already been developed 
that, in several cases, have already passed human clinical-trial safety testing for the 
treatment of other human disorders (Arulkumaran et al., 2011), creating a potential 
fast-track avenue to explore secondary medicinal applications. 
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6 
General discussion 
 
 
The current study has sought to investigate the role of the P2X7 purinoceptor in the 
pathogenesis of DMD using the mdx mouse model of this disease. Molecular and 
functional parameters were compared in mdx to two specifc strains of mdx/P2X7-/- 
double-mutant mouse and it was found that P2X7 ablation in this most widely used 
animal model of DMD produced significant improvements observed both in leg 
muscles at 4 weeks as well as in diaphragms and hearts at 20 months. At these stages 
and in these muscles, mdx diease features mimic DMD pathology. In addition to 
amelioration of key molecular and functional parameters of muscle damage, 
decreased inflammation and a reduction of non-muscle symptoms were also evident. 
This wide impact reflects convergence of P2X7 ablation on multiple pathological 
mechanisms, thus revealing a potential new strategy for treating this debilitating 
disease (see below). 
The main comparison was performed between the mdx animal and the Pfizer 
mdx/P2X7-/- mouse strain. The Pfizer P2X7 KO mouse varies from the Glaxo strain 
through differing targeted modifications of the P2X7 gene such that in the Glaxo 
P2X7 KO mouse a low expression but gain of function splice variant, the P2X7k, 
escapes inactivation (Nicke et al., 2009). The P2X7k variant can contribute to 
enhanced receptor mediated pore formation and enhanced context specific cell-death 
compared to the predominant P2X7a variant (Nicke et al., 2009). Interestingly, the 
differential expression of the gain-of-function P2X7k variant in the Glaxo P2X7 KO 
mouse has been suggested as a potential reason behind differing bone resorption 
across the two knockout strains (Syberg et al., 2012), even though its overall 
expression is much lower than of the normal P2X7a isoform (Masin et al., 2012). 
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Throughout this study, a pattern has emerged in which the Glaxo mdx/P2X7-/- dKO 
mouse has presented qualitatively intermediate phenotype between mdx and the Pfizer 
mdx/P2X7-/- mouse (Table 6.1). For example, in a measure of total body muscle 
membrane permeability, Glaxo mdx/P2X7-/- serum CK was qualitatively intermediate 
between mdx and Pfizer mdx/P2X7-/- levels. This was corroborated by a non-
significant but intermediate muscle cytoplasmic IgG staining levels found in the 
Glaxo mdx/P2X7-/- mouse compared to mdx and the Pfizer variant. Also compelling 
are the many intermediate values in the panel of inflammatory genes expression, 
including IFNγ, TNFα, and Ly6G, also coupled to the muscle protein analysis of 
F4/80 and CD163 by western blotting. Finally, intermediate skeletal-muscle protein 
expressions were found for the myogenic factors eMyHC and myogenin.  
These partial effects of P2X7 ablation observed in Glaxo mdx/P2X7-/- and also 
observed in heterozygous mdx/P2X7+/-, which were found to have intermediate P2X7 
levels, suggest that even incomplete inhibition of this receptor may have some 
therapeutic effects. Indeed, broad purinoceptor antagonists showed some impact in the 
mdx model of DMD (Taniguti et al., 2011; de Oliveira Moreira et al., 2013b) and the 
short-term administration of CBB antagonists in this study also gave promising 
results. As mentioned earlier, CBB does not competitively block agonist activation 
(Jiang et al., 2000) and suramin used in other studies is non-specific not only with 
respect to its receptor antagonism but also regarding the off-target effects. Therefore, 
future studies should concentrate on high affinity, competitive antagonists, which are 
significantly more effective. 
Moreover, as the Pfizer mdx/P2X7-/- dKO mouse consistently presented values further 
from mdx and more indicative of amelioration of disease parameters, it provided 
justification for preferential use of this strain in most of the subsequent comparisons.  
Regarding mechanisms by which P2X7 ablation produced muscle recovery, these 
could involve both direct effects in muscle cells (Yeung et al., 2006; Young et al., 
2012; 2013; 2015; Valladares et al., 2013) as well as the reduced inflammation (Porter 
et al., 2002; Vidal et al., 2012; Idzko et al., 2014). 
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4 week C57 BL/10 Pfizer dKO Glaxo dKO mdx 
General Histology Qualitative Qualitative Qualitative Qualitative 
Pax7 expression  n.s. n.s. Dystrophic 
baseline 
Central nucleation Qualitative n.s.  Dystrophic 
baseline 
Myofibre Feret’s 
CoV 
 n.s.  Dystrophic 
baseline 
Muscle min. 
Feret’s diameter 
 P<0.05  Dystrophic 
baseline 
Myogenin 
expression 
 P<0.005 P<0.005 Dystrophic 
baseline 
eMyHC 
expression 
Qualitative P<0.05 n.s. Dystrophic 
baseline 
Revertant fibres None Qualitative but 
n.s. 
n.s. Dystrophic 
baseline 
Utrophin 
expression 
 n.s.  Dystrophic 
baseline 
Macrophage 
infiltration 
P<0.05 P<0.05 P<0.05 Dystrophic 
baseline 
M1/M2 MØ ratio P<0.05 P<0.05 Qualitative but 
n.s. 
Dystrophic 
baseline 
Key inflammatory 
mRNAs 
 4 genes 
P<0.05 
3 genes 
P<0.05 
Dystrophic 
baseline 
Neutrophil 
infiltration 
 P<0.05  Dystrophic 
baseline 
Serum CK P<0.005 P<0.05 Qualitative but 
n.s. 
Dystrophic 
baseline 
Mouse IgG 
infiltration 
 P<0.05 Qualitative but 
n.s. 
Dystrophic 
baseline 
Diaphragm tetanic 
force 
P<0.005 P<0.05 Qualitative but 
n.s. 
Dystrophic 
baseline 
Table 6.1. Summary table showing a relative distribution of phenotypes across genotype at 4 weeks. 
In each case a colour coding system is employed to indicate positive difference (green: along with 
indicated P value) from the dystrophic baseline (peach) presented by the mdx mouse. Positive 
difference represents statistical and qualitatively determined differences between individual means that 
have been considered healthier. n.s. = non-significant. Where a qualitative difference in continuous 
variable was observed that was not statistically significant, that box was coloured yellow-green 
(chartreuse). Boxes are shaded-out where variables were not recorded for a particular genotype. Note, 
the general pattern in which the Pfizer mdx/P2X7-/- dKO mouse presents more variables that are 
different from mdx than the Glaxo mdx/P2X7-/- animal. See Appendix 9.10 for a more detailed version 
of this summary table. 
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Dystrophin-deficient muscles chronically release ATP together with other DAMPs 
and resulting immune cell infiltrations contribute to disease progression (Porter et al., 
2002; Villalta et al., 2009). Deletion of P2X7, with its unique capability to respond to 
high ATPe levels and to shape the inflammatory pathway through release of pro-
inflammatory cytokines would be expected to have an impact.  Indeed, in mdx/P2X7-/-
, there was a clear overall decrease in the muscle inflammatory signature. In 
particular, there were lower total macrophage specific F4/80 marker expressions and 
an indication of a shift in macrophage subtype from an M1 to an M2 (pro-
regenerative) phenotype. Importantly, this shift did not result in exacberated fibrosis 
in either aged mdx hearts or diaphragms. Moreover, 4 week mdx/P2X7-/- dKO mouse 
muscle consistently presented lower expressions values of pro-inflammatory 
transcripts compared to mdx. These included markers such as TNFα and RORC, both 
of which are positively associated with Th1 and Th17 T-cell induction. Consistent 
with the reduced level of the mRNA and protein levels of the granulocyte marker 
Ly6G in mdx/P2X7-/- dKO muscle compared to mdx, there also were reduced numbers 
of infiltrating leukocytes. 
It is therefore interesting to explore two aspects of P2X7-evoked modulation of DMD 
biology. These include an effect on DMD inflammation and a potentially fundamental 
interaction with cellular pathways. 
A typical feature of DMD is the sterile inflammatory response that is also autoreactive 
and, at least partly, T-cell mediated. CD4 and CD8 positive cells were amongst the 
first immune cells to be recognised as contributing to myotube cytolysis in DMD 
(Spencer et al., 1997; 2002). The autoimmune features of DMD, such as abnormal 
major histocompatibility complex I and II expression and chronic inflammation, are 
gaining attention (Tidball & Wehling-Henricks, 2005). P2X7 is a likely candidate to 
effect a T-cell mediated autoimmunity in DMD. For example, in a sterile form of 
inflammation following cardiac muscle transplantation, P2X7 expression was elevated 
and found to promote Th1 and Th17 cell induction in a STAT3-dependent manner 
(Vergani et al., 2013). Moreover, certain populations of T-cell are known to regulate 
macrophage cell sub-types. For instance, CD4+CD25+ T-cells (including T-regs) 
promote M2 macrophage induction in vivo (Liu et al., 2011). In one recent study, this 
time directly applicable to the mdx mouse, the P2 receptor antagonist suramin, 
applied for 8 months, reduced inflammation, fibrosis, and necrosis in the heart (de 
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Oliveira Moreira et al., 2013b). This result directly parallels the reduced heart fibrosis 
and inflammation observed in 20 month Pfizer mdx/P2X7-/- compared to mdx mice 
presented earlier, adding much greater support to the hypothesis of a leading 
purinergic mechanism involved in mdx pathogenesis. TGFβ levels did not change in 
the heart after the 3 month suramin treatment of the de Oliveira Moreira (2013b) 
study but did increase in the diaphragm. TGFβ in particular is associated with fibrosis 
pathways, so it was important to explore the possibility of increased diaphragm 
fibrosis upon P2X7 ablation. Fibrosis has been linked to the activity of regenerative 
M2-type macrophages, which were also increased relative to M1-type macrophages, 
at least in earlier stages of the dystrophinopathy in mdx/P2X7-/- compared to mdx 
mice. However, despite concerns raised by both of these previous observations, 
fibrosis was not increased in aged 20 month Pfizer mdx/P2X7-/- compared to mdx 
diaphragms, whilst reduced inflammation was maintained. 
Another important finding in this thesis has been the reduction in TNFα levels in 
mdx/P2X7-/- muscle compared to mdx at 4 weeks, since TNFα has been previously 
linked to the key P2X7 function as well as to DMD disease progression. The 
inflammatory cytokine TNFα is known to promote satellite cell activation and 
proliferation (Li, 2003; Tidball & Villalta, 2010) whilst also inhibiting the 
differentiation and fusion of myotubes (Miller et al., 1988; Szalay et al., 1997; Layne 
& Farmer, 1999; Langen et al., 2001; 2002; 2004), providing some mechanistic 
support for the enhanced muscle fibre diameters observed in 4 week hindlimb and 20 
month diaphragms in Pfizer mdx/P2X7-/- compared to mdx mice. Enhanced 
proliferation, as is found in DMD, may contribute to satellite cell replicative 
senescence (Decary et al., 2000) and fibrosis (Alexakis et al., 2007) whilst enhanced 
differentiation, without a large decline in satellite cell or myoblast proliferation, may 
result in the larger myotubes and reduced fibrosis as seen in the mdx/P2X7-/- mouse 
compared to mdx. Reduced TNFα expression due to reduction of macrophage 
numbers also correlated with improved insulin sensitivity in a human study (Di 
Gregorio et al., 2005). A similar effect on muscle metabolic potential has been found 
for another pro-inflammatory mediator down-stream of P2X7 receptor activation, 
namely IL-1β. In a human study of type-2 diabetes, it has been shown that IL-1β 
blockade could improve outcome by reducing inflammation and increasing cellular 
glucose levels (Larsen et al., 2007; 2009). Finally, TNFα and IL-1β are both elevated 
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from early stages of DMD (Kumar & Boriek, 2003), and both have been found to 
interfere with IGF1 signalling in dystrophic muscles (Broussard et al., 2003; 2004; 
Strle et al., 2004). This factor also impinges on myogenic potential and muscle fibre 
size. Of interest in the debate regarding macrophage polarisation, the generally anti-
inflammatory and M2 macrophage-associated cytokine IL-10 limits IGF1 interference 
by IL-1β (Strle et al., 2008). 
It has been suggested that the degenerative nature of the dystrophic muscle pathology 
may also be associated with the deterioration of the function of myogenic precursor 
cells over repeated cycles of proliferation and self-renewal (Bigot et al., 2008). As has 
been mentioned previously, this could also be linked to the increased systemic and 
tissue level inflammation present in dystrophic muscle. In the mdx mouse model, 
disease phenotype is less severe and does not result in the marked chronic 
degeneration and drastically premature mortality seen in human patients, with the 
possible exception of diaphragm muscle. When telomere length is artificially 
shortened by experimental intervention to remove the RNA component of telomerase, 
the mdx pathology is significantly more severe and also presents an obvious 
degenerative profile (Sacco et al., 2010), hinting at a fundamnetal compensatory 
advantage in the mouse compared to human and also evidence for a muscle-cell-
specific challenge in DMD. 
That targeting of P2X7 could be used to challenge even the directly muscle specific 
origins of the DMD pathology has been hinted at by our laboratory and others. 
Previous work by our laboratory has discovered ERK1/2 phosphorylation to be 
downstream of P2X7 receptor activation in dystrophic muscle (Young et al., 2012). 
ERK1/2 is a member of the mitogen activated protein kinases (MAPKs), whose 
activation is also linked to myoblast proliferation. Upon MAPK inhibition, it has also 
been shown that there was a corollary increase in the differentiation of skeletal muscle 
cells in vitro (Coolican et al., 1997), indicating the potential reciprocal relationship 
between the ERK1/2 – proliferation pathway with, in that case, a PI3K/p70S6k – 
differentiation pathway. By here showing an increased muscle fibre size and 
myogenin expression upon P2X7 receptor loss in the mdx mouse, it is possible that 
regenerative emphasis was shifted towards differentiation by limiting ERK1/2 
activation in vivo. It should also be noted that in the Coolican et al. (1997) study, it 
was shown that myogenin, whilst important, was not sufficient to induce 
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differentiation in the absence of factors such as MEF-2. Without having monitored for 
many of the other MRFs, we cannot therefore exclude the possible involvement of 
these proteins in the increase of myofibre size upon reduced P2X7 activation. In terms 
of a potential benefit upon dystrophic disease pathology, there is evidence to suggest 
that mdx skeletal muscle is pathologically weighted towards hyper-proliferation of 
muscle precursor cells over their eventual differentiation; an observation with obvious 
impact on a supposed satellite cell replicative senescence. For instance, at an 
epigenetic level it was shown that mdx skeletal muscle expresses higher levels of a 
class I histone deacetylase 2 (HDAC2) than non-dystrophic controls (Colussi et al., 
2008). This enzyme was shown to limit the formation of multi-nucleated myotubes 
via the regulation of the follistatin-myostatin pathway. Part of the cause for enhanced 
HDAC2 activity in dystrophic muscle is the loss of key DAPC members, resulting in 
reduced NO mediated S-nitrosylation of HDAC2 (Colussi et al., 2008). In more 
global measures of protein mediated genetic regulation, it was further shown that 
wider ranging histone modifications were potentiating proliferative and inflammatory 
cell pathways in humans and mice, also partly via reduced NO production in DMD 
muscle (Colussi et al., 2009). 
The P2X7 receptor is a particularly interesting disease target in this regard since it too 
has been linked with proliferation, including of muscle precursor cells. In one study, 
purinergic receptors including P2X7 were shown to promote ERK1/2 mediated, 
intracellular Ca2+ dependent, satellite cell proliferation in vitro (Banachewicz et al., 
2005). In another more recent study, it was shown that ATPe promoted C2C12 muscle 
myoblast proliferation via purinergic receptor activation, except at excessive levels 
when it became cytotoxic (Martinello et al., 2011). Also important for the current 
hypothesis, was their claim that myoblasts had an inherent reduced resistance to ATP 
due to a lower ATP hydrolysing capability compared to C2C12 myotubes. If true of 
regenerating mouse muscle fibres in vivo, this reduced NTPDase activity in myoblasts 
may partly explain the presence of increased centrally nucleated muscle fibre size in 
the mdx/P2X7-/- dKO mouse compared to mdx. Regenerating muscle fibres mostly 
recapitulate developing muscle cells. Therefore, P2X7-deficient and regenerating 
fibres may be less susceptible to the higher levels of ATPe that Martinello et al. 
(2011) defined as cytotoxic. This raises the alluring possibility that targeting of the 
P2X7 receptor in DMD may increase muscle fibre re-growth potential and 
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sarcolemmal stability, perhaps concomitant with a decreased susceptibility to 
apoptotic and necrotic cell death via Ca2+ dependent and independent mechanisms. 
Without eliminating satellite cell proliferation and self-renewal, a shift towards 
enhanced differentiation seems likely to alleviate DMD disease severity, concomitant 
with a reduction in the hyper-proliferation of myogenic precursor cells normally 
observed in dystrophic muscle. Another interesting reason for this, may be related to 
the exaggerated fibrosis also seen in human, and to a lesser extent mouse, 
dystrophinopathy. Specifically, it has been shown that dystrophic myogenic cells 
themselves express the extracellular matrix component collagen type-I inversely 
proportional to their expression of the differentiation MRF myogenin (Alexakis et al., 
2007). This early collagen expression was also correlated with the later expression of 
non-myogenic cells in aged muscle, indicating the hyper-proliferation of satellite cells 
as a self-perpetuating mechanism of collagen overproduction linked to an ultimate 
myogenic defect (Alexakis et al., 2007). The effect of P2X7 ablation on dystrophic 
fibrosis, including collagen-Ia deposition, is an aspect of pathological mediation that 
has been addressed here. 
Specifically, cardiac fibrosis was reduced in the mdx/P2X7-/- dKO mouse compared to 
mdx at ~20 months. In relation to the above discussion, it was interesting that levels of 
myogenin were higher in younger mdx/P2X7-/- compared to mdx hindlimb muscle, 
perhaps indicating a shift away from hyper-proliferative myogenesis upon P2X7 
receptor ablation, subsequently coinciding with reduced long-term collagen 
production and fibrosis. The generally activatory and proliferative effect of immune 
cells on MPCs has also been described, providing an alternative or adjacent 
mechanism by which P2X7 could affect myogenesis, and finally mediating fibrosis. 
That aged hearts and diaphragms from Pfizer mdx/P2X7-/- compared to mdx mice also 
showed reduced immune cell infiltrations, strongly supports the correlation even if it 
does not prove causality. A likely explanation for the improvement in these 
histological markers of dystrophic pathology, probably involves the interruption of 
purinergic mediation of the communication between the complex milieu of cells 
present in dystrophic muscle, even if single disease pathways may be more important 
than others. Exaggerated skeletal and cardiac muscle fibrosis is a defining histological 
feature of dystrophinopathy; present in the most common mammalian models, the 
mdx mouse and the Golden Retriever muscular dystrophy dog, and DMD (Willmann 
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et al., 2009; Nakamura & Takeda, 2011). Therefore, irrespective of the precise 
mechanisms leading to the reduced fibrosis and inflammation in aged hearts and 
diaphragms from mdx/P2X7-/- compared to mdx mice, these results should be seen as 
highly significant. The improvements found in 20 month old hearts and diaphragms of 
mdx/P2X7-/- demonstrated that similar mechanisms operate in both skeletal and 
cardiac muscles and that these mechanisms remain active throughout the mdx 
pathology at least in muscles undergoing continuous, severe degeneration/ 
regeneration akin to human disease. The cardiac improvement is also of clinical 
importance because with prolonged survival (due to advances in general care) heart 
failure becomes a more common cause of death in DMD. 
At the cellular level, and without relying on its modulation of immune cells only, the 
P2X7 receptor may be modifying mdx and DMD disease outcome in the following 
additional ways. As already mentioned, the P2X7 receptor has been linked to ERK1/2 
activation in dystrophic muscle cells (Young et al., 2012). ERK1/2 has recently also 
been shown to reciprocally-negatively interact with AMPK to induce a form of 
muscle specific cellular insulin resistance (Hwang et al., 2013). It is therefore 
plausible that P2X7 over-activation may also result in skeletal muscle metabolic 
instability, which is linked to a general state of cell stress and chronic intracellular 
Ca2+ elevation (Park et al., 2011; 2013) as seen in DMD and the mdx mouse (Figure 
6.1). More directly, high ATPe acting on P2X7, which is over-expressed on 
dystrophic muscle cells (Young et al., 2012; 2013; Valladares et al., 2013), could 
activate both ion channel and large pore opening, producing an efflux of the 
intracellular content and activation of signalling cascades involving both ERK 
phosphorylation and increases in intracellular Ca2+ levels, which contribute to 
deregulation of Ca2+ homeostasis in mdx fibres. Therefore, P2X7 ablation or 
inhibition would eliminate Ca2+ influx occurring via this receptor and that can also 
trigger secondary modulation of other Ca2+ channels;  effects that have been described 
in mdx myofibres (Friedrich et al., 2004; Vandebrouck et al., 2006). Thirdly, given 
that P2X7-activation in dystrophic muscle cells has recently been linked to autophagy 
induction, then this may be a primary mechanism through which enhanced purinergic 
signalling may be effecting DMD atrophy, metabolic instability, and muscle fibre 
susceptibility to cell death processes (Jahnke et al., 2012). Indeed, our laboratory has 
recently shown P2X7 large pore formation to induce a novel form of autophagic cell 
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death in mdx myoblasts and myotubes, which involves heat-shock proteins (Young et 
al., 2015). This mechanism may contribute both to fibre loss and exhaustion of the 
pool of muscle-resident stem cells required for regeneration (Sacco et al., 2010). A 
seeming contradiction is that has been suggested that autophagy is a generally 
beneficial process in muscular dystrophy via elimination of defective mitochondria 
(De Palma et al., 2012; Pauly et al., 2012). However, while P2X7 ablation reduced 
autophagy in 4 week old mdx TA, it is not clear whether, or to what extent, it affected 
muscle or immune cells. Future research is needed to clarify the cell-type dependency 
as well as the reported shift between positive and negative roles for autophagy in 
young and old dystrophic muscles, respectively (Hindi et al., 2014). 
Another interesting observation is that glucocorticoid therapies for DMD, including 
the widely used prednisone, may actually activate autophagy by interfering with 
glucose metabolism, thus potentially decreasing muscle oxidative potential in the 
chronic disease state (Louard et al., 1994; Short et al., 2009). Specifically addressing 
this issue, Huynh et al. (2013) have compared prednisolone treatment, with a non-
steroidal glucocorticoid receptor modulator, in mdx. Both treatments were successful 
at reducing key inflammatory markers associated with disease severity but the non-
steroid compound resulted in significantly less osteopontin, Foxo1, and Foxo3 
induction compared to prednisolone. Yet more evidence indicating that autophagy is 
generally detrimental for skeletal muscle in DMD come from a study in which 
sarcolemmal-delocalised nNOS was shown to enhance muscle atrophy by 
upregulating Foxo3-mediated atrogin-1 and MuRF1 (Suzuki et al., 2007). De-
localised nNOS is recognised as a fundamental feature of DMD, contributing to 
disease pathogenesis and a reduced muscle force potential (Li et al., 2010a; Li et al., 
2011b, Figure 6.1). 
Finally, targeting the P2X7 receptor is, to our knowledge, the first clinically-relevant 
treatment for the non-muscle symptoms of DMD. The P2X7 receptor plays 
significantly different roles in bone physiology and in disease states (Kvist et al., 
2014). Importantly, ablation of P2X7 in mdx model did not exacerbate but improved 
the dystrophic bone phenotype. As bone abnormalities in mdx mice have been linked 
to chronic inflammation (Abou-Khalil et al., 2014), the reduced inflammatory 
signature in mdx/P2X7-/- muscles may also translate into reduced bone loss in these 
mice. 
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Figure 6.1. A Schematic representation of potential roles for the P2X7 receptor in the pathological 
progression of DMD. Absence of dystrophin and resulting loss of the DAPC leads to reduced cell membrane 
stability with a chronic increase in Ca2+, ROS, and RNS causing protein damage, apoptosis, necrosis and 
metabolic instability. Damaged muscle releases large quantities of ATP and DAMPs, which trigger a chronic 
inflammatory response. P2X7 purinoceptor up-regulation on dystrophic myofibres could be involved in several 
pathogenic pathways: 1) intracellular Ca2+ build-up; 2) PKC mediated p47phox translocation and subsequent 
ROS generation; 3) sterile activation of immune cells leading to sarcolemmal breakdown, cell death, and 
reduced myocyte differentiation. High extra-cellular ATP levels may skew responses of muscle macrophages by 
promoting the M1 over the pro-regenerative M2 population while P2X7 purinergic over-activation in dystrophic 
myoblasts (not shown) may contribute to their death and thus reduce muscle regeneration further still. 
NADPH oxidase may be expressed at the skeletal muscle membrane where it can contribute 
significantly to ROS generation (Whitehead et al., 2006). ATP is now a recognised extracellular signal 
promoting the translocation of NADPH oxidase subunits via secondary signalling molecules such as PKC 
(Cheng et al., 2013). In terms of cellular ROS generation, the NADPH oxidase complex may be a greater 
contributing factor than even acute inflammatory cells. Although the NADPH oxidase organizer subunit p47phox 
is shown in the figure based on recent evidence of P2X receptor involvement in A549 epithelial cells, gp91phox 
and p67phox subunits have been highlighted as increased in even pre-symptomatic mdx TA muscle compared to 
wild-type controls (Whitehead et al., 2010). 
Chronically elevated cytosolic Ca2+ is a classical feature of DMD leading to calpain activation and 
increased Ca2+ uptake into mitochondria. The P2X7 receptor is capable of passing high Ca2+ levels into cells but 
has also been linked to the release of Ca2+ from intracellular stores via inositol- 1,4,5-triphsophate (IP3) receptor 
(IP3R) activation, at least in neuronal cells (Chao et al., 2012). 
Recent evidence has shown that long-term increased levels of intracellular Ca2+ has an inhibitory effect 
on the metabolic energy sensor AMPK in muscle via CaMKII and protein phosphatase 2A (PP2A) induction 
(Park et al., 2011; 2013). Reduced AMPK activation will lower available intracellular ATP. 
 Linking endoplasmic reticulum stress to the pathogenesis of insulin resistance and type2 diabetes, 
recent work has highlighted an inhibitory cross-talk between AMPK and ERK signalling pathways in skeletal 
muscle (Hwang et al., 2013). Since we have previously established elevated ERK1/2 phosphorylation as a 
downstream effect of P2X7 over-activation in mdx muscle (Young et al., 2012), it may be that this is also 
contributing to tissue specific insulin de-sensitisation, resulting in the reduced cytosolic glucose levels found in 
DMD muscle. 
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7 
Future studies 
 
 
Many aspects of the current model for the potential involvement of the P2X7 receptor 
in the pathology of DMD (Figure 6.1) are currently speculative, based partly on 
findings presented here and partly on literature-based evidence. As well as important 
clinical therapeutic concerns associated with targeting of the P2X7 receptor, possible 
future studies therefore represent experimental testing of model claims, as suggested 
below: 
 Extend the analysis of inflammatory mediators in mdx/P2X7-/- dKO mice 
compared to mdx, to include IL-1β, TGFβ, and T-cell marker expression. 
Including the previously mentioned TGFβ, all of the above factors have been shown 
to be modulated by P2X7 receptor activation. IL-1β is a pro-inflammatory cytokine 
whose maturation from zymogen and secretion is effected by a secondary stimulation 
of human macrophages by ATP, or other agonists, acting on the P2X7 receptor 
(Ferrari et al., 1997; Elssner et al., 2004). Despite the consistent observation that this 
P2X7-dependent IL-1β release requires priming of macrophages with LPS, IL-1β 
levels are still elevated in DMD without pathogenic cause (Lundberg et al., 1995; 
Kumar & Boriek, 2003). With recent data indicating that P2X7 receptor activation has 
a fundamental impact on T-cell subset selection (Hubert et al., 2010; Schenk et al., 
2011), it would be especially interesting to see if reducing P2X7 receptor activation 
has any impact on T-regulatory cells within mdx skeletal muscle. qPCR transcript 
comparisons in the current study already qualitatively indicated that Foxp3 may be 
elevated in 4 week old mdx/P2X7-/- dKO muscle compared to mdx but this study 
needs extending to statistically support or to deny this claim. 
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 Immunophenotype primary-cell extracts by flow cytometry. A standard approach 
to quantify and to compare immunophenotype between experimental groups is via 
flow cytometry. A focus would be made on macrophage subtype and total neutrophil 
infiltrations. Due to T-cell sub-type also emerging as a promising P2X7 –related 
immune regulatory factor, in addition to the conventional association of CD4 and 
CD8 positive lymphocytes with pathological progression in DMD (Spencer et al., 
1997; 2001), this cell type would also be a focus for flow cytometry. 
 
Preliminary studies have already been carried out, evaluating a primary cell extraction 
method for the isolation of immune cells from homogenised skeletal muscles (data not 
shown). 
 
 Perform pathway analysis on P2X7 inflammatory response. Whilst above normal 
Ca2+ influx may be important in the complicated disease pathology of dystrophic 
muscle, downstream of P2X7 over-activation (Fig 6.1), it is also worth considering 
adjuvant or alternative cellular processes such as the reduction of intracellular K+ also 
associated with inflammatory response and proteolysis. In this pathway it has been 
shown that the inflammatory effect of an efflux of intracellular K+ operates via the 
NALP3 inflammasome (that protein complex controlled by the NLRP3 gene) rather 
than via the IPAF (ICE [interleukin-1β converting enzyme]-protease activating 
factor), ASC (apoptosis-associated speck-like protein containing caspase activation 
and recruitment domain) independent, inflammasome in both mouse and human 
monocyte cultures (Petrilli et al., 2007). Interestingly, the K+ efflux activated NALP3 
inflammasome may be, at least partly, triggered by P2X7 pore-forming activation in 
macrophages (Perregaux & Gabel, 1994) or elsewhere. 
 
 Extend the pharmacological study with the use of modern P2X7 antagonists, 
including A740003, A438079, and A804598 from Tocris bioscience. The current 
study has administered only CBB. It is an effective P2X7 receptor antagonist which 
has been used to aid recovery by reducing inflammation in an animal model of acute 
spinal injury (Peng et al., 2009). However, it does not have pharmacological 
properties of a clinical drug. Alternative specific P2X7 antagonists include 
GSK314181A, AZ10606120, AZ11645373, AZD-9056, CE-224535, and EVT-401 
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(Syed & Kennedy, 2012). One should also consider the use of sub-cutaneous drug-
delivery implantation devices to administer P2X antagonists, reducing stress-inducing 
injections. To additionally evaluate the clinical therapeutic potential of these P2X7 
antagonists for the treatment of DMD, it may be necessary to administer P2X7 
antagonists for the mdx mouse simultaneous with steroid treatments. Without a 
significant compound benefit over steroid-only treatment, the use of P2X7 antagonists 
may not be justifiable considering that most DMD patients already use 
glucocorticoids to manage their condition. 
 
 Challenge other P2X receptor subtypes. The pan-P2X receptor blocker suramin has 
been recently used to reduce mdx cardiomyopathy (de Oliveira Moreira et al., 2013b). 
Although the improvement using suramin could be significantly mediated by a 
reduction in P2X7 receptor activation, it is also worth considering the involvement of 
other P2X receptors, many of which are more potently antagonised by suramin than is 
the case for P2X7 (North & Surprenant, 2000; Gever et al., 2006). It should also be 
remembered that P2X7 is not the only P2X subunit to be expressed in muscle tissue. 
During various stages of development skeletal muscle fibres have been shown to 
express P2X1, 2, 4, 5, 6, and 7 receptors (Ryten et al., 2001; 2004; Jiang et al., 2005; 
Yeung et al., 2006), indicating their importance during proliferation and 
differentiation phases of muscle (re)generation. This is additional to the expression of 
P2X receptors on numerous other infiltrating cell types, including immune cells, 
smooth muscle, fibroblasts, and nervous tissue. 
 
In relation to other P2X receptors, P2X4 has been shown to have a similar expression 
profile to P2X7, even heterotrimerising with it to form a functional purinoceptor (Guo 
et al., 2007). Interestingly, analyses of publically available microarray datasets have 
failed to confirm P2X7 as being significantly upregulated in dystrophic mouse 
compared to healthy samples (one representative study shown in Figure 7.1). This 
result is difficult to explain other than as an experimental inadequacy given that P2X7 
is well-established to be expressed on macrophages and its presence on these cells 
infiltrating mdx muscles has been shown in this study. It is likely that the microarray 
results reflect low sensitivity of this assay. Nevertheless, P2X4, which is known to co-
localise with P2X7 in macrophages has been is found upregulated in mdx skeletal 
hindlimb muscle (GC/soleus) compared to wild-type samples at multiple ages and 
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correlated with the macrophage specific marker CD68 (Figure 7.1). Moreover, P2X4 
expression correlated with macrophage infiltration, a finding previously published by 
our laboratory (Yeung et al., 2004). Considering these findings, it might be worth 
investigating the effects of P2X4 inhibition in mdx mice or even in mdx/P2X7-/- 
double mutants. In a limited adjacent western blotting study, P2X4 expression was 
qualitatively lower in Pfizer mdx/P2X7-/- compared to mdx GC muscle at 4 week, 
without reaching statistical significance (Appendix 9.7). Regarding other P2X 
receptors, it has been recently proposed that P2X2 and P2X5 can also heterotrimerise 
to form a P2X7-like receptor (Compan et al., 2012). The significance of this 
interaction has not been explored in the current study but might also be tested in 
future studies. 
 
 Further bone remodelling experiments. It is very interesting that this study has 
shown reduced bone mineral resorption in mdx/P2X7-/- mice compared to mdx at 6 
months of age, since osteopenia is a ubiquitous disease feature in DMD that may be 
exacerbated with conventional therapies, such as glucocorticoids (Mayo et al., 2012). 
As well as extending the mdx/P2X7-/- to mdx comparison to include a greater N 
number, it may also be beneficial to test the possible pathways involved in bone 
resorption and rescue. For instance, controlling levels of IL-6 may elucidate the 
endogenous role of this cytokine in inflammation mediated bone mineral loss in DMD 
and the induction by P2X7 activation. 
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 Consider some of the off-target effects of reducing the activation of P2X7 in vivo. 
There are recorded mood-stabilising properties of P2X7 antagonists and genetic 
ablation in mice (Basso et al., 2009; Csolle et al., 2013a; 2013b). This off-target 
effect, if proven reliable in humans, may have obvious therapeutic and psychological 
 
Figure 7.1. Microarray meta-analysis from the gene-expression-omnibus database, showing 
correlation in elevated CD68 (a) and P2X4 (b) mRNA levels in mdx compared to wild-type 
skeletal muscles at various ages. P2X7 is not qualitatively different between mdx and C57 
wild-type samples at any recorded age (c). Query submitted to NCBI GEO-database 
(http://www.ncbi.nlm.nih.gov/geo/) (original article: Porter et al., 2003). 
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benefits for human DMD patients. However, as a more immediate consideration, 
mood improvement in mice is often defined by reduced immobility, a behaviour that 
could influence DMD disease features. P2X7 receptor pore formation is already 
impaired in mice on certain genetic backgrounds, including the BL/6 and BL/10 
strains, due to a nucleotide polymorphism that results in a proline to leucine amino 
acid substitution at position 451 (Adriouch et al., 2002). This was a factor that was 
earlier considered as potentially influencing our study of P2X7 receptor function in 
DMD. When considering that P2X7 receptor antagonists are also the focus of clinical 
trials for chronic pain therapy, we must consider the possibility that mdx/P2X-/- mice 
used in the current study may sympathetically and parasympathetically experience 
fewer dystrophic sensations than mdx mice, in parallel with a modified biology that 
may or may not be physically attenuating cellular and molecular disease pathology. 
Whilst ostensibly good for the well-being of the animal, this may also mask 
improvements as measured by standard operating procedures. For instance, if an 
mdx/P2X7-/- mouse is moving about more in their cage and entertaining other normal 
physical pursuits, like fighting siblings, with a greater tendency than the mdx mouse, 
then they may be artificially elevating disease markers, like sarcolemmal tear and 
elevated serum CK. Therefore, further studies should also make some effort to record 
and to control for this potential disease model masking. 
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Appendix 9.1. CD68 and F4/80 immunofluorescence in 4 week mdx TA. Three microscope 
fields of view are shown (rows) for each of three individual animals (columns). Note, CD68 
labels all macrophage subsets.  
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Appendix 9.2. CD68 and F4/80 immunofluorescence in 4 week mdx/P2X7-/- dKO TA. Three 
microscope fields of view are shown (rows) for each of three individual animals (columns). 
Note, CD68 labels all macrophage subsets. 
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Appendix 9.3. Macro used for Fiji semi-automatic morphometry.  
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Appendix 9.4. Average minimum Feret’s diameter comparison between mdx, mdx/P2X7-/- 
and mdx/P2X7+/- F1 heterozygous mice. Centrally nucleated muscle fibres from mdx/P2X7+/- 
F1 heterozygous mice showed a similar size distribution to samples from mdx/P2X7-/-. 
Chapter 9: Appendices 
Page 231 
 
Appendix 9.5. RNA quality control by agrose gel electrophoresis and spectrophotometry. a) 
Extracted total RNA was electrophoretically run on a non-denaturing agarose gel to infer the 
quality of RNA from rRNA 28S (top band) and 18S (bottom band) subunits. Representative 
example images shown. b) Summary table, including spectrophotometry data used to 
determine RNA concentration and non-nucleic acid contaminant content, measured by 
comparison of OD values recorded at 260/280 and 260/230 wavelength .  
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Appendix 9.6. Ly6G (red) and IL-1β (green) co-localisation in 4 week GC muscles of mdx 
(left) and mdx/P2X7-/- (right) mice. Mdx muscle seemed to present a greater concentration of 
Ly6G positive signal in muscle than presented in mdx/P2X7-/- samples. IL-1β expression 
appeared increased in mdx compared to mdx/P2X7-/- muscles but comparative quantitative 
studies are required for confirmation. 
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Appendix 9.7. Comparison of P2X4 receptor expression in mdx, mdx/P2X7-/- and C57 (wild 
type) 4 week GC muscles. The difference between P2X4 expression in mdx and Pfizer 
mdx/P2X7-/- did not reach statistically significant levels (T-test, T=1.17, P=0.307, df=4). 
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Appendix 9.8. Eosin and Alcian Blue staining of mast cells in mdx tibialis anterior at 8 
weeks. Note, infrequent mast cell signals (blue) in endomysial regions at the end of an acute 
degenerative period in the mdx mouse. 
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 Disease feature 
Genotype General 
histology 
Pax7 expression Central 
nucleation 
Myofibre 
Feret’s CoV 
Muscle fibre 
size (min Feret’s 
diameter) 
C57 BL/10 4W,+; 4M,+  Negligible  18M, dia, 
20.37μm, 
P<0.001 
mdx 4W, x 
4M, x 
4W, TA, 0.57AU 
4W, GC, 0.71AU 
4W, 15.4% 
4M, 63.7% 
4W, 369AU 
4M, 535AU 
4W, TA, 
22.89μm, 
4M, TA, 
32.43μm, 
18M, dia, 
12.72μm 
Pfizer dKO 4W, x 
4M, x 
4W, TA, 0.98AU, 
P=0.139 
4W, GC, 0.85AU, 
P=0.406 
4W, 24.5%, 
P=0.309 
4M, 63.1%, 
P=0.825 
4W, 400AU, 
P=0.162 
4M, 548AU, 
P=0.475 
4W, TA, 
27.62μm, 
P=0.012 
4M, TA, 
35.08μm, 
P=0.184 
21M, dia, 
15.83μm, 
P=0.011 
Glaxo 
dKO 
4W, x 
4M, x 
4W, TA, 0.54AU, 
P=0.925 
4W, GC, 0.87AU, 
P=0.366 
   
Genotype Myogenin 
expression 
eMyHC 
expression 
Revertant 
fibres 
Utrophin 
expression 
Macrophage 
infiltration 
C57 BL/10 Not expected None 
(n=2) 
None  4W, 0.003AU, 
P=0.0304 
mdx 4W, 0.221AU 4W, 0.876AU 4M, TA, 
1.31% 
18M, 
22.61 (.mm-2)
4W, 1.33AU 4W, 1.805AU 
Pfizer dKO 4W, 
1.17AU, 
P=0.001 
4W, 
0.05AU, 
P=0.0187 
4M, TA, 
1.0%, 
P=0.197 
21M, 
11.29 (.mm-2),
P=0.036 
4W, 
1.62AU, 
P=0.415 
4W, 
0.262AU, 
P=0.0304 
Glaxo 
dKO 
4W, higher, 
1.04AU, 
P=0.001 
4W, 
0.336AU, 
P=0.0933 
4M, TA, 
1.26%, 
P=0.772 
 4W, 
0.401AU, 
P=0.0304 
Genotype M1/M2 MØ 
ratio 
Key inflammatory 
mRNAs 
Neutrophil 
infiltration 
Serum CK Mouse IgG 
infiltration 
C57 BL/10 4W, 
0.04AU, 
P=0.0304 
4W 
(n=2) 
Not expected 4W, 
150.83 IU/L, 
P<0.001 
Negligible 
mdx 4W, 
2.96AU 
4W 4W, 
0.97AU 
4W, 
1461.6 IU/L 
4W, 
6.34% 
Pfizer dKO 4W, 
0.109AU, 
P=0.0304 
4W 
++++ 
P=0.002-0.029 
4W, 
0.29AU, 
P=0.006 
4W, 
796.85 IU/L, 
P=0.012 
4W, 
1.47%, 
P=0.02 
Glaxo 4W, 4W  4W, 4W, 
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dKO 0.557AU, 
P=0.1124 
+++ 
P=0.002-0.022 
988.97 IU/L, 
P=0.056 
3.11%, 
P=0.111 
Genotype Diaphragm 
tetanic force 
Bone 
histomorphometry
Aged 
inflammation
Aged 
fibrosis 
 
C57 BL/10 4W, 32.38N/g, 
P<0.001 
4M, 32.36N/g, 
P<0.001 
6M 18M, dia 
(CD68), 
261.72 (.mm-2),
[N=1] 
18M, heart 
(CD11b), 
24.4 (.mm-2), 
P=0.004 
18M, dia 
(collagen-Ia), 
38.1 (%), 
P=0.001 
18M, heart 
(trichrome), 
1.424 (%), 
P<0.001 
 
BV/TV, Tb.N., 
Tb.Sp 
mdx 4W, 5.07N/g 
4M, 12.68N/g 
6M 18M, dia 
(CD68), 
1157.5 (.mm-2)
18M, heart 
(CD11b), 
101 (.mm-2) 
18M, dia 
(collagen-Ia), 
64.64 (%) 
18M, heart 
(trichrome), 
6.957 (%) 
 
Pfizer dKO 4W, 12.57N/g, 
P=0.049 
4M, 23.43N/g, 
P<0.001 
6M 21M, dia 
(CD68), 
810 (.mm-2), 
P=0.042 
21M, heart 
(CD11b), 
33 (.mm-2), 
P=0.012 
21M, dia 
(collagen-Ia), 
59.16 (%), 
P=0.32 
21M, heart 
(trichrome), 
3.091 (%), 
P=0.001 
 
BV/TV, 
Tb.Sp 
Glaxo 
dKO 
4W, 13.16N/g, 
P=0.135 
    
4M, 17.57N/g, 
P=0.011 
 
Appendix 9.9. Summary of the comparisons of disease phenotypes between C57, mdx, and 
both mdx/P2X7-/- double mutants, including statistical details. For each disease feature and 
genotype, a colour is given to denote the direction of the statistically significant change from 
the dystrophic (mdx) baseline (also denoted by the P value given): blue = increase; pink = 
decrease. For continuous variables, specific values and units of measurements are given, 
sometimes indicating qualitative differences, where significant difference cannot be 
determined. 
The following is a summary of the individual statistical tests used for each disease 
feature: Pax7 – equal variance T-test; Central nucleation – T-test; Myofibre Feret’s CoV – 
equal variance T-test; Muscle fibre size – equal variance T-test; Myogenin – equal variance 
T-test; eMyHC Mann Whitney non-parametric; Revertant Fibres – equal variance T-test; 
Utrophin expression – equal variance T-test; Macrophage infiltration – Mann Whitney non-
parametric; M1/M2 macrophage ratio – Mann Whitney non-parametric; Neutrophil 
infiltration – equal variance T-test; Serum CK – equal variance T-test; Mouse IgG – equal 
variance T-test; Diaphragm tetanic force – equal variance T-test; Aged inflammation – equal 
variance T-test; Aged fibrosis – equal variance T-test. 
Note, for the qPCR array, only the genes that gave significantly different expression levels 
are presented: ++++ = 4 significantly reduced genes (TNFA, RORC, GR1, CXC3L1), +++ = 
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3 reduced genes (RORC, GR1, CXCL1). Ages of samples represented by W=weeks; 
M=months. 
  
Chapter 9: Appendices 
Page 238 
 
 
Appendix 9.10. Power analysis of serum CK analysis, including CBB injected mice, 
showing higher and lower estimates for numbers of animals required to achieve set powers. 
a) An analysis required for higher (left) and lower (right) N-number estimates using two 
observed group standard-deviations of 800 and 550, respectively. The expected maximal 
difference between groups was set based on the average serum CK difference observed 
between mdx and Pf-mdx/P2X7-/- samples. b) A re-representation of data in (a) with power 
plotted againt N number. Assuming there is a difference, for the CBB injected mice, we have 
between ~25-55% chance to identify a 665 unit difference at the current N=10. 
This analysis was undertaken with the hope of achieving an a posteriori power analysis 
intended to refine future N number use, as well as to assess confidence in current estimates 
and the potential for type-ii error. 
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